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Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental 
disorders that imposes an enormous cost to individual, family and society across lifespan and 
generations in the U.S. This dissertation sought to systematically examine three potentially 
important early life factors in relation to ADHD, specifically, maternal cholesterol levels, early 
childhood lead exposure, and maternal acetaminophen use, using the data of mother-infant pairs 
already enrolled and followed in the Boston Birth Cohort (BBC), a high risk, predominantly 
urban low income minority population.  
First, I investigated the prospective association of maternal cholesterol levels measured within a 
few days of delivery with the risk of offspring ADHD diagnosis among 1479 mother-infant pairs 
of the BBC. A low maternal high-density lipoprotein level (≤60 mg/dL) was associated with an 
increased risk of ADHD. A “J” shaped relationship was observed between triglycerides and 
ADHD risk. These associations were more pronounced among boys.  
Second, I investigated the prospective associations between early childhood lead exposure and 
ADHD diagnosis and its potential effect modifiers among 1479 mother-infant pairs in the BBC. I 
found that the elevated lead levels (5-10µg/dL) in early childhood was associated with a 66% 
increased risk of ADHD. Boys were more vulnerable than girls at a given lead level. This risk of 
ADHD was reduced by half if the mother had adequate high-density lipoprotein level or low 
stress.  
Third, I examined the prospective association between maternal plasma biomarkers of 
acetaminophen intake measured within a few days of delivery and offspring ADHD diagnosis 
iii 
 
among 1180 mother-infant pairs of the BBC. There were significant dose-response associations 
between ADHD diagnosis and each maternal acetaminophen biomarker; and such associations 
were specific to ADHD, rather than other neurodevelopmental disorders.   
These findings not only raise a new mechanistic perspective for understanding the origins of 
ADHD but also shed new light on the sex difference in ADHD and point to opportunities for 
early risk assessment and primary prevention of ADHD.  
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BBC: Boston Birth Cohort  
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Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental 
disorders in the U.S.; its prevalence has increased significantly from 7.0% to 10.2% among 
children ages 4-17 years during the past two decades.1 ADHD is defined as a chronic 
neurobehavioral disorder,2-4 which can be categorized into three major presentations: 
predominantly hyperactive/impulsive, predominantly inattentive, and combined.5 Previous 
studies have primarily shown that ADHD is much more common among males, while the range 
of rates varies greatly by studies.6,7 Approximately 66% to 85% of ADHD children will carry 
their disorder into adolescence and adulthood.8,9 The high prevalence along with a tendency for 
the disorder to persist into later life have serious short-term and long-term consequences. At a 
young age, children diagnosed with ADHD have been shown to be more likely to miss school, 
encounter learning difficulties, have tense relationships with others, engage in more spontaneous 
sexual activities, and suffer from more motor vehicle accidents and/or unintentional injuries.4,8,10-
13 As they age into adulthood, individuals with ADHD not only have a higher risk of 
oppositional, conduct, and substance abuse disorders, but also tend to have a poorer 
psychological adaptation to the social environment, and as a result, their chances to hold a job 
and expand their professional career have been shown to be significantly affected by their 
disorder.14 Additionally, adults diagnosed with ADHD have been shown to be likely to have 
comorbidities associated with a range of other mental and substance-related disorders.15 The 
most recent estimation of the annual cost of ADHD to society, including costs related to health 
care utilization, medication, education, crime, and unemployment is $14,500 USD per individual 




increasing by nearly 5% each year since 2003,17 the annual health care costs attributable to 
ADHD have been rising in parallel with the increasing prevalence of ADHD. 8,16,18 
Unfortunately, the current understanding of this highly prevalent and costly disorder is 
insufficient. The exact cause of ADHD is still unknown, not to mention the biological 
mechanisms behind the sex difference in ADHD risk. Gene variants, brain structural 
abnormalities, and neurotransmitter deficiency and deregulation are potential etiological 
mechanisms.19,20 However, no study to date has identified any specific gene that could explain a 
large amount of variation in the probability of ADHD development. On the other hand, multiple 
social and environmental risk factors can potentially influence the development of ADHD, 
including family-related factors,21-33 maternal obesity,34 maternal smoking,26,35,36, maternal 
drinking,26 low birthweight and preterm birth,37 and exposure to phthalates,38 bisphenol A,39 
organophosphates,40 polychlorinated biphenyls,41,42 and lead. 41,43-45 My recent analyses on 
maternal stress and child ADHD has lent further support to the role of early life psychosocial 
factors in child risk of ADHD. However, it has been difficult to identify which factors are in the 
causal pathways of ADHD.46 This is partly due to limitations in previous clinical and 
epidemiological studies of ADHD, including a lack of accurate ADHD measurement, biased 
sample selection, unmeasured confounders, and cross-sectional or retrospective study designs. 
To avoid those limitations, my studies described here used a large, prospective birth cohort 
design to examine several understudied, but potentially important and modifiable, early life risk 
factors of ADHD, taking into account multiple pre-/perinatal and early childhood factors 
previously reported as risk factors for ADHD.46 While a comprehensive review of each of the 
previously studied risk factors of ADHD is beyond the scope of this dissertation, below is a 




maternal nutrition), early childhood blood lead levels (environmental toxin), and maternal 
acetaminophen levels (maternal medication). Table 1-1 provides a snapshot of the available 
published findings for each of these factors. 
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The maternal nutrient condition at each reproductive stage can have a profound impact on the 
development and well-being of the offspring.54 During pregnancy, fetal neurodevelopment is 
dependent on stable and optimal levels of nutrients from the mother. Recent studies have 
reported prenatal exposure to maternal metabolic syndrome could influence children’s 
neurodevelopment outcomes, including autism spectrum disorder (ASD) and ADHD.34,55,56 As 
the major biomarker of metabolic syndrome, the maternal cholesterol profile might play essential 
roles in maintaining fetal neurodevelopment. To date, the role of the maternal cholesterol profile 




roles in development and maintenance of the neural system.57,58 Moreover, maternal cholesterol 
levels increase with gestational age during healthy pregnancy and are transferred to the fetus via 
the placenta;59 this synchronized increase indicates that the cholesterols are essential for the 
proper development of the fetus.59 However, no published study was found to investigate the 
relationship between maternal cholesterol profiles and childhood ADHD.  
While lead has been extensively studied in relation to neurodevelopmental outcomes, its 
association with ADHD as a clinical entity has not been well studied. To date, only three large 
studies have investigated this association.43,44,47 These studies showed a strong dose-response 
association between lead levels and risk of ADHD. However, there were multiple drawbacks in 
these existing studies. First, the outcome assessment may have been flawed: all existing large 
sample studies defined ADHD cases via caregiver/school report, stimulant medication use 
record, or diagnostic interview by the researcher. No large study used the clinical specialist 
diagnosis as their case definition. Second, none of the studies investigated if lead affected boys 
and girls differently or had a large enough sample size to test the potential interaction between 
lead and sex on ADHD. Lastly, while both prenatal and postnatal lead exposures may affect 
ADHD risk, most study designs were either cross-sectional or retrospective. Most studies 
examined childhood lead exposure, with a mean age of measurement ranging from 7-14 years,60 
and the time of the lead measurement was either at the same time or after the ADHD diagnosis. 
There has not been a large longitudinal study designed to investigate the prospective association 
between early life lead exposure (before the age of 2) and the development of ADHD in 
childhood. 
Acetaminophen is a widely used and highly recommended medication for fever and pain relief 




is over 65% in the U.S. and over 50% in Europe.61,62 Since 2013, multiple independent research 
studies analyzing five prospective cohorts from Europe and New Zealand have consistently 
shown a positive association between maternal intake of acetaminophen during pregnancy and 
increased risk of ADHD and its related symptoms.48-53 However, the Society for Maternal-Fetal 
Medicine and the Food and Drug Administration both have issued statements regarding their 
belief that the evidence from those studies is inconclusive for showing a causal relationship 
between prenatal acetaminophen use and ADHD in the offspring.63,64 Their primary criticisms 
include self-reported exposure, lack of dose quantification, unmeasured confounders, and lack of 
adjustment for multiple testing.63 However, given its widespread usage, it is too risky to ignore 
any potential unknown side effects of this drug considering the health consequences of exposed 
fetus.65 Given the infeasibility of conducting any randomized trial, a well-designed prospective 
birth cohort with measurements of acetaminophen blood biomarker levels is needed. Currently, 
no published such study exists. 
In summary, to date, there remains insufficient knowledge regarding the role of maternal blood 
cholesterol profiles, early childhood blood lead levels, and maternal blood acetaminophen levels 
in the development of ADHD. Likewise, although remarkable sex difference in ADHD has been 
well observed, the cause for male dominance in ADHD is still unknown. Additionally, there is a 
paucity of prospective birth cohort studies designed to investigate the influences of these factors 
on the risk of physician-diagnosed ADHD in the U.S., especially among high risk, low-income 
urban minority populations. To fill in these significant research gaps, I used the data of mother-
infant pairs already enrolled and followed from birth up to age of 21 years in the Boston Birth 
Cohort (BBC), along with maternal cholesterols levels measured in blood samples collected 1-3 




maternal acetaminophen levels measured in blood samples collected 1-3 days postpartum. The 
study participants of the BBC are primarily drawn from an urban, low-income and minority 
setting, which has much higher rates of maternal obesity66, elevated lead exposure67, and ADHD 
as compared to U.S. general populations. As detailed in the subsequent chapters, this dissertation 
leveraged the BBC’s extensive molecular, epidemiological, and clinical databases and 
biospecimen repository to address the following novel specific aims.  
1.2 SPECIFIC AIMS AND HYPOTHESES 
Aim 1. To investigate the role of maternal cholesterol (total cholesterol (TC), high-density 
lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides (TG)), independently and 
jointly, in the development of ADHD in childhood, adjusting for pertinent pre- and peri-natal and 
childhood factors. In addition, I aimed to investigate whether the associations differ by sex. 
Hypotheses: Maternal dyslipidemia during pregnancy can increase the risk of ADHD in 
childhood, and there is a sex difference in the association.    
Aim 2a. To investigate the role of early childhood lead exposure, independently and jointly, in 
the development of ADHD in childhood, adjusting for pertinent pre- and peri-natal and 
childhood factors. In addition, I aimed to investigate whether the associations differ by sex. 
Hypotheses: Lead exposure during early childhood can independently and jointly 
increase the risk of ADHD in childhood, and there is a sex difference in the association.    
Aim 2b. To investigate the potential protective effects of optimal maternal cholesterol levels in 




Hypotheses: Optimal maternal cholesterol levels during pregnancy can mitigate the 
adverse effect of lead exposure on the risk of ADHD in childhood. 
Aim 3a. To investigate the role of maternal plasma levels of acetaminophen metabolites, 
independently and jointly, in the development of ADHD in childhood, adjusting for pertinent 
pre- and peri-natal and childhood factors.  
Hypotheses: Maternal plasma levels of acetaminophen metabolites during the perinatal 
period can increase the risk of ADHD in childhood.   
Aim 3b. To investigate the potential protective effects of optimal maternal cholesterol levels in 
reducing the risk of ADHD caused by maternal acetaminophen exposure. 
Hypotheses: Optimal maternal cholesterol levels during pregnancy can mitigate the 
adverse effects of maternal acetaminophen exposure on the risk of ADHD in childhood. 
1.3 CONCEPTUAL FRAMEWORK 
 
Figure 1-1 Conceptual framework. 
Figure 1-1 illustrates the conceptual framework for the three studies presented in this 
dissertation. This framework serves as a visual aid that supports the rationale for the specific 




childhood ADHD diagnosis (the bottom grey box), this framework illustrates the potential actors 
in the early life origin of ADHD development using a life-course perspective. 
1.4 DISSERTATION OVERVIEW 
This dissertation is arranged as follows. Chapter 1 provides the background and significance of 
this topic, major research gaps, and specific aims designed to fill in the research gaps on this 
topic.  It also provides an overview of the entire dissertation structure. In Chapter 2, the current 
understanding of ADHD and the major risk factors of interest are described in detail. Chapter 3 
provides a description of the measurements and methods used related to each specific aim. 
Chapter 4 presents the manuscript that was developed in support of Aim 1 with the title “Do 
maternal cholesterol levels affect attention deficit hyperactivity disorder in offspring? A 
prospective birth cohort study”. Chapter 5 presents the manuscript that was developed in support 
of Aim 2 with the title “A prospective birth cohort study on early childhood lead levels and 
attention deficit hyperactivity disorder: new insight on sex differences.” Chapter 6 presents the 
manuscript that was developed in support of Aim 3 with the title “Maternal biomarkers of 
acetaminophen use and offspring attention deficit hyperactivity disorder.” Chapter 7 addresses 
the implications of findings presented in this dissertation in terms of public health and clinical 
research. Chapter 8 synthesizes the major findings across each specific aim and discusses the 






1. Pastor PN, Duran C, Reuben C. QuickStats: percentage of children and adolescents aged 5-17 
years with diagnosed attention-deficit/hyperactivity disorder (ADHD), by race and Hispanic 
ethnicity—National Health Interview Survey, United States, 1997-2014. MMWR Morb Mortal 
Wkly Rep. 2015;64(33):925. 
2. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an 
American condition? World Psychiatry. 2003;2(2):104-113. 
3. Barkley RA. Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment. 
Guilford Publications; 2014. 
4. Childress AC, Berry SA. Pharmacotherapy of attention-deficit hyperactivity disorder in 
adolescents. Drugs. 2012;72(3):309-325. 
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-
5®). American Psychiatric Pub; 2013. 
6. Stergiakouli E, Thapar A. Fitting the pieces together: current research on the genetic basis of 
attention-deficit/hyperactivity disorder (ADHD). Neuropsychiatr Dis Treat. 2010;6:551-560. 
7. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of 
ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942-948. 
8. Getahun D, Jacobsen SJ, Fassett MJ, Chen W, Demissie K, Rhoads GG. Recent trends in 
childhood attention-deficit/hyperactivity disorder. JAMA Pediatr. 2013;167(3):282-288. 
9. Mannuzza S, Klein RG. Long-term prognosis in attention-deficit/hyperactivity disorder. Child 
Adolesc Psychiatr Clin N Am. 2000;9(3):711-726. 
10. Bagwell CL, Molina BS, Pelham WE, Jr., Hoza B. Attention-deficit hyperactivity disorder and 
problems in peer relations: predictions from childhood to adolescence. J Am Acad Child Adolesc 
Psychiatry. 2001;40(11):1285-1292. 
11. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ. Long-term school outcomes 
for children with attention-deficit/hyperactivity disorder: a population-based perspective. J Dev 
Behav Pediatr. 2007;28(4):265-273. 
12. Barkley RA, Anastopoulos AD, Guevremont DC, Fletcher KE. Adolescents with attention deficit 
hyperactivity disorder: mother-adolescent interactions, family beliefs and conflicts, and maternal 
psychopathology. J Abnorm Child Psychol. 1992;20(3):263-288. 
13. Dopheide JA. ASHP therapeutic position statement on the appropriate use of medications in the 
treatment of attention-deficit/hyperactivity disorder in pediatric patients. Am J Health Syst 
Pharm. 2005;62(14):1502-1509. 
14. Murphy K, Barkley RA. Attention deficit hyperactivity disorder adults: comorbidities and 
adaptive impairments. Comprehensive psychiatry. 1996;37(6):393-401. 
15. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the 
United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 
2006;163(4):716-723. 
16. Pelham WE, Foster EM, Robb JA. The economic impact of attention-deficit/hyperactivity 
disorder in children and adolescents. Ambul Pediatr. 2007;7(1 Suppl):121-131. 
17. Visser SN, Danielson ML, Bitsko RH, et al. Trends in the parent-report of health care provider-
diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011. J Am 
Acad Child Adolesc Psychiatry. 2014;53(1):34-46 e32. 
18. Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2006. Natl 
Health Stat Report. 2008(8):1-29. 
19. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biological 
psychiatry. 2005;57(11):1215-1220. 
20. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity 




21. Patterson GR, DeGarmo D, Forgatch MS. Systematic changes in families following prevention 
trials. J Abnorm Child Psychol. 2004;32(6):621-633. 
22. Scott S, O'Connor TG, Futh A, Matias C, Price J, Doolan M. Impact of a parenting program in a 
high-risk, multi-ethnic community: the PALS trial. Journal of child psychology and psychiatry, 
and allied disciplines. 2010;51(12):1331-1341. 
23. Jaffee SR, Caspi A, Moffitt TE, Polo-Tomas M, Price TS, Taylor A. The limits of child effects: 
evidence for genetically mediated child effects on corporal punishment but not on physical 
maltreatment. Dev Psychol. 2004;40(6):1047-1058. 
24. Costello EJ, Compton SN, Keeler G, Angold A. Relationships between poverty and 
psychopathology: a natural experiment. JAMA. 2003;290(15):2023-2029. 
25. Langley K, Rice F, van den Bree MB, Thapar A. Maternal smoking during pregnancy as an 
environmental risk factor for attention deficit hyperactivity disorder behaviour. A review. 
Minerva Pediatr. 2005;57(6):359-371. 
26. Linnet KM, Dalsgaard S, Obel C, et al. Maternal lifestyle factors in pregnancy risk of attention 
deficit hyperactivity disorder and associated behaviors: review of the current evidence. Am J 
Psychiatry. 2003;160(6):1028-1040. 
27. Glover V. Annual Research Review: Prenatal stress and the origins of psychopathology: an 
evolutionary perspective. Journal of child psychology and psychiatry, and allied disciplines. 
2011;52(4):356-367. 
28. Grizenko N, Shayan YR, Polotskaia A, Ter-Stepanian M, Joober R. Relation of maternal stress 
during pregnancy to symptom severity and response to treatment in children with ADHD. J 
Psychiatry Neurosci. 2008;33(1):10-16. 
29. Pheula GF, Rohde LA, Schmitz M. Are family variables associated with ADHD, inattentive type? 
A case-control study in schools. Eur Child Adolesc Psychiatry. 2011;20(3):137-145. 
30. Scahill L, Schwab-Stone M, Merikangas KR, Leckman JF, Zhang H, Kasl S. Psychosocial and 
clinical correlates of ADHD in a community sample of school-age children. J Am Acad Child 
Adolesc Psychiatry. 1999;38(8):976-984. 
31. Lifford KJ, Harold GT, Thapar A. Parent-child relationships and ADHD symptoms: a 
longitudinal analysis. J Abnorm Child Psychol. 2008;36(2):285-296. 
32. O'Connor TG, Rutter M. Attachment disorder behavior following early severe deprivation: 
extension and longitudinal follow-up. English and Romanian Adoptees Study Team. J Am Acad 
Child Adolesc Psychiatry. 2000;39(6):703-712. 
33. Rutter M, Beckett C, Castle J, et al. Effects of profound early institutional deprivation: An 
overview of findings from a UK longitudinal study of Romanian adoptees. European Journal of 
Developmental Psychology. 2007;4(3):332-350. 
34. Rodriguez A, Miettunen J, Henriksen TB, et al. Maternal adiposity prior to pregnancy is 
associated with ADHD symptoms in offspring: evidence from three prospective pregnancy 
cohorts. Int J Obes (Lond). 2008;32(3):550-557. 
35. Sengupta SM, Fortier ME, Thakur GA, Bhat V, Grizenko N, Joober R. Parental psychopathology 
in families of children with attention-deficit/hyperactivity disorder and exposed to maternal 
smoking during pregnancy. Journal of child psychology and psychiatry, and allied disciplines. 
2015;56(2):122-129. 
36. Gard AM, Owens EB, Hinshaw SP. Prenatal Smoke Exposure Predicts Hyperactive/Impulsive 
but Not Inattentive ADHD Symptoms in Adolescent and Young Adult Girls. Infant Child Dev. 
2016;25(4):339-351. 
37. Bhutta AT, Cleves MA, Casey PH, Cradock MM, Anand KJ. Cognitive and behavioral outcomes 
of school-aged children who were born preterm: a meta-analysis. JAMA. 2002;288(6):728-737. 
38. Park S, Lee JM, Kim JW, et al. Association between phthalates and externalizing behaviors and 





39. Braun JM, Kalkbrenner AE, Calafat AM, et al. Impact of early-life bisphenol A exposure on 
behavior and executive function in children. Pediatrics. 2011;128(5):873-882. 
40. Bouchard MF, Bellinger DC, Wright RO, Weisskopf MG. Attention-deficit/hyperactivity 
disorder and urinary metabolites of organophosphate pesticides. Pediatrics. 2010;125(6):e1270-
1277. 
41. Eubig PA, Aguiar A, Schantz SL. Lead and PCBs as risk factors for attention 
deficit/hyperactivity disorder. Environ Health Perspect. 2010;118(12):1654-1667. 
42. Sagiv SK, Thurston SW, Bellinger DC, Tolbert PE, Altshul LM, Korrick SA. Prenatal 
organochlorine exposure and behaviors associated with attention deficit hyperactivity disorder in 
school-aged children. American journal of epidemiology. 2010;171(5):593-601. 
43. Braun JM, Kahn RS, Froehlich T, Auinger P, Lanphear BP. Exposures to environmental toxicants 
and attention deficit hyperactivity disorder in U.S. children. Environ Health Perspect. 
2006;114(12):1904-1909. 
44. Froehlich TE, Lanphear BP, Auinger P, et al. Association of tobacco and lead exposures with 
attention-deficit/hyperactivity disorder. Pediatrics. 2009;124(6):e1054-1063. 
45. Nigg JT, Nikolas M, Mark Knottnerus G, Cavanagh K, Friderici K. Confirmation and extension 
of association of blood lead with attention-deficit/hyperactivity disorder (ADHD) and ADHD 
symptom domains at population-typical exposure levels. Journal of child psychology and 
psychiatry, and allied disciplines. 2010;51(1):58-65. 
46. Thapar A, Cooper M, Eyre O, Langley K. What have we learnt about the causes of ADHD? 
Journal of child psychology and psychiatry, and allied disciplines. 2013;54(1):3-16. 
47. Wang HL, Chen XT, Yang B, et al. Case-control study of blood lead levels and attention deficit 
hyperactivity disorder in Chinese children. Environ Health Perspect. 2008;116(10):1401-1406. 
48. Ystrom E, Gustavson K, Brandlistuen RE, et al. Prenatal Exposure to Acetaminophen and Risk of 
ADHD. Pediatrics. 2017;140(5). 
49. Stergiakouli E, Thapar A, Davey Smith G. Association of Acetaminophen Use During Pregnancy 
With Behavioral Problems in Childhood: Evidence Against Confounding. JAMA Pediatr. 
2016;170(10):964-970. 
50. Avella-Garcia CB, Julvez J, Fortuny J, et al. Acetaminophen use in pregnancy and 
neurodevelopment: attention function and autism spectrum symptoms. Int J Epidemiol. 
2016;45(6):1987-1996. 
51. Liew Z, Ritz B, Rebordosa C, Lee PC, Olsen J. Acetaminophen use during pregnancy, behavioral 
problems, and hyperkinetic disorders. JAMA Pediatr. 2014;168(4):313-320. 
52. Thompson JM, Waldie KE, Wall CR, Murphy R, Mitchell EA, group ABCs. Associations 
between acetaminophen use during pregnancy and ADHD symptoms measured at ages 7 and 11 
years. PloS one. 2014;9(9):e108210. 
53. Brandlistuen RE, Ystrom E, Nulman I, Koren G, Nordeng H. Prenatal paracetamol exposure and 
child neurodevelopment: a sibling-controlled cohort study. Int J Epidemiol. 2013;42(6):1702-
1713. 
54. Symonds ME, Sebert SP. The impact of diet during early life and its contribution to later disease: 
critical checkpoints in development and their long-term consequences for metabolic health. 
Proceedings of the …; 2009. 
55. Li M, Fallin MD, Riley A, et al. The Association of Maternal Obesity and Diabetes With Autism 
and Other Developmental Disabilities. Pediatrics. 2016;137(2):1-10. 
56. Gardner RM, Lee BK, Magnusson C, et al. Maternal body mass index during early pregnancy, 
gestational weight gain, and risk of autism spectrum disorders: Results from a Swedish total 
population and discordant sibling study. Int J Epidemiol. 2015;44(3):870-883. 
57. Fodor G. Primary prevention of CVD: treating dyslipidemia. American Family Physician. 
2011;83(10). 
58. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of the Cell 




59. Brizzi P, Tonolo G, Esposito F, et al. Lipoprotein metabolism during normal pregnancy. 
American journal of obstetrics and gynecology. 1999;181(2):430-434. 
60. Goodlad JK, Marcus DK, Fulton JJ. Lead and Attention-Deficit/Hyperactivity Disorder (ADHD) 
symptoms: a meta-analysis. Clin Psychol Rev. 2013;33(3):417-425. 
61. Lupattelli A, Spigset O, Twigg MJ, et al. Medication use in pregnancy: a cross-sectional, 
multinational web-based study. BMJ Open. 2014;4(2):e004365. 
62. Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA. Use of over-the-counter medications 
during pregnancy. American journal of obstetrics and gynecology. 2005;193(3 Pt 1):771-777. 
63. Society for Maternal-Fetal Medicine Publications Committee. Prenatal acetaminophen use and 
outcomes in children. American journal of obstetrics and gynecology. 2017;216(3):B14-B15. 
64. Food  and   Drug  Administration. FDA has reviewed possible risks of pain medication during 
pregnancy.  https://www.fda.gov/Drugs/DrugSafety/ucm429117.htm. Accessed Jan. 7, 2018. 
65. Olsen J, Liew Z. Fetal programming of mental health by acetaminophen? Response to the SMFM 
statement: prenatal acetaminophen use and ADHD. Expert Opin Drug Saf. 2017;16(12):1395-
1398. 
66. Bryant AS, Worjoloh A, Caughey AB, Washington AE. Racial/ethnic disparities in obstetric 
outcomes and care: prevalence and determinants. American journal of obstetrics and gynecology. 
2010;202(4):335-343. 
67. Aelion CM, Davis HT, Lawson AB, Cai B, McDermott S. Associations between soil lead 
concentrations and populations by race/ethnicity and income-to-poverty ratio in urban and rural 










2.1 BACKGROUND AND SIGNIFICANCE 
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder, which is 
highly prevalent in the U.S. The prevalence of ADHD has increased significantly from 7.0% to 
10.2% among children aged 4-17 years during the past two decades.1 This chronic 
neurobehavioral disorder is characterized by inattention, hyperactivity, or impulsiveness.2-4 
Although stimulant medications are used as first-line treatment for ADHD, their potential side 
effects short and long-term on health outcomes are of concern.5,6 For example, taking these 
medications for ADHD can cause sleep disturbances, reduced appetite, and suppressed growth, 
which has been shown to impact on ADHD children’s development and quality of life.7 Like 
autism spectrum disorder (ASD), ADHD diagnosis is also disproportionately high among boys,8-
11 with a three times higher risk compared to girls per most recent estimates.10,12 ADHD can 
affect multiple aspects of a child’s life, such as school performance, social involvement, and 
overall quality of life.13-17 In the school setting, children diagnosed with ADHD tend to leave 
their seat frequently, talk incessantly, play loudly, and call out answers before question are stated 
completely. It is also harder for ADHD children to organize tasks and sustain attention during 
schoolwork or extracurricular activities.18 Due to their disruptive and aggressive behaviors, 
ADHD children are likely to be alienated by their classmates as early as the first day of school.19 
Thus, ADHD children are more liable to miss school, encounter learning difficulties, have tense 
relationships with others, engage in more spontaneous sexual activities, and suffer from more 
motor vehicle accidents and unintentional injuries.4,10,13,20-22  
Approximately 66% to 85% of ADHD children will carry their disorder into adolescence and 
adulthood.10,23 The high and rising prevalence of ADHD along with a tendency for it to persist 




older, ADHD adults not only have an increased risk of oppositional, conduct, and substance 
abuse disorders but also have a poorer psychological adjustment. As a result, their chances to 
hold a job and advance their professional career are significantly affected by their ADHD.24 
Additionally, ADHD adults are likely to share comorbidities with many other mental and 
substance-related disorders.25 These coexisting disorders not only aggravate the deterioration 
linked with ADHD during adulthood but also inflate the economic burden.26 For instance, 
ADHD students contribute to a higher annual cost to the U.S. education system due to special 
education placement, grade retention, and disciplinary incidents.27 Moreover, studies have shown 
that those with ADHD had higher annual medical costs than those without ADHD due to higher 
utilization of hospitalization, primary care visits, outpatient mental health visits, and pharmacy 
fills.18 Claims data indicate that the excess medical costs of ADHD were $31.6 billion in the U.S. 
in 2000.28 The most recent estimation of the annual total cost of ADHD to society, including 
costs related to health care utilization, medication utilization, education, crime, and 
unemployment, is $14,500 per individual and $42.5 billion in total.29 Moreover, as the 
prevalence of ADHD diagnosis has been increasing by nearly 5% each year since 2003,8 the 
annual health care costs attributable to ADHD and related ambulatory care visits are becoming 
synchronized with the increasing prevalence of ADHD.10,29,30  
2.2 DEFINITION AND DIAGNOSIS 
ADHD is defined as a behavioral disorder characterized by symptoms of inattention, impulsivity, 
and hyperactivity.2 Based on these characteristics, ADHD is categorized into three major 
presentations: predominantly hyperactive/impulsive, predominantly inattentive, and combined.31 
Moreover, one presentation might shift to another one as the disorder progresses over time.32 




the U.S. currently use the Diagnostic and Statistical Manual of Mental Disorders, 5th edition 
(DSM-5) to diagnose ADHD.31 The DSM-5 criteria for ADHD in children up to age 16 are “six 
or more symptoms of inattention” (symptoms present over six months) and/or “six or more 
symptoms of hyperactivity-impulsivity” (symptoms present over six months).31 For an individual 
aged 17 years and older, the criteria are “five or more symptoms of inattention” (symptoms 
present over six months) and/or “five or more symptoms of hyperactivity-impulsivity” 
(symptoms present over six months).31 Based on these two types of symptoms, the DSM-5 
categorizes ADHD into three presentations: predominantly hyperactive-impulsive, 
predominantly inattentive, and a combined presentation.31 Moreover, those symptoms should 
clearly interfere with or reduce the quality of functioning in two or more settings, such as social, 
academic or occupational; a symptom would not be counted if it only occurs in one of these 
settings.31 In addition, a symptom would not be counted if it occurs exclusively in other mental 
disorders or is better explained by another mental disorder.31 Noteworthy, the ASD diagnosis is 
no longer an exclusion criterion for ADHD diagnosis.31 
In 2002, Vanderbilt ADHD Diagnostic Rating Scale (VADRS), a toolkit for assessment and 
treatment of ADHD in children between the ages of 6 and 12 in primary care settings, was 
developed jointly by American Academy of Pediatrics and National Initiative for Children’s 
Healthcare Quality.36-38 This toolkit consists of two versions: a parent version with 55 questions 
and a teacher version with 43 questions.37 Both the parent and teacher versions consists of two 
sections: symptom assessment and performance impairment.37 The VADRS has screening items 
corresponding to the ADHD diagnostic criteria in DSM-IV.38,39 Having at least 6 positive 
responses towards either the core 9 inattentive symptoms or core 9 hyperactive symptoms, or 




ADHD assessment, 39,40 VADRS is a commonly used diagnostic scale for physicians.41 
Moreover, VADRS also includes symptoms screening items for three common comorbidities for 
ADHD, including oppositional defiant disorder, conduct disorder, and anxiety/depression.39 By 
calculating the scores for each comorbidity domain, VADRS could provide possibility of 
comorbidity according to the recommended threshold.39 
In addition to clinical diagnosis, behavior rating scales have become great additions for 
providing information about children’s symptoms in different settings, such as home and 
school.42 Because they are cost-efficient and easily administrable, the Child Behavior Checklist–
Attention Problem (CBCL-AP) subscale 43 and Conners Rating Scale-Revised (CRS-R)44 are the 
commonly used ADHD assessment tools for children and adolescents in schools and 
communities.42,45 While CBCL-AP has strong discriminatory power for screening ADHD among 
children and adolescents, CRS-R is more suitable for assessing ADHD and related behavioral 
problems.42 For instance, the CRS-R has an ADHD index, different length versions for parents 
and teachers, and various subscales for various behavioral domains, such as oppositional 
disorders, cognitive problems or inattention, and hyperactivity subscales.42 Based on meta-
analysis results, the sensitivity and specificity for ADHD diagnosis are moderate for both the 
CBCL-AP and CRS-R.42 Furthermore, the Conners’ Abbreviated Symptom Questionnaire 
(ASQ), an abridged version of the CRS-R, is considered to be the most effective diagnostic tool 
for assessing ADHD because of its high accuracy and conciseness.42 
2.3 CURRENT UNDERSTANDING OF ADHD ETIOLOGY 
Brain Structure and Function: Brain structural abnormalities, and neurotransmitter deficiency 




observed global reduced volume and/or functionality of gray, especially in the right lentiform 
nucleus and extending to the caudate nucleus,48 and white matter among ADHD patients.49 
Moreover, ADHD patients have also shown smaller volume and/or reduced activity in the 
prefrontal cortex (PFC), caudate, and cerebellum areas, which are primarily in charge of 
attention, thoughts, emotions, behaviors, and actions.50,51 The functionalities across those areas 
are sensitively controlled by neurotransmitters, such as dopamine (DA) and norepinephrine 
(NE), through multiple receptors.52-57 Specifically, too little DA/NE release will cause an 
individual to become easily distracted and impulsive, while too much release will cause 
misguided attention and responses.58 Several studies have found reductions in DA and/or NE 
functioning in those diagnosed with ADHD.49,50,59-61 In contrast, several other studies have 
identified a hyperactive DA response in ADHD.56,62,63 These findings suggest a U-shaped 
relationship between the functioning level of DA/NE and ADHD symptoms, that is, the complex 
etiology of ADHD involves both hypoactive and hyperactive DA/NE systems.58  
Genetic Factors: One meta-analysis of 20 twin studies from the U.S., Australia, Scandinavia, 
and the European Union indicated that ADHD is a highly heritable psychiatric disorder with a 
mean heritability estimate of 76%.47 Although this study showed that the genes coding for 
SNAP25, DRD4, SLC6A3, HTR1B, SLC6A4, and DBH might play pivotal roles in the etiology 
of ADHD, single nucleotide polymorphisms (SNPs) in these genes and many biologically 
plausible genes did not show genome-wide significance (i.e., a P-value of <5×10−8) in the 
International ADHD Genetics (IMAGE) project that included 909 family trios.64 Moreover, 
grouped SNPs only showed weak associations with ADHD. These findings indicate that the 




Epigenetics and gene-environment interactions should be investigated in future studies to expand 
the understanding of the role of genetics in the etiology of ADHD.  
Environmental Factors: Growing evidence suggests that environmental factors may also play a 
major role. The longitudinal, randomized control treatment trials, the quasi-experimental, and 
genetically informative studies have all shown that negative parenting, maltreatment, and 
poverty are strongly associated with the risk of ADHD, especially among a genetically 
susceptible population.65-68. In addition to those factors, other well-recognized environmental 
risk factors include family-related factors,65-77 maternal obesity,78 maternal smoking,70,79,80 
maternal drinking,70 low birthweight and preterm birth,81 and exposure to phthalates,82 bisphenol 
A,83 organophosphates,84 polychlorinated biphenyls,85,86 and lead.85,87-89 My recent analyses on 
maternal stress and child ADHD lend further support for the role of early life psychosocial 
factors in child risk of ADHD. It has been difficult to identify which among them are definitively 
causal;90 this is in part due to the limitations of previous clinical and epidemiological studies of 
ADHD, including lack of accurate ADHD measurements, biased sample selection, unmeasured 
confounders, and non-longitudinal designs. For instance, multiple studies using a genetically 
sensitive design have shown that the effect of maternal smoking is mostly confounded by genetic 
or other unidentified environmental factors.91,92 Furthermore, the possibility of reverse causality 
could not be excluded. For instance, a longitudinal study using a twin design found that it is 
more likely that the child’s ADHD symptoms are the causes for mother-son hostility rather than 
that hostility is the cause of ADHD.93 Moreover, another study showed that ADHD children 
identified from a nonclinical setting were more likely to show a sex difference in levels of 




examine the potential environmental risks and their modifications on ADHD, a large, prospective 
birth cohort design is needed to overcome these confounding and reverse causality issues. 
Sex Difference: Like ASD, ADHD diagnosis is also disproportionately high among boys,8-11 
with a three times higher risk compared to girls per most recent estimates.10,12 The results from 
two recent meta-analyses indicated that this sex difference in prevalence is caused by “potential 
confounding effects of referral bias, comorbidity, developmental patterns, diagnostic procedures, 
and rater source.”94,95 For instance, ADHD girls were shown to have a more severe intellectual 
impairment, lower level of hyperactivity, and less externalizing behaviors compared to ADHD 
boys.94 Those differences strongly indicate that sex-specific biological mechanisms are 
underlying the neurodevelopmental factors and interaction with environmental factors. However, 
there is still no well-established biological theory to help unravel the exact etiology of sex 
difference in ADHD.   
In the following, I will further elaborate on the three early life factors that this dissertation will 
focus on. 
2.3.1 Maternal nutrition 
The maternal nutrient condition at each reproductive stage can have a profound impact on the 
development and well-being of offspring.96 During pregnancy, fetal neurodevelopment is 
dependent on stable and optimal levels of nutrients from the mother. A suboptimal maternal 
nutrient condition during critical developmental periods could drastically increase the risk of 
multiple adverse neurodevelopmental problems, such as neural tube defects and schizophrenia.97 
Previous studies have shown that maternal nutrient imbalance or deprivation, especially during the 




of the fetal brain.98,99 Thus, maternal nutritional status during pregnancy is biologically plausible to 
influence neurodevelopment in the offspring.  
Recent studies have reported that prenatal exposure to maternal metabolic syndrome could 
influence a child’s neurodevelopment outcomes, including ASD and ADHD.78,100,101 A study 
using BBC data showed a strong association between maternal obesity and diabetes and 
increased risk of ASD.100 Moreover, a vast longitudinal study, using prospective pregnancy 
cohorts from the Nordic Network, showed that both overweight moms and moms with excessive 
weight gain during gestation had an over 2-fold higher risk of having ADHD children.78 
However, these studies did not specifically examine a major component of metabolic syndrome, 
the maternal cholesterol profile, and it remains unclear what is the role of maternal cholesterols 
in fetal neurodevelopment.  
Cholesterol plays multiple essential functions in the human body. 102 First, it is the building 
block for synthesizing steroids or cortisone-like hormones, such as vitamin D and the sex 
hormones testosterone, estrogen and cortisone.102 Those steroids or hormones, in turn, regulate 
development and metabolism. Second, it assists in digestion and absorption of fat-soluble 
vitamins including vitamin A, D, E and K.102 Third, it is the critical component for stabilizing 
cell membranes and facilitating inter-cellular communication. Lastly, it plays crucial roles in 
myelin sheath formation, which is a neuron in charge of aiding the route of electrical impulses.102 
As such, a lack of abundant cholesterol might on its own lead to memory loss and focus problem. 
High-density lipoproteins (HDL) and low-density lipoproteins (LDL) are both complex particles 
composed of multiple fat-transporting proteins.103 As shown in Figure 2-1, HDL plays essential 
roles in transporting excess cholesterol from the periphery to the liver via a reverse cholesterol 




cells, and adipocytes through Scavenger receptor class B member 1 (SR-BI), a receptor for 
HDL.103 In addition to HDL, LDL is another crucial player in reverse cholesterol transport. LDL 
could exchange cholesteryl esters (CE), triglycerides (TG) and phospholipids (PL) with HDL via 
Cholesteryl ester transfer protein (CETP). Next, the LDL receptors (LDLR) recognize and take 
up LDL in hepatocytes.103 The central nervous system contains nearly 25% of the un-esterified 
cholesterol in the entire body, while it only accounts for 2% of bodyweight.106 Those sterols 
primarily reside in two locations in the brain: 1) plasma membranes of glial cells and neurons; 2) 
specialized membranes of myelin.106  
While the cholesterol in the CNS is primarily synthesized locally in the brain, the evidence for 
cholesterol transfer from maternal plasma into the brain of a fetus or newborn is limited.106 The 
formation and excretion of 24S-hydroxycholesterol out of the brain is the primary mechanism for 
eliminating excessive cholesterol and keeping a steady state in the brain.106 Indirect findings 
show that a significant amount of cholesterol recycling occurs among glial cells and neurons 
during neurodevelopment and neuron repair and remodeling.106 Ligands, such as apolipoproteins 
E and AI, and membrane transport proteins, such as HDL and LDL, may be involved in the 
sterol recycling process for both the brain and other parts of the body.107,108 Although there is no 
direct transport of sterol across the brain, studies suggest that an imbalance of cholesterol in the 
body may alter internal sterol recycling within the CNS, which would affect the integrity of both 
neurons and myelin.106 Moreover, another biological study showed that diabetes could cause a 
wide-spectrum of changes in sterol regulatory element-binding protein 2 (SREBP-2) and its 
downstream cholesterol synthetic genes expression in brain.109 As shown in Figure 2-2, those 
changes would result in a low production of brain cholesterol and its precursors, which in turn 










Figure 2-1 Role of HDL and LDL in lipoprotein metabolism. (adapted from 103) 
 




In sum, maternal cholesterols have important biological functions as outlined above. In fact,  
maternal cholesterol levels increase with gestational age during normal pregnancy and are 
transferred to the fetus via the placenta; 110 and this increase in normal pregnancy indicates that 
the cholesterols are essential for the proper development of the fetus.110 Moreover, the clinical 
cut points for abnormal levels of cholesterol may not apply to the unique physiological 
conditions during pregnancy, given it was derived for preventing cardiovascular diseases in 
adults. As such, a prospective birth cohort study is critically needed to investigate the association 
between maternal cholesterol levels and offspring ADHD risk.  
2.3.2 Environmental toxins 
Maternal exposure to chemical agents and pollutants have a potential negative impact on the 
nervous system of the developing fetus. Moreover, environmental toxins could further have a 
postnatal influence through the daily use of contaminated soil, water and air.111 For instance, 
exposure to pesticides, herbicides, and polychlorinated biphenyls has been associated with 
increased risk of perinatal mortality, growth restriction, and intellectual function.112 Specifically, 
growing evidence indicates a link between the risk of ADHD and multiple environmental toxin 
exposures, including phthalates,82 bisphenol A,83 organophosphates,84 polychlorinated 
biphenyls,85,86 and lead.85,87-89  
Lead will be the primary research focus of this dissertation. Lead has the potential to damage 
multiple organ systems within the human body across the lifespan. 113 The toxicity of lead 
exposure on the central neuron system makes it extremely harmful during infancy and childhood, 
which is the critical period for neurodevelopment.114 As the understanding of lead’s toxicity 
advances, the threshold to define lead toxicity has been revised from as high as 30 μg/dL in 1975 




fetus or young child.115-119 High exposures to lead could result in grave outcomes, including 
neurological impairments, coma, and even death.118 Even under low levels of lead exposure, 
increased risks have been identified for multiple outcomes including intellectual reduction,120,121 
executive functioning impairment,122 and socio-behavioral problems.123 Furthermore, 
accumulating literature suggests that lead exposure is associated with the core symptoms of 
ADHD.113  
Although lead has been extensively studied for neurodevelopmental outcomes, its association 
with ADHD as a clinical entity has not been well studied. Currently, only three large sample 
sized studies have investigated this association.87,88,124 Two large cross-sectional studies using 
different time periods of National Health and Nutrition Examination Survey (NHANES) data 
consistently showed a dose-response relationship between childhood blood lead level and ADHD 
diagnosis.87,88 The adjusted odds ratios between the highest lead group and the lowest lead group 
were 4.1 (95%CI, 1.2–14.0)87 and 2.3 (95%CI, 1.5–3.8),88 respectively. This dose-response trend 
was still observed for the group of children with blood lead levels lower than 2 µg/dL.87 A 
relatively large matched case-control study in China also observed a similar dose-response 
relationship.124 However, there have been multiple drawbacks in these existing studies. First, the 
definition of ADHD in the sizable studies was mainly based on caregiver/school report, stimulant 
medication use record, or diagnostic interview by the researcher. No large study used the clinical 
specialist diagnosis as their case definition. Second, none of these studies investigated the lead-
sex interaction or had a large enough sample size to test the potential interaction. Lastly, while 
there has been plenty of evidence to support the link between the effects of both prenatal and 
postnatal lead exposure and risk for ADHD, most studies only examined the consequences of 




that the time of measurement was either at the same time or after the ADHD diagnosis. So far, 
there has been no large longitudinal study to investigate ADHD in relation to blood lead levels 
measured before the age of 2. 
The neurotoxicity induced by lead is determined by both age125 and lead level.126 Compared to 
adults, children absorb more lead into the brain due to higher potential intake from the 
environment and an underdeveloped blood-brain barrier.127,128 The lead-induced damage in the 
developing brain preferentially occurs in the prefrontal cortex (PFC), hippocampus, and 
cerebellum,129-131 while the brains of ADHD individuals also show a reduction in the volume and 
activity of the PFC and cerebellum.58 Although the exact neurotoxicological pathways induced 
by lead exposure are still understudied, current biological studies suggest that lead disrupts the 
hippocampus region through interacting with the NMDA receptor both synaptically and extra-
synaptically.132 Figure 2-3 summarizes the detailed mechanisms of synaptic interactions between 
lead and the NMDA receptor.132 When the Pb+2 ion enters the hippocampus synaptic region, it 
binds to the NMDA receptor with a much higher affinity compared to glutamate.132 The Pb-
NMDA complex formed by this binding causes a low release of the Ca+2 ion. When there is a 
lack of Ca+2 ion, the Ca+2 dependent pathways, such as calmodulin-II (CAM-II), neuronal nitric 
oxide synthase (n-NOS) and cAMP response element-binding protein (CERB), are inhibited, 
which can lead to long-term potentiation (LTP) dysfunction.133 Figure 2-4 summarizes the lead-
NMDA receptor interactions in the extra-synaptic region.132 In the extra-synaptic region, the 
picomolar level of Pb+2 can efficiently substitute a micromolar level of Ca+2 on the NMDA 
receptor’s NR2 B subunit, which induces an inflow of Ca+2.134 However, in this case, the 




expression.134 Overactivation of these two pathways can cause an imbalance between apoptosis 
factors and antioxidants factors, which leads to neuron cell death.134 
 
Figure 2-3 The synaptic interaction between lead and the NMDA receptor. (adapted from 132) 
 





Although lead exposure in children has declined in the U.S. since the ban on leaded gasoline.117 
lead has remained an important risk factor for certain children for two important reasons. First, 
accumulating evidence has revealed that even low-level lead exposure still has adverse effects on 
neurodevelopment. In agreement with this finding, the blood lead level of concern was reduced 
from 30 μg/dL in 1975 to 5 μg/dL in 2012 in the U.S.118,135 Even further, accumulating new 
findings together with recent CDC guidelines suggest that there is no threshold for the adverse 
health effects of lead exposure.117,136 Second, there still is a profound disparity of lead exposure 
in the U.S. A study conducted in South Carolina showed that the soil lead concentration was 
much higher in the urban areas because of more potential lead sources, such as road networks 
and industries.137 In relation to this, low-income and racial/ethnic minority individuals including 
children younger than 6 years old have a much higher risk of lead exposure because they tend to 
live in urban areas and in neighborhoods that are closer to these lead sources;137 this is not a 
matter of choice; these are the urban areas in which low-income individuals can afford to and 
hence are forced to live. Consistently, many other studies have also found that low-income 
minority populations are more likely to live in the highly lead-contaminated regions and have 
higher median blood lead concentrations, particularly among children, as a result.137-140 The 
Flint, Michigan drinking water crisis is a clear example of the deep disparity of lead exposure in 
the U.S. Before the water source was switched, the population of Flint, which is home to many 
low-income minority populations, had already suffered multiple risks due to high lead exposure, 
including poor nutrition, condensed poverty, and older housing, which also increases the 
potential for lead exposure.141 Data shows that there was already 2.4% of children who had 
elevated blood lead levels (>5 µg/dL) before the water source switch, while the percentage 




proportion of children with elevated blood lead levels was shown to be doubled after the water 
crisis.141 The latest CDC report shows that the percentage of children in the U.S. with a 
confirmed blood lead level higher than 10 μg/dL increased from 7.6% to 13.4% from 2009-
2011.142 In the BBC, all of the cord blood samples had detectable levels of lead. The high 
prevalence of lead exposure along with exposures to other psychosocial and environmental 
toxins could have an enormous negative impact on children’s neurodevelopment, particularly 
among most vulnerable segments of populations in the U.S.141  
In sum, early life exposure to lead remains a clinical and public health concern in the US, 
especially, among disadvantaged populations. The role of early life exposure to lead in ADHD is 
biologically plausible, but not well-established.  As such, a prospective birth cohort study is 
critically needed to investigate the association between early life exposure to lead and ADHD 
risk. Such investigation will be most relevant and revealing among high-risk U.S. populations 
such as urban, low income, minority children. 
2.3.3 Maternal medication use 
The average childbearing age in North America and Europe overlaps with the typical age of drug 
misuse.143 According to the 2013 National Survey on Drug Use and Health in the U.S., 5.4% of 
pregnant women aged 15 to 44 in 2012-2013 reported as current illicit drugs users.144 Given the 
underestimated nature of self-reported illicit drug use into consideration,145 the true prevalence of 
drug misuse is likely much higher. Due to challenges associated with lifestyle changes in the face 
of addiction as well as both a lack of timely awareness about conception and the potential 
toxicity of drugs on the fetus, women might keep using harmful medications before and during 
pregnancy.111 The potential fetal toxicity as a result of maternal illicit drug and medication 




transfer of gestational drug exposure by identifying detectable levels of illicit drugs, medications, 
tobacco ingredients, and alcohol metabolites from neonatal hair samples.146 Heroin and 
methadone exposure during pregnancy have both been linked to an increased risk of neonatal 
abstinence syndrome, preterm birth, low birthweight, and even perinatal mortality.143 At the 
same time, the prenatal use of anticonvulsants, a group of medications prescribed for the 
treatment of epileptic seizures, could lead to multiple congenital disabilities, including neural 
tube defects and developmental delays.147  
Accumulating literature suggests that early child neurodevelopment could be highly influenced 
by prenatal prescribed and over-the-counter medication exposure.148,149 One example is 
acetaminophen. Since 2013, multiple independent research studies analyzing five prospective 
cohorts from Europe and New Zealand have consistently shown a positive association between 
maternal intake of acetaminophen during pregnancy and risk of ADHD and its related symptoms 
in offspring.150-154 The most recent study investigated the relationship between maternal 
acetaminophen intake during pregnancy and risk of ADHD in offspring further adjusting for 
familial risk for ADHD and acetaminophen-related indications.150 This study, using the 
Norwegian Mother and Child Cohort Study (MoBa), collected data on maternal acetaminophen 
use through MoBa questionnaires at week 18, week 30, and 6 months after delivery. Children’s 
ADHD diagnosis (2246 ADHD cases identified out of 112973 children) was based on the 
electronic medical record. Cox proportional hazard model results showed that short-term 
maternal acetaminophen use during pregnancy was negatively associated with the risk of ADHD, 
while long-term use was strongly associated with the risk of ADHD after adjusting for major 
known risk factors and other potential confounders. However, both the Society for Maternal-




belief that the findings from these current studies are still too inconclusive to draw any causal 
inference between prenatal acetaminophen use and ADHD in the offspring.155,156 Their primary 
criticisms include the use of self-reported exposure, lack of dose quantification, unmeasured 
confounders, and lack of model adjustment for multiple testing.155 Given the infeasibility of 
conducting any randomized clinical trial, a well-designed prospective birth cohort with 
acetaminophen levels measured in maternal blood samples will be needed to address the noted 
concerns about previous studies and improve the understanding of acetaminophen’s effects 
during pregnancy. Currently, no such study of this kind exists. 
Acetaminophen is a widely used and commonly recommended medication for fever and pain 
relief for mother during pregnancy157 and for babies in early life.158 The percentage of pregnant 
women who use acetaminophen during pregnancy is over 65% in the U.S. and over 50% in 
Europe.157,159 Starting from the early 1980s, acetaminophen replaced the carcinogenic and toxic 
phenacetin, which can be metabolized into acetaminophen in the human body.160 The liver is the 
primary location for metabolism of acetaminophen.161 As illustrated in Figure 2-5, the main 
metabolites of acetaminophen include unchanged acetaminophen, acetaminophen glucuronide, 
acetaminophen sulfate, and hepatotoxic N-acetyl-p-benzoquinone imine (NAPQI).162 Under a 
therapeutic dose, the majority of acetaminophen is converted into nontoxic glucuronide (52-57% 
of urine metabolites) and sulfate (30-44%) conjugates.162 However, 5-10% of acetaminophen is 
processed into highly toxic metabolite NAPQI, which is responsible for the major hepatotoxicity 
of acetaminophen.162 The process of NAPQI detoxification is a glutathione-dependent process. 
Within the glutathione capacity, NAPQI is ultimately excreted in the urine as acetaminophen 
mercapturate.161,163 In contrast, under supra-therapeutic doses of acetaminophen, the production 




glutathione proceeds, the undetoxified NAPQI leads to energy production loss, ion channel 
disturbance, and cell death.161,163,164 
 
 
Figure 2-5 Pathways of acetaminophen metabolism. 
 
Although the causality and biological mechanisms underlying the maternal acetaminophen and 
child ADHD association remain to be determined, its potential neurotoxicity is plausible 
according to previous findings. First, acetaminophen can be transferred through the placenta and 
stays in the infant’s circulation much longer than in adults.165 One study showed that maternal 
intake of phenacetin (which can be converted into acetaminophen rapidly in adults) containing 
tablets 5.5 hours before delivery can lead to detectable acetaminophen and its metabolites in an 




their undeveloped livers, which is in charge of  acetaminophen metabolism.166 On one hand, 
children’s low metabolic capacity makes it safer for them to use acetaminophen, while on the 
other hand, it makes the fetus more vulnerable to maternal metabolized toxic NAPQI during 
pregnancy. The challenge that remains is that, while current opinions supporting 
acetaminophen’s safety are based on findings related to the low toxic burden of the liver, kidney, 
and intestines in the short-term,167,168, the long-term neurodevelopmental outcomes related to 
acetaminophen exposure have remained to be clarified.169 
Second, as illustrated in Figure 2-6, the therapeutic effect of acetaminophen involves inhibition 
of prostaglandin production.170 Prostaglandin H2 is the precursor of prostaglandin, which is 
converted from arachidonic acid by membrane-bound enzyme cyclo-oxygenase (COX).171 COX 
exists in two major isoforms: COX-1 and COX-2.172 COX-1 isoform is detectable in most 
tissues, while COX-2 isoform is only detectable in neuronal tissues under normal physiological 
conditions.173 The therapeutic effect of acetaminophen can selectively inhibit COX-2.174 As a 
result, the inhibition of prostaglandin production by acetaminophen primarily occurs in the 
brain.174 However, prostaglandin synthesis in the brain involves multiple essential biological 
processes underlying the function and development of neural systems, such as long-term 
potentiation,175 learning,176 and cerebellar development.170 While acetaminophen has some 
therapeutic effects, these disruptions in neuronal development and regulation caused by 





Figure 2-6 Action and metabolism of acetaminophen in babies and children. (adapted from 169) 
Third, accumulating studies have shown that acetaminophen not only rapidly enters the 
cerebrospinal fluid but also shows a profound influence on adult brain function. Again, except 
for its therapeutic effect, acetaminophen can also reduce adults’ response to stimuli and social 
rejection, and make them less likely to be aware of mistakes made during simple tasks.177-180 
These impacts on neural function also provide indirect evidence in support of acetaminophen’s 
potential neural toxicity.  
In sum, long-term exposure to maternal acetaminophen metabolites during pregnancy combined 
with a lack of metabolic capacity within the fetus might lead to both direct toxic damage from 
maternal NAPQI exposure and potential disruption in neurodevelopment due to prostaglandin 
inhibition. Considering the widespread use of acetaminophen in pregnant and peripartum women 




Prospective birth cohort study using objective biomarkers of exposure is critically needed to 
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3.1 DATA SOURCE AND STUDY SAMPLE 
The Boston Birth Cohort (BBC) is an ongoing prospective birth cohort, which was initiated by 
Dr. Xiaobin Wang at the Boston Medical Center (BMC) in 1998. This cohort was initially 
designed to support a molecular epidemiological study to capture the risk factors for low 
birthweight and prematurity among an urban, low-income, minority population in the Boston 
region. Since 1998, the BBC has used a rolling enrollment. To date, the BBC has successfully 
recruited over 8500 mother-infant pairs at birth; the participation rate was about 90% among 
eligible mothers approached by the research staff. Since 2003, a subset of children of BBC who 
continue to receive primary pediatric care at BMC are being enrolled in a postnatal follow-up 
study: Children’s Health Study.1-3 Besides collecting extensive demographic and environmental 
exposure assessments, the BBC has significantly benefited from the implementation of EMR 
since 2003 and the clinical data warehouse since 2005, which allows to access electronic medical 
records of the study children, including inpatients, outpatients, the emergency room, the 
operating room and billing, along with physician diagnoses based on the International 
Classification of Diseases, Ninth Revision or Tenth Revision (ICD-9 or ICD-10) for each 
postnatal visit were obtained from each child’s EMR from 2003 through 2016.  
The analyses presented here use data from the Children’s Health Study (n~=3000). The sample 






Table 3-1 Sample size calculation. 









Sample size for Aim 1     
 Maternal cholesterol biomarkers 1479 303 1176  
Sample size for Aim 2     
 Early childhood lead exposure 
(before age 2 years) 
1479 299 1180  
Sample size for Aim 3     
 Maternal acetaminophen 
metabolites 
1180 188 604 388 
 
Table 3-2 Power calculation. 
Alpha 
(α) 
Effect Size for acetaminophen 
(ψ) 
Power 





0.7385 5.44 176 957 
0.10 0.8301 5.44 176 957 
Note: The power calculation for acetaminophen (Aim 3b) is presented above. Aim 3b for 
maternal blood unchanged acetaminophen was chosen to demonstrate the power since this sub-
aim has the smallest sample size (n=1133). Due to a lack of appropriate data from other sources, 
BBC data was used for the power calculation. The mean difference in maternal unchanged 
acetaminophen levels between non-ADHD children and those with ADHD was 0.21 (inverse 
transformed intensity). The prevalence of ADHD in the BBC is 12%. Using a two-tailed alpha of 
0.05 and 0.10, detecting an effect size of 0.21, with an N2/N1 ratio of 5.44 yielded a power of ~ 
0.7385-0.8301%. 
3.2 DATA COLLECTION 
After obtaining informed consent and recruiting mothers into the BBC within a few days of 
delivery, a standard questionnaire interview was used to collect data on maternal demographics, 
smoking status, drug use, alcohol consumption, and several other variables. A medical 
abstraction form was used to review and collect clinical-related data from the maternal and 
newborn medical records, including parity, pre-pregnancy weight and height, gestational weight 
gain, pregnancy-related complications, intrauterine infection, and birth outcomes, such as 




analyzed for maternal plasma HDL, LDL, TG, and acetaminophen metabolites. ADHD diagnosis 
and early childhood blood lead levels were obtained from the EMR at every postnatal clinical 
visit since 2003.  
The study was approved by the Institutional Review Boards of the Johns Hopkins Bloomberg 
School of Public Health and Boston University Medical Center. 
3.3 MEASURES 
3.3.1 Primary outcomes 
The primary outcome of this dissertation is ADHD. ADHD cases in this study are defined by 
clinician diagnosis based on ICD codes in the EMR. Specifically, ICD-9 codes 314.0-314.9 or 
ICD-10 codes F90.0-F90.9 documented by developmental-behavioral specialists or general 
physicians in each child’s EMRs. The developmental-behavioral specialists included 
developmental-behavioral pediatricians, pediatric psychologists, pediatric neurologists, and child 
psychiatrists; general physicians were pediatricians and family medicine physicians. While there 
is a possibility of under- or misdiagnosis of ADHD, the validity of such diagnosis should be high 
in the BBC, given that most of the ADHD diagnoses in the BBC were made by developmental-
behavioral specialists (301 out of 418 ADHD diagnosis). Prescribed medications documented in 
the EMR can further verify the ADHD diagnoses.  
The ICD-9 codes have been listed in the Diagnostic and Statistical Manual of Mental Disorders 
(DSM) since 1980. The Diagnostic and Statistical Manual of Mental Disorders, 5th edition 
(DSM-5) is the latest DSM version published, on May 18, 2013, which lists both ICD-9 and 
ICD-10 codes for transitional purposes.4 Starting from October 1, 2015, all entities covered by 




Clinicians in the U.S. currently use the DSM-5 to diagnose ADHD, superseding the DSM-IV-TR 
published in 2000.4 The diagnostic criteria for ADHD in the DSM-5 are similar to those in the 
DSM-IV. For example, the same 18 symptoms are divided into two symptom domains 
(inattention and hyperactivity-impulsivity), of which at least six symptoms in each domain are 
required for diagnoses of children less than 17 years of age. However, several changes were 
made in the DSM-5: 1) criterion items now are applicable across the life span; 2) the cross-
situational requirement has been strengthened to “several” symptoms in each setting; 3) the onset 
criterion has been changed from “symptoms that caused impairment were present before age 7 
years” to “several inattentive or hyperactive-impulsive symptoms were present prior to age 12”; 
4) subtypes have been replaced with presentation specifiers that map directly to the prior 
subtypes; 5) a comorbid diagnosis of autism spectrum disorder is now allowed; and 6) a 
symptom threshold change has been made from six required symptoms to five for adults, both 
for the inattention and for the hyperactivity–impulsivity domain. Finally, ADHD is placed in the 
neurodevelopmental disorders chapter in DSM-5 to reflect brain developmental correlates with 
ADHD.4,6 Because the study population of this dissertation is younger than age 17 years, the 
transition from DSM-IV to DSM-5 is not expected to have an impact on my ADHD diagnosis 
determination.   




Table 3-3. Figure 3-1 presents the distribution of diagnosis age for the first and last ADHD 
diagnosis. Age of diagnosis information can be used for sensitivity analysis by using survival 
analysis or more stringent ADHD case criteria (such as excluding the last diagnosis age younger 





Table 3-3 List of primary outcomes. 
Name Case definition N Non-case definition N 
Any ADHD 
diagnosis 
Having at least one 
ADHD clinician 
diagnosis from any of 
the postnatal visits 
418 Not having any ADHD 
clinician diagnosis through 




Having at least one 
ADHD specialist 
diagnosis from any of 
the postnatal visits 
301 Not having any ADHD 
clinician diagnosis through 





Having at least one 
ADHD general 
physician diagnosis 
from any of the 
postnatal visits 
117 Not having any ADHD 
clinician diagnosis through 




strict case and 
non-case 
definition 
Having at least one 
ADHD specialist 
diagnosis from any of 
the postnatal visits 
301 Not having any ASD, 
ADHD, DD clinician 





Figure 3-1 The age distributions of first and last ADHD diagnosis. 
 
3.3.2 Primary exposures 
The primary exposures are listed in Table 3-4. Maternal plasma total cholesterol, HDL, LDL, 




obtained between 24 to 72 hours after delivery. Early childhood blood lead levels were obtained 
from the EMR of postnatal clinical visits.  
Table 3-4 List of primary exposures. 
Primary exposures N Distribution, median (IQR) 
Aim 1   
  Maternal total cholesterol (mg/dL) 2126 213.8 (175.6-254.1) 
  Maternal HDL (mg/dL) 2125 60.3 (49.9-72.7) 
  Maternal LDL (mg/dL) 2127 121.0 (95.9-150.4) 
  Maternal TG (mg/dL) 2124 176.7 (134.6-231.2) 
Aim 2   
  Early childhood lead (μg/dL) 2276 2 (1-3) 
Aim 3  Percentage detectable 
  Unchanged acetaminophen 1412 100% 
  Acetaminophen glucuronide 1412 62.6% 
  3-(N-Acetyl-L-cystein-S-yl) acetaminophen 1412 55.0% 
3.3.3 Other covariates 
Table 3-5 provides a list of pertinent pre- and peri-natal and child factors that could potentially 
confound the relationship between maternal cholesterol, early childhood lead, maternal 
acetaminophen and ADHD risk; these factors will be adjusted for in the multivariate models. 
Table 3-5 Pertinent pre- and peri-natal and child factors to be adjusted in the models. 
Variables  Definition Type 
Pre- and peri-natal factors   
Maternal age Maternal age at the time of enrollment Continuous 
Parity Number of previous deliveries not including index 
pregnancy - nulliparous vs. multiparous 
Binary 
Maternal education Below college degree vs. college or more Binary 
Maternal race/ethnicity Black, White, Hispanic and Other Categorical 
Smoking during pregnancy Whether mother ever smoked 3 months before 
pregnancy/during pregnancy - never, quit, 
continuous 
Categorical 
Intrauterine infection Maternal intrauterine infection during pregnancy Binary 
Child factors     
Sex Child's sex  Binary 
Delivery type C-section vs. vaginal Binary 
Gestational age Preterm (<37 weeks) vs. term delivery Binary 
Birthweight Low birthweight (<2500 g) vs. normal birthweight Binary 




3.4 DATA ANALYSIS 
3.4.1 General analytical approach 
Descriptive data analyses: The primary outcomes are binary (any ADHD diagnosis). The 
primary exposures of interest, such as maternal total cholesterol, HDL, LDL, TG (Aim 1), early 
childhood lead (Aim 2) and maternal acetaminophen metabolites (Aim 3), were analyzed as 
continuous, categorical, or binary variables. For key exposures, I first delineated their ranges and 
distributions and then determined appropriate transformations (i.e., natural logarithm 
transformation) to render the distributions approximately Gaussian as well as to stabilize the 
variance, if necessary. Group comparisons used ANOVA for continuous variables and Chi-
square or Fisher’s exact tests for categorical variables.  
Consideration of pertinent covariates: Due to different biological theories and previous 
literature findings, the selection of pertinent covariates in each aim was different. The initial 
analysis started with a saturated model, which included all the potential covariates and 
interaction terms. After that, I gradually eliminated insignificant terms with the help of model 
comparison tools such as the likelihood ratio test.  
3.4.2 Analysis for Aim 1 
Aim 1 intended to investigate the role of maternal cholesterols (total, HDL, LDL, TG), 
independently and jointly, on the development of ADHD in childhood, adjusting for pertinent 
pre- and peri-natal and childhood factors. I further investigated whether the associations differed 
by sex. I hypothesized that maternal dyslipidemia during pregnancy can increase the risk of 
ADHD in childhood and that there is a sex difference in the association.  
The relationship between maternal cholesterol biomarkers and ADHD was explored using a 




continuous variable. With the visual aid of the lowess plot, each cholesterol biomarker was 
grouped into categorical variables using both clinical cut-off points and other cut-points (e.g., 
tertiles, quintiles, quartiles).  
Generalized linear models (GLM) were used to analyze exposure-outcome associations 
systematically. GLM represent a large model class with well-established methods for model 
fitting and statistical inference.7 I chose appropriate models from the class depending on the data 
type of the outcomes. For example, I used logistic regression for a binary outcome. The logit-
transformed event probability was assumed to be a function of exposure and covariates: ln (Pr(Yi 
= ADHD)/Pr(Yi = non-ADHD))= β0 + β1Ei+ βcCi+εi  , where Yi is the outcome for subject i, Ei 
and Ci are exposures and a set of covariates for subject i, and β1 and βc are the corresponding 
regression coefficients. After accounting for confounding covariates, the exposure-outcome 
associations can be studied using a maximum likelihood estimate, hypothesis test, and 
confidence interval of β1. The odds ratio (OR) can be estimated based on exp(β1), which, for a 
common binary outcome, relative risk (RR) can be estimated as RR=OR/[(1-P0)+(P0*OR)], 
where P0=prevalence of the outcome in the unexposed group.
8  
With the help of the GLM method, a set of sequential models were executed in STATA. Below 




𝐏𝐫(𝐘𝐢 = 𝐧𝐨𝐧 − 𝐀𝐃𝐇𝐃)
) = β0 + β1Ei + βcCi + β2Ei*sex + εi 
Independent effect of HDL 
Crude     HDL       
Adjusted     HDL  covariates     
Adjusted+interaction     HDL  covariates  interaction   
Independent effect of LDL 
Crude     LDL       
Adjusted     LDL  covariates     





3.4.3 Analysis for Aim 2 
Aim 2a intended to investigate the role of early childhood lead exposure on the development of 
ADHD in childhood, adjusting for pertinent pre- and peri-natal and childhood factors. I further 
investigated whether the associations differed by sex. Aim 2b intended to investigate the 
potential protective effects of optimal maternal cholesterols in reducing the risk of ADHD 
associated with lead exposure. My hypotheses were as follows: lead exposure during early 
childhood can independently increase the risk of ADHD in childhood, and there is a sex 
difference in the association. Additionally, optimal maternal cholesterol during pregnancy can 
mitigate the adverse effect of lead on the risk of ADHD in childhood.      
The relationship between early childhood lead exposure and ADHD was explored using a lowess 
plot with and without adjustment for other covariates, with each exposure considered to be a 
continuous variable. With the visual aid of the lowess plot, lead levels were grouped into 
categorical variables using multiple cut-off points (e.g., tertiles, quintiles, quartiles).  
As described previously, the GLM was also used as the primary analytical method for Aim 2. 
The sequential analysis plan is provided below:   
Independent effect of TG 
Crude     TG       
Adjusted     TG  covariates     
Adjusted+interaction     TG  covariates  interaction   
Independent effect of total cholesterol 
Crude     total 
cholesterol 
      
Adjusted     total 
cholesterol 
 covariates     
Adjusted+interaction     total 
cholesterol 
 covariates  interaction   
Joint effect of cholesterol 
     Based on 
findings 







3.4.4 Analysis for Aim 3 
Aim 3a intended to investigate the role of maternal blood acetaminophen metabolites, 
independently and jointly, on the development of ADHD in childhood, adjusting for pertinent 
pre- and peri-natal and childhood factors. I further investigated whether the associations differed 
by sex. Aim 3b intended to investigate the potential protective effects of optimal maternal 
cholesterols in reducing the risk of ADHD associated with maternal acetaminophen exposure. 
My hypotheses were as follows: maternal acetaminophen exposure during the perinatal period 
could independently and jointly increase the risk of ADHD in childhood, and there is a sex 
difference in the association. Additionally, optimal maternal cholesterol during pregnancy can 
reduce the adverse effect of maternal acetaminophen exposure on the risk of ADHD in 
childhood.      
The relationship between each maternal acetaminophen metabolite and ADHD was explored 
using a lowess plot with and without adjustment for other covariates, with each maternal 
acetaminophen metabolite considered to be a continuous variable. Based on previous findings 
regarding the proportions of acetaminophen metabolites typically found in blood samples,9 I 
Analytical goal 𝐥𝐧⁡(
𝐏𝐫(𝐘𝐢 = 𝐀𝐃𝐇𝐃)
𝐏𝐫(𝐘𝐢 = 𝐧𝐨𝐧 − 𝐀𝐃𝐇𝐃)
) = β0 + β1Ei + βcCi + β2Ei*sex + εi 
Independent effect of early childhood lead 
Crude     early childhood lead       
Adjusted     early childhood lead  covariates     
Adjusted+interaction     early childhood lead  covariates  interaction   
Analytical goal 𝐥𝐧⁡(
𝐏𝐫(𝐘𝐢 = 𝐀𝐃𝐇𝐃)
𝐏𝐫(𝐘𝐢 = 𝐧𝐨𝐧 − 𝐀𝐃𝐇𝐃)
) = β0 + β1Ei + βcCi + β2Ei*cholesterol + εi 
Test the interaction between optimal cholesterol and lead on ADHD 
Early childhood lead* 
optimal cholesterol 
    Early 
childhood 
lead 




further calculated a variable to reflect overall “acetaminophen burden” by combining all of the 
acetaminophen metabolite levels with a weight based on their proportions in the acetaminophen 
metabolic pathway [acetaminophen burden=(unchanged acetaminophen/5%+ acetaminophen 
glucuronide/50%+ 3-(N-Acetyl-L-cystein-S-yl) acetaminophen/5%)/60%].9 With the visual aid 
of the lowess plot, each maternal acetaminophen metabolite level was grouped into categorical 
variables using multiple cut-off points (e.g., tertiles, quintiles, quartiles).  
As described previously, the GLM was also used as the primary analytical method for Aim 3. 






𝐏𝐫(𝐘𝐢 = 𝐧𝐨𝐧 − 𝐀𝐃𝐇𝐃)
) = β0 + β1Ei + βcCi + β2Ei*sex + εi 
Independent effect of unchanged acetaminophen 
Crude     unchanged 
acetaminophen 
      
Adjusted     unchanged 
acetaminophen 
 covariates     
Adjusted+interaction     unchanged 
acetaminophen 
 covariates  interaction   
Independent effect of acetaminophen glucuronide 
Crude     acetaminophen 
glucuronide 
      
Adjusted     acetaminophen 
glucuronide 
 covariates     
Adjusted+interaction     acetaminophen 
glucuronide 
 covariates  interaction   
Independent effect of 3-(N-Acetyl-L-cystein-S-yl) acetaminophen 
Crude     3-(N-Acetyl-L-cystein-
S-yl) acetaminophen 
      
Adjusted     3-(N-Acetyl-L-cystein-
S-yl) acetaminophen 
 covariates     
Adjusted+interaction     3-(N-Acetyl-L-cystein-
S-yl) acetaminophen 
 covariates  interaction   
Independent effect of acetaminophen burden 
Crude     acetaminophen burden       
Adjusted     acetaminophen burden  covariates     








𝐏𝐫(𝐘𝐢 = 𝐧𝐨𝐧 − 𝐀𝐃𝐇𝐃)
) = β0 + β1Ei + βcCi + β2Ei*cholesterol + εi 
Test the interaction between optimal cholesterol and maternal acetaminophen metabolite on ADHD 
maternal 
acetaminophen 
metabolite * optimal 
cholesterol 
    maternal 
acetaminophen 
metabolite 
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Chapter 4 AIM 1: A PROSPECTIVE BIRTH COHORT STUDY 
ON MATERNAL CHOLESTEROL LEVELS AND OFFSPRING 
ATTENTION DEFICIT HYPERACTIVITY DISORDER: NEW 
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4.1 ABSTRACT  
Growing evidence suggests that maternal cholesterol levels are important in the offspring’s brain 
growth and development. Previous studies on cholesterols and brain functions were mostly in 
adults. We sought to examine the prospective association between maternal cholesterol levels 
and the risk of attention deficit hyperactivity disorder (ADHD) in the offspring. We analyzed 
data from the Boston Birth Cohort, enrolled at birth and followed from birth up to age 15 years. 
The final analyses included 1479 mother-infant pairs: 303 children with ADHD, and 1176 
neurotypical children without clinician-diagnosed neurodevelopmental disorders. The median 
age of the first diagnosis of ADHD was seven years. The multiple logistic regression results 
showed that a low maternal high-density lipoprotein level (≤60 mg/dL) was associated with an 
increased risk of ADHD, compared to a higher maternal high-density lipoprotein level, after 
adjusting for pertinent covariables. A “J” shaped relationship was observed between triglycerides 
and ADHD risk. The associations with ADHD for maternal high-density lipoprotein and 
triglycerides were more pronounced among boys. The findings based on this predominantly 
urban low-income minority birth cohort raise a new mechanistic perspective for understanding 
the origins of ADHD and the gender differences and future targets in the prevention of ADHD. 






In the U.S., attention deficit hyperactivity disorder (ADHD) is one of the most common 
neurodevelopmental disorders in children; its prevalence has risen from 7.0% to 10.2% among 
children aged 4-17 years during the past two decades1 representing a nearly 5% increase each 
year since 2003.2  ADHD is characterized by inattention, hyperactivity, or impulsiveness,3-5 and 
is three times more common among males than females.6 Approximately 66% to 85% of children 
diagnosed with ADHD will carry their disorder into adolescence and adulthood.7,8 A 2007 
estimation of the annual cost of ADHD in the U.S., including the cost of related health care 
utilization, medication, education, crime, and unemployment, was $14500 per child ($42.5 
billion in total).9 While ADHD medications have shown to be effective in controlling ADHD 
symptoms, they neither preclude the rising incidence of ADHD nor cure ADHD, not to mention 
that they are also the causes for additional costs and potential side effects.2 Given its high 
prevalence and continuously rising trend, the impact of ADHD on individual families and society 
is expected to increase dramatically.7,9,10  
At present, our knowledge regarding the biological mechanisms of ADHD development and 
effective ways to prevent ADHD is insufficient. While research has identified several potential 
etiological mechanisms, such as gene variants, brain structural abnormalities, and 
neurotransmitter deficiency and dysregulation,11,12 much more work is needed to fully 
understand the early life determinants of ADHD and significant sex differences in ADHD risk. 
There is an urgent need to identify modifiable early life risk factors for ADHD, which are 
essential to the primary prevention efforts. Well-recognized environmental risk factors for 
ADHD include parent-related factors,13-25 low birthweight and preterm birth,26 exposure to 




multiple recent studies indicate that maternal metabolic profiles may also influence offspring’s 
neurodevelopment. For example, findings in the Boston Birth Cohort showed a strong 
association between maternal obesity and diabetes and increased risk of autism in childhood. 33 
A large longitudinal study, using prospective pregnancy cohorts from the Nordic Network, 
showed that both overweight moms and moms with excessive weight gain during gestation had 
an over 2-fold higher risk of having ADHD children. 34 However, no study has investigated the 
role of maternal dyslipidemia (a condition often associated with obesity or metabolic syndrome) 
in offspring’s ADHD development.  
Maternal cholesterol levels are biologically plausible to influence neurodevelopment in the 
offspring. 33-40 Besides cholesterol’s key functions, such as hormone synthesis, fat-soluble 
vitamin digestion and absorption, cell membrane stabilization, and inter-cellular communication, 
it is essential for normal brain development, especially during in-utero and early childhood. 
36,41,42 Nearly 70% to 80% of brain cholesterol is present in myelin. 43 While fetal cholesterol can 
be synthesized endogenously 38, the placenta also delivers cholesterol from maternal circulation 
to the fetus through multiple cholesterol-carrying lipoproteins, such as low-density lipoproteins 
(LDL), high-density lipoproteins (HDL) and very low-density lipoproteins (VLDL). 39,40 It was 
estimated that up to 20% of fetal cholesterol in the first trimester is derived from maternal 
cholesterol via the placenta. 38  
During normal pregnancy in humans, maternal blood cholesterol levels increase with gestational 
age to meet the increasing demands of fetal growth and development, especially with regards to 
the fetal brain.44-46 Conceivably, dysregulation in the amount and the type of cholesterol during 
critical developmental windows could lead to suboptimal neurodevelopment, and subsequently, 




knowledge, existing cholesterol studies in humans have mainly focused on mental health 
outcomes in adults, in which HDL levels have been found to be associated with multiple 
cognitive impairments and neurodegenerative diseases.47-49 Particularly, there is a lack of 
prospective birth cohort study to investigate the inter-generational impact of cholesterol on 
ADHD.  
To fill in the aforementioned knowledge gaps, in this study, we sought to examine the 
prospective association between maternal cholesterol levels 24-72 hours after delivery and the 
development of ADHD in the offspring using a longitudinal birth cohort design. Findings from 
such a study have important clinical and public health implications. The current clinical 
guidelines for optimal cholesterol levels have been set for non-pregnant women based on cardio-
metabolic outcomes, aiming to control cholesterol levels. However, the requirements for optimal 
nutrition, including cholesterols, are higher during pregnancy due to the increasing demands of 
the uterus, placenta, and fetal growth. Furthermore, no guidelines for cholesterol levels have 
been established for pregnant women in the context of fetal brain growth and long-term 
neurodevelopmental outcomes. 
4.3 MATERIALS AND METHODS 
4.3.1 Study Sample 
The Boston Birth Cohort (BBC) has successfully recruited mother-infant pairs at birth; the 
participation rate has been >90% among eligible mothers approached by the research staff. 
Details of the recruitment of the BBC were published previously.50,51 Eligible mothers were 
those who delivered a single live birth at Boston Medical Center (BMC). Pregnancies resulting 




or newborns with substantial congenital disabilities were not eligible for enrollment. The 
Institutional Review Board (IRB) of the Boston University Medical Center and Johns Hopkins 
Bloomberg School of Public Health approved the BBC study. Informed consent was obtained 
from each participant under the IRB approved protocol (IRB No. 00003966). 
Of enrolled mother-infant pairs at birth in the BBC, 3098 who continued to receive pediatric 
primary care at BMC were enrolled in a postnatal follow-up study.33,50,52 Our study sample 
excluded participants who had missing maternal cholesterol measurements and key covariates. 
We further excluded children with physician-diagnosed neurodevelopmental disorders other than 
ADHD (Table S1). Our final analyses consisted of 1479 mother-infant pairs, including 303 
children with ADHD and 1176 neurotypical children (Figure 4-1). The maternal and child 





Figure 4-1 Flowchart of the sample included in the analyses. 
4.3.2 Data Collection Procedures and Measures of Key Variables 
Mother-infant pairs were enrolled 24 to 72 hours after birth. After obtaining informed consent, 
face-to-face interviews using a standardized questionnaire were conducted to collect mothers’ 
reports on family socio-demographics, substance use, and other prenatal exposure information. 
The maternal and newborn medical records were extracted using a standardized abstraction form. 
Since 2003, electronic medical records (EMRs) became part of routine clinical data collection for 
the BBC, including both well-child and specialty medical visits at BMC. For each primary care 
visit, the EMRs contain the primary and secondary diagnoses from the International 
Classification of Diseases, Ninth Revision (ICD-9) (before October 1, 2015) and ICD-10 (after 
October 1, 2015). 
Maternal serum total cholesterol (TC), triglycerides (TG), and high-density lipoprotein (HDL) 




delivery. Serum low-density lipoprotein (LDL) levels were calculated using the Friedwald 
equation. The detailed measurement and calculation methods are described in our previous 
publication.53 Of note, nonfasting samples primarily impact TC and TG levels, which may be 
higher than in a fasting state. 
The “ADHD group” was defined as having any of the following clinician-diagnosed ICD-9 
codes: [314.0 (Attention deficit disorder of childhood), 314.00 (Attention deficit disorder without 
mention of hyperactivity), 314.01 (Attention deficit disorder with hyperactivity), 314.1 
(Hyperkinesis with developmental delay), 314.2 (Hyperkinetic conduct disorder), 314.8 (Other 
specified manifestations of hyperkinetic syndrome), and 314.9 (Unspecified hyperkinetic 
syndrome)], or any of the following ICD-10 codes: [F90.0 (ADHD, predominantly inattentive 
type), F90.1 (ADHD, predominantly hyperactive type), F90.2 (ADHD, combined type), F90.8 
(ADHD, other type), and F90.9 (ADHD, unspecified type)] as documented in the child’s EMRs. 
The “neurotypical (NT) group” was defined as not having any clinician diagnosis of autism 
spectrum disorder, ADHD, conduct disorders, developmental delays, intellectual disabilities, 
failure to thrive, or congenital anomalies. This definition was established by clinical experts and 
has been applied by multiple published papers. 54,55 The ICD-9 and ICD-10 codes for the 
diagnoses of these developmental disorders are listed in Table S1. 
4.3.3 Statistical Analysis 
The characteristics of the study sample between the “ADHD” and the “NT” groups were 
examined by t-test for continuous variables and χ2 test for categorical variables. TC, HDL, LDL, 
and TG were further analyzed as categorical variables based on clinically-established cut-off 
points,56,57 in addition to quartiles and the linear trend test. The clinical cut-off point for low 




mg/dL.56 The quartile cut-off points were: TC (<176 mg/dL, 176-214 mg/dL, 215-254 
mg/dL, >254 mg/dL), TG (<135 mg/dL, 135-176 mg/dL, 177-232 mg/dL, >232 mg/dL), HDL 
(<50 mg/dL, 50-60 mg/dL, 61-73 mg/dL, >73 mg/dL), and LDL (<96 mg/dL, 96-121 mg/dL, 
122-150 mg/dL, >150 mg/dL). Next, we conducted multiple logistic regression (MLR) to 
examine the association between TC, HDL, LDL, and TG and the risk of ADHD diagnosis, both 
categorically and continuously, adjusting for maternal age at delivery, maternal race/ethnicity, 
maternal education, smoking during pregnancy, intrauterine infection, parity, child's sex, mode 
of delivery, preterm birth, and birthweight. The effect of the interaction between child’s sex and 
each type of lipid or lipoprotein level on the risk of ADHD was tested using MLR and adjusted 
for the same set of covariates. Similarly, the joint effect of the child's sex with each type of lipid 
or lipoprotein on the risk of ADHD was tested using MLR and adjusted for the same set of 
covariates except for child’s sex. In the sensitivity analyses, stratified analysis by each major 
covariate was conducted for the association between maternal HDL and ADHD. Furthermore, 
we repeated the above analyses within two subsets. One subset only included specialist-
diagnosed ADHD as cases, while the other subset only included the ADHD cases whose age of 
last ADHD diagnosis was 6 years or older. All analyses were performed using STATA® version 
14.0 software (Stata Corporation, College Station, TX, USA). 
4.4 RESULTS 
There were 303 children with a clinician diagnosis of ADHD. Of these, 214 were diagnosed by a 
developmental specialist and 89 only by a general pediatrician. The median age at the first 
ADHD diagnosis was seven years. Table 4-1 presents the bivariate comparisons of maternal and 
child characteristics between the “ADHD” and “NT” groups. The mothers of children with an 




during pregnancy, C-section delivery, lower TC, lower HDL, and lower LDL, compared with the 
neurotypical group. The children with any ADHD diagnosis were more likely to be male, born 
prematurely and have had low birthweight, compared with the neurotypical group. The 
comparison results of major characteristics between excluded and included samples indicate that 
the included sample had less exposure to multiple risk factors, such as smoking during 
pregnancy, C-section delivery, lower gestational age, and lower birthweight (Table S2). 
Table 4-1 Maternal and child characteristics for children with any ADHD diagnosis and neurotypical children (NT). 
Variable Total, No. (%) NT, No. (%) ADHD, No. (%) P-valueǂ 
Total 1479 (100) 1176 (79.5) 303 (20.5)  
Maternal Age     0.317 
  <20 148 (10.0) 111 (9.4) 37 (12.2)  
  20-34 1080 (73.0) 867 (73.8) 213 (70.3)  
  >=35 251 (17.0) 198 (16.8) 53 (17.5)  
Education level     0.022 
  Below college degree 1278 (86.4) 1004 (85.4) 274 (90.4)  
  College degree or above 201 (13.6) 172 (14.6) 29 (9.6)  
Race-ethnicity     0.230 
  Black 968 (65.5) 759 (64.5) 209 (69.0)  
  White 74 (5.0) 56 (4.8) 18 (5.9)  
  Hispanic 357 (24.1) 293 (24.9) 64 (21.1)  
  Others 80 (5.4) 68 (5.8) 12 (4.0)  
Parity     0.901 
  Nulliparous 625 (42.3) 496 (42.2) 129 (42.6)  
  Multiparous 854 (57.7) 680 (57.8) 174 (57.4)  
Smoking during pregnancy    <0.001 
  Never 1229 (83.1) 998 (84.9) 231 (76.2)  
  Quitter 111 (7.5) 72 (6.1) 39 (12.9)  
  Continuous 139 (9.4) 106 (9.0) 33 (10.9)  
Intrauterine infection     0.060 
  No 1292 (87.4) 1037 (88.2) 255 (84.2)  
  Yes 187 (12.6) 139 (11.8) 48 (15.8)  
Child's sex    <0.001 
  Female 749 (50.6) 664 (56.5) 85 (28.1)  
  Male 730 (49.4) 512 (43.5) 218 (71.9)  
Delivery type     0.008 
  C-section 500 (33.8) 378 (32.1) 122 (40.3)  
  Vaginal 979 (66.2) 798 (67.9) 181 (59.7)  




  Jan to March 333 (22.5) 264 (22.5) 69 (22.8)  
  April to June 350 (23.7) 279 (23.7) 71 (23.4)  
  July to September 402 (27.2) 314 (26.7) 88 (29.0)  
  October to December 394 (26.6) 319 (27.1) 75 (24.8)  
Preterm birth (<37 weeks)     0.005 
  No 1125 (76.1) 913 (77.6) 212 (70.0)  
  Yes 354 (23.9) 263 (22.4) 91 (30.0)  
Low birthweight (<2500 g)     0.028 
  No 1148 (77.6) 927 (78.8) 221 (72.9)  
  Yes 331 (22.4) 249 (21.2) 82 (27.1)  
Gestational age, week    <0.001 
  Mean (SD) 38.1 (3.1) 38.2 (2.9) 37.5 (3.8)  
Birthweight, g     0.007 
  Mean (SD) 2996.7 (754.0) 3023.3 (716.4) 2893.5 (878.9)  
Maternal TC, mg/dL     0.018 
  Mean (SD) 219.6 (60.9) 221.5 (61.3) 212.2 (58.9)  
Maternal TG, mg/dL        0.838 
  Mean (SD) 191.9 (80.6) 192.2 (80.1) 191.1 (83.0)  
Maternal HDL, mg/dL       <0.001 
  Mean (SD) 62.0 (17.6) 62.8 (17.9) 58.8 (15.8)  
Maternal LDL, mg/dL     0.011 
  Mean (SD) 126.6 (41.8) 128.0 (42.1) 121.2 (39.9)   
NT was defined as without any mental disorder diagnosis; ADHD was defined as any ADHD diagnosis; ǂThe p-values were obtained 
from chi-square tests or t-tests between children with and without any ADHD diagnosis. 
Table 4-2 shows the MLR results for the effects of TC, HDL, LDL, and TG on the risk of any 
ADHD diagnosis, after adjusting for pertinent covariates. HDL <50 mg/dL, indicating a 
moderate risk of heart disease, was not associated with an increased risk of ADHD diagnosis 
(OR=1.30, 95% CI (0.96, 1.74)). When HDL levels were analyzed as quartiles, mothers with 
first or second quartile HDL levels showed a similarly increased odds of having a child with any 
ADHD diagnosis compared to those with fourth quartile HDL levels (Q2 vs. Q4: OR=1.42, 95% 
CI (0.96, 2.09); Q1 vs. Q4: OR=1.54, 95% CI (1.04, 2.28)). Mothers with ≤ median HDL levels 
had a 39% increased odd of having a child with any ADHD diagnosis as compared to mothers 
with > median HDL levels (OR=1.39, 95% CI (1.06, 1.82)). When HDL was analyzed as a 
continuous variable, the average odds of having a child with any ADHD diagnosis dropped 19% 








NT, No. (%) 
Crude 
OR 
95% CI P-value 
Adjusted 
OR 
95% CI P-value 
HDL clinical 
cut-off 
≥ 50 mg/dL 213 (19.2) 898 (80.8) 1.00    1.00    




55 (15.3) 304 (84.7) 1.00    1.00    
 Q3 (61-73 
mg/dL)  
67 (18.1) 304 (81.9) 1.22 0.82 1.80 0.322 1.11 0.74 1.67 0.606 
 Q2 (50-60 
mg/dL) 
91 (23.9) 290 (76.1) 1.73 1.20 2.51 0.004 1.42 0.96 2.09 0.079 
 Q1 (< 50 
mg/dL)  
90 (24.5) 278 (75.5) 1.79 1.23 2.60 0.002 1.54 1.04 2.28 0.031 
HDL binary 
> median (60 
mg/dL) 
122 (16.7) 608 (83.3) 1.00    1.00    
 ≤ median (60 
mg/dL) 
181 (24.2) 568 (75.8) 1.59 1.23 2.05 <0.001 1.39 1.06 1.82 0.016 
HDL linear trend (every 20 
mg/dL increase) 
303 (20.5) 1176 (79.5) 0.76 0.65 0.88 <0.001 0.81 0.69 0.95 0.011 
           
TG clinical cut-
off 
< 200 mg/dL 184 (19.8) 744 (80.2) 1.00    1.00    




90 (23.9) 287 (76.1) 1.00    1.00    
 Q2 (135-176 
mg/dL) 
58 (16.3) 297 (83.7) 0.62 0.43 0.90 0.012 0.63 0.43 0.93 0.020 
 Q3 (177-232 
mg/dL) 
76 (20.7) 291 (79.3) 0.83 0.59 1.18 0.300 0.88 0.61 1.27 0.495 
 Q4 (>232 
mg/dL) 
79 (20.8) 301 (79.2) 0.84 0.59 1.18 0.309 0.98 0.66 1.44 0.909 
TG binary Q2 58 (16.3) 297 (83.7) 1.00    1.00    
 Q1, Q3, Q4 245 (21.8) 879 (78.2) 1.43 1.04 1.96 0.027 1.51 1.08 2.10 0.015 
TG linear trend (every 20 
mg/dL increase) 
303 (20.5) 1176 (79.5) 1.00 0.97 1.03 0.838 1.02 0.98 1.06 0.348 




87 (23.6) 282 (76.4) 1.00    1.00    
 Q2 (96-121 
mg/dL) 
80 (21.8) 287 (78.2) 0.90 0.64 1.28 0.565 0.91 0.63 1.31 0.603 
 Q3 (122-150 
mg/dL) 
67 (18.2) 301 (81.8) 0.72 0.50 1.03 0.074 0.82 0.57 1.20 0.316 
 Q4 (>150 
mg/dL) 
69 (18.4) 306 (81.6) 0.73 0.51 1.04 0.083 0.76 0.52 1.11 0.153 
LDL linear trend (every 20 
mg/dL increase) 
303 (20.5) 1176 (79.5) 0.92 0.87 0.98 0.011 0.93 0.87 0.99 0.033 




92 (24.6) 282 (75.4) 1.00    1.00    
 Q2 (176-214 
mg/dL) 
73 (20.3) 287 (79.7) 0.78 0.55 1.10 0.161 0.82 0.57 1.18 0.289 
 Q3 215-254 
mg/dL) 
72 (19.9) 290 (80.1) 0.76 0.54 1.08 0.125 0.86 0.59 1.25 0.424 
 Q4 (>254 
mg/dL) 
66 (17.2) 317 (82.8) 0.64 0.45 0.91 0.013 0.73 0.50 1.08 0.111 
TC linear trend (every 20 
mg/dL increase) 




NT was defined as without any mental disorder diagnosis; ADHD was defined as any ADHD diagnosis; the multiple logistic 
regression model was adjusted for maternal age at delivery, maternal race/ethnicity, maternal education, smoking during pregnancy, 
intrauterine infection, parity, child's sex, mode of delivery, preterm birth, and birthweight. 
For TG, the risk of ADHD diagnosis for the children whose maternal TG levels were ≥200 
mg/dL (indicating marginal risk of heart disease) was not statistically significantly different to 
those children whose mothers with <200 mg/dL TG levels (OR=1.26, 95% CI (0.94, 1.68)). 
Compared to mothers with second quartile TG levels, the mothers with first, third or fourth 
quartile TG levels had a 51% increased odds of having a child with any ADHD diagnosis 
(OR=1.51, 95% CI (1.08, 2.10)), suggesting a “J” shaped association.  
When LDL was analyzed as a continuous variable, the average odds of having a child with any 
ADHD diagnosis dropped 7% for every 20 mg/dL increase in maternal LDL levels (OR=0.93, 
95% CI (0.87, 0.99)). The MLR results for maternal TC levels did not show any significant 
association with the child’s ADHD diagnosis.  
Table 4-3 shows the associations between maternal HDL levels and the risk of any ADHD 
diagnosis stratified by the child’s sex and the joint effect of maternal HDL levels and the child’s 
sex on ADHD risk. As expected, compared to girls, boys had 3 times higher risk of ADHD 
(OR=3.25, 95% CI (2.45, 4.30)). The joint effects of maternal HDL and sex showed that boys 
whose mothers had ≤ median HDL levels had increased odds of having any ADHD diagnosis 
(OR=4.25, 95% CI (2.88, 6.26)), compared to girls whose mothers had > median HDL levels. 
The interaction term between sex and HDL was not statistically significant (OR=1.35, 95% CI 
(0.77, 2.37)). Table S3 shows the stratified analysis results for the association between maternal 
HDL and ADHD. The results indicate that, besides child’s sex, smoking during pregnancy, 
intrauterine infection, parity, mode of delivery, gestational age, and birthweight also influence 




associated with a reduced risk of ADHD in the following stratum: boy, none smoker during 
pregnancy, no intrauterine infection during pregnancy, multiparous, vaginal delivery, full term 
and normal birth weight.  
Table S4 shows the sensitivity analysis results on the joint effect of maternal HDL and sex by 
comparing children with specialist ADHD diagnosis and neurotypical children; and the findings 
were similar. Table S6 shows the results of the sensitivity analyses on the joint effect of maternal 
HDL and sex by excluding the children whose age of last ADHD diagnosis is under 6 years old; 
and the findings were also similar.  
Table 4-3 The joint association of maternal HDL levels and child's sex with the risk of ADHD in offspring. 
Sex Maternal HDL  ADHD, No. (%) NT, No. (%) Adjusted OR 95% CI P-value 
Female  85 (11.4) 664 (88.6) 1.00    
Male  218 (29.9) 512 (70.1) 3.25 2.45 4.30 <0.001 
Joint effects of maternal HDL and sex     
Female > median 42 (10.5) 359 (89.5) 1.00    
 ≤ median 43 (12.4) 305 (87.6) 1.14 0.72 1.81 0.564 
Male > median 80 (24.3) 249 (75.7) 2.75 1.82 4.16 <0.001 
 ≤ median 138 (34.4) 263 (65.6) 4.25 2.88 6.26 <0.001 
NT was defined as without any mental disorder diagnosis; ADHD was defined as any ADHD diagnosis; covariates included 
maternal age at delivery, maternal race/ethnicity, maternal education, smoking during pregnancy, intrauterine infection, parity, 
child's sex, mode of delivery, preterm birth, and birthweight. 
Table 4-4 shows the association between maternal TG levels and the risk of any ADHD 
diagnosis, stratified by the child’s sex and the joint effect of maternal TG levels and the child’s 
sex. The joint effects results showed that boys whose mothers had first, third or fourth quartile 
TG levels had a 394% increased odd of having any ADHD diagnosis (OR=4.94, 95% CI (2.84, 
8.58)), as compared to girls whose mothers had second quartile TG levels. The interaction term 
between sex and TG was not statistically significant (OR=1.03, 95% CI (0.51, 2.07)). Table S5 
shows the results of the sensitivity analyses on the joint effect of maternal TG and sex by 




were similar. Table S7 shows the results of the sensitivity analyses on the joint effect of maternal 
TG and sex by excluding the children whose age at the last ADHD diagnosis was under 6 years 
old; and the findings were also similar. These joint effects across HDL, TG, and sex are further 
illustrated in Figure 4-2 using MLR estimation and adjusting for the same covariates. 
Table 4-4 The joint association of maternal TG levels and child's sex with the risk of ADHD in offspring. 
Sex Maternal TG ADHD, No. (%) NT, No. (%) Adjusted OR 95% CI P-value 
Female  85 (11.4) 664 (88.6) 1.00    
Male  218 (29.9) 512 (70.1) 3.31 2.50 4.39 <0.001 
Joint effects of maternal TG and sex      
Female Q2 16 (8.8) 166 (91.2) 1.00    
 Q1, Q3, Q4 69 (12.2) 498 (87.8) 1.48 0.83 2.65 0.184 
Male Q2 42 (24.3) 131 (75.7) 3.25 1.73 6.09 <0.001 
 Q1, Q3, Q4 176 (31.6) 381 (68.4) 4.94 2.84 8.58 <0.001 
NT was defined as without any mental disorder diagnosis; ADHD was defined as any ADHD diagnosis; covariates included 
maternal age at delivery, maternal race/ethnicity, maternal education, smoking during pregnancy, intrauterine infection, parity, 









Figure 4-2 (a) The odds ratio of any ADHD diagnosis across maternal HDL and child’s sex groups using multiple 
logistic regression estimation; (b) the odds ratio of any ADHD diagnosis across maternal TG and child’s sex groups 
using multiple logistic regression estimation. 
4.5 DISCUSSION 
Despite the notion that cholesterol is essential for brain health, few prospective birth cohort 
studies have examined the effect of maternal cholesterol on offspring’s neurodevelopment. In the 
Boston Birth Cohort, we found a significant association between maternal cholesterol levels, 
particularly HDL and TG measured 24-72 hours after delivery (a proxy of peripartum maternal 
cholesterol levels), and ADHD risk in offspring. Furthermore, our study sheds new light on the 
ADHD sex difference by demonstrating that boys are more vulnerable than girls to suboptimal 
maternal cholesterol levels.  
Our study findings were further strengthened by several aspects of our study design. We used 
clinician diagnosis extracted from the EMRs to define ADHD cases. More than half of the 
children in the ADHD group had over 3 ADHD clinician diagnoses in their EMRs. Additionally, 
over 80% of ADHD cases in the BBC were diagnosed by a neurodevelopmental specialist, thus, 
with much higher specificity and less probability of case misclassification. The results of our 
sensitivity analyses, which restricted ADHD cases to those with a neurobehavioral specialist 
diagnosis and excluded those with a diagnosis at an age younger than 6 years old, showed similar 
effect sizes and levels of significance as for our major findings. 
While we cannot make a causality inference, and although biological mechanisms underlying the 
maternal HDL and child ADHD association remain to be determined, our findings are 
biologically plausible and in alignment with previous research. The central nervous system 
(CNS) is insulated from the systemic circulation by the blood-brain barrier (BBB). Cholesterol 




cholesterol carried by plasma lipoproteins cannot move freely across the BBB.37,60 Most 
lipoproteins found in the brain are synthesized by glial cells and astrocytes.59 Additionally, the 
apolipoprotein B-containing lipoproteins, such as LDL, VLDL, and chylomicron cannot enter the 
brain via the BBB.59 Nevertheless, studies have suggested that plasma-based cholesterol may still 
affect the integrity and function of neurons and myelin.36,59 For instance, the discoidal 
apolipoprotein A-I-containing HDL particles may enter the brain through scavenger receptor 
class B type I (SR-BI)-mediated uptake and transcytosis.59,61 Notably, apolipoprotein A-I, which 
is the major component of plasma HDL, cannot be synthesized in the CNS.62,63 After entering the 
CNS, it can further collect phospholipids and unesterified cholesterol and undergo maturation 
into HDL-like lipoproteins in the brain.59 In addition to small plasma HDL particles, the side-
chain oxidized oxysterols, such as 27-hydroxycholesterol, can also cross the BBB.64 Moreover, 
peripheral HDL, even without crossing the BBB, may still influence fetal brain development due 
to its potential protective effect on cerebrovascular endothelial cell function.65 In sum, the 
available evidence supports our findings regarding the protective effect of higher maternal HDL 
levels against ADHD risk in offspring. 
The mechanism underlying the actions of maternal TG appears to be different from that 
underlying HDL. TG cannot cross the BBB but can influence multiple hormonal transportations 
across the BBB. For example, TG can effectively inhibit leptin transport across the BBB.66 
Besides the beneficial role in reducing obesity risk, leptin is also a multifunctional hormone that 
influences many brain functions including appetite, motivation, learning, memory, and 
cognition.67  
If further confirmed by future investigation, our findings may have important research, clinical 




relatively higher level of HDL to meet the need for rapid fetal brain development during 
pregnancy and to reduce ADHD risk; this is particularly important for male fetuses. Our data 
indicate that the current clinical cut-off point for HDL (>50 mg/dL) for nonpregnant women, as 
recommended by the American Heart Association for reducing the risk of heart disease56,57 may 
not be adequate for protecting against ADHD in offspring; thus, a higher cut-off point (>60 
mg/dL) may be needed for identifying the fetus at risk for future ADHD. Lipid screening is not 
currently part of prenatal care guidelines, but it is relatively inexpensive and easily measured. 
Low HDL is modifiable by dietary and lifestyle changes and is treatable with pharmaceuticals.  
The long-observed and striking sex difference in ADHD risk continues to be poorly understood. 
Our study revealed that the maternal HDL and TG effects on ADHD are most pronounced 
among boys. This sex differences in response to suboptimal nutritional status are also found in 
other chronic diseases. For example, both human and animal studies showed that male fetuses 
are more likely to develop hypertension in response to the mother’s unfavorable nutrition and 
metabolic status during pregnancy.68-72 One potential explanation is that male fetus is more 
vulnerable to suboptimal maternal nutrition due to their more rapid in-utero growth compared to 
females.68-72 
Our study had the following limitations. First, our study only included a single measurement of 
maternal cholesterol, taken 24-72 hours after delivery. Ideally, a serial collection of lipid levels 
throughout pregnancy would best inform our hypotheses. At best, our one-time measurement 
reflects maternal cholesterol levels during peripartum. Second, our study used non-fasting blood 
samples. The values for TC and TG levels may have been inflated in non-fasting blood samples, 
and thus may have biased our study results towards the null. Further studies using fasting blood 




pregnancy. Third, our study was conducted in a U.S. urban, low-income primarily minority 
setting; thus, this was a population at higher risk of exposure to other risk factors for ADHD. Our 
analyses adjusted for known risk factors of ADHD, but could not adjust for multiple parent-
related factors identified in previous studies such as poor parenting,13,14 maltreatment,15 
conflict/parent-child hostility,23 and severe early deprivation.24,25 Although our study sample is 
not representative of the general U.S. population, research in urban minority populations is 
limited, and our study findings help to fill in this important data gap. Finally, our adjustment for 
known risk factors did not include some post-natal factors that could be related to both maternal 
cholesterol levels and ADHD risk, such as the child’s lipid levels. Although it is beyond the 
scope of this report, a study of the joint effects of cholesterol with other components of 
metabolic syndrome such as obesity, diabetes, and hypertension, may help to provide greater 
understanding about the associations between the maternal metabolic constellation and child 
neurodevelopmental outcomes. A previously published study did show that diabetes could cause 
a low production of brain cholesterol and its precursors, which in turn could lead to disruptions 
in synaptic formation and function.73 Although our study occurred during the transition of the 
American Psychiatric Association’s Diagnostic and Statistical Manual (DSM) from the IV to the 
V edition, the diagnosis of ADHD in children did not change appreciably.74 Moreover, the DSM-
V lists both ICD-9 and ICD-10 codes for transition purposes.75   
4.6 CONCLUSIONS 
In this large, prospective, predominantly U.S. urban, low income, minority birth cohort, we 
found that suboptimal maternal cholesterol levels, in particular, low HDL, may increase the risk 
of ADHD in offspring. The male fetus appears to be particularly vulnerable to suboptimal 










4.7 SUPPLEMENTARY MATERIALS 
Table S1. ICD-9 and ICD-10 codes for the diagnosis of each neurodevelopmental disorder. 
Neurodevelopmental disorder ICD-9 codes ICD-10 codes 
ASD 299.0, 299.00, 299.01, 299.8, 
299.80, 299.81, 299.9, 299.90, 
299.91 
F84.0, F84.8, F84.9 
ADHD 314.0, 314.00, 314.01, 314.1, 
314.2, 314.8, 314.9 
F90, F90.0, F90.1, F90.2, F90.8, 
F90.9 
Disturbance of conduct 312.0-312.9 F91, F91.0, F91.2, F91.3, F91.8, 
F91.9 
Delays in development 315.0-315.9 F81.0, R48.0, F81.81, F81.2, 
F81.89, F80.1, F80.2, H93.25, 
F80.4, F80.81, F80.0, F80.82, 
F80.89, F82, F88, F81.9, F89 
Intellectual disabilities 317-317 F70, F71, F72, F73, F78, F79 
Failure to thrive 783.4, 783.40, 783.41, 783.42, 
783.43 
R62.50, R62.51, R62.0, R62.52 






Table S2. Maternal and child characteristics for participants excluded and included in the analysis. 
Variable Total, No. (%) Excluded, No. (%) Included, No. (%) P-valueǂ 
Total 3098 (100) 1619 (52.26) 1479 (47.74)  
Maternal Age    0.209 
  <20 288 (9.30) 140 (8.65) 148 (10.01)  
  20-34 2246 (72.50) 1166 (72.02) 1080 (73.02)  
  >=35 556 (17.95) 305 (18.84) 251 (16.97)  
Education level    0.844 
  Below college degree 2642 (85.28) 1364 (84.25) 1278 (86.41)  
  College degree or above 420 (13.56) 219 (13.53) 201 (13.59)  
Race ethnicity    <0.001 
  Black 1965 (63.43) 997 (61.58) 968 (65.45)  
  White 227 (7.33) 153 (9.45) 74 (5.00)  
  Hispanic 682 (22.01) 325 (20.07) 357 (24.14)  
  Others 209 (6.75) 129 (7.97) 80 (5.41)  
Smoking during pregnancy   0.045 
  Never 2496 (80.57) 1267 (78.26) 1229 (83.10)  
  Quitter 238 (7.68) 127 (7.84) 111 (7.51)  
  Continuous 330 (10.65) 191 (11.80) 139 (9.40)  
Child's sex    0.181 
  Female 1529 (49.35) 780 (48.18) 749 (50.64)  
  Male 1567 (50.58) 837 (51.70) 730 (49.36)  
Delivery type    0.008 
  C-section 1116 (36.02) 616 (38.05) 500 (33.81)  
  Vaginal 1967 (63.49) 988 (61.03) 979 (66.19)  
Season of child's birth    0.697 
  Jan to March 721 (23.27) 388 (23.97) 333 (22.52)  
  April to June 725 (23.40) 375 (23.16) 350 (23.66)  
  July to September 848 (27.37) 446 (27.55) 402 (27.18)  
  October to December 802 (25.89) 408 (25.20) 394 (26.64)  
Gestational age, week    <0.001 
  Mean (SD) 37.6(3.5) 37.2(3.8) 38.1(3.1)  
Birthweight, g    <0.001 
  Mean (SD) 2898.3(819.7) 2808.3(865.9) 2996.7(754.0)  





Table S3. The stratified analysis results on the association between maternal HDL levels (every 20 mg/dL 
increase) and the risk of ADHD in offspring.  
 
Covariates included maternal age at delivery, maternal race/ethnicity, maternal education, smoking during pregnancy, 








Table S4. The Joint association of child's gender and maternal HDL levels with the risk of any specialist ADHD 
diagnosis. 
Gender Maternal HDL Level ADHD, No. (%) NT, No. (%) OR 95% CI P-value 
Female  59 (8.16) 664 (91.84) 1.00      
Male  155 (23.24) 512 (76.76) 3.26 2.35 4.53 <0.001 
Maternal HDL effects within gender        
Female   Q4 9 (4.59) 187 (95.41) 1.00      
   Q3 19 (9.95) 172 (90.05) 2.24 0.98 5.16 0.057 
   Q2 17 (10.83) 140 (89.17) 2.59 1.10 6.09 0.029 
   Q1 14 (7.82) 165 (92.18) 1.65 0.68 3.99 0.266 
Male   Q4 29 (19.86) 117 (80.14) 1.00      
   Q3 28 (17.50) 132 (82.50) 0.80 0.44 1.46 0.474 
   Q2 48 (24.24) 150 (75.76) 1.21 0.70 2.07 0.494 
   Q1 50 (30.67) 113 (69.33) 1.65 0.95 2.86 0.073 
Joint effects of maternal HDL and gender        
Female   > median 28 (7.24) 359 (92.76) 1.00      
   ≤ median 31 (9.23) 305 (90.77) 1.24 0.72 2.12 0.440 
Male   > median 57 (18.63) 249 (81.37) 2.87 1.77 4.67 <0.001 
    ≤ median 98 (27.15) 263 (72.85) 4.44 2.81 7.02 <0.001 
NT was defined as free of any mental disorder diagnosis; ADHD was defined as any specialist ADHD diagnosis; 
covariates included maternal age at delivery, maternal race/ethnicity, maternal education, smoking during pregnancy, 





Table S5. The Joint association of child's gender and maternal TG levels with the risk of any specialist 
ADHD diagnosis. 
Gender Maternal TG Level ADHD, No.(%) NT, No.(%) OR 95% CI P-value 
Female  59 (8.16) 664 (91.84) 1.00      
Male  155 (23.24) 512 (76.76) 3.31 2.39 4.59 <0.001 
Maternal TG effects within gender        
Female   Q1 14 (8.05) 160 (91.95) 1.24 0.55 2.77 0.605 
   Q2 13 (7.26) 166 (92.74) 1.00      
   Q3 13 (7.30) 165 (92.70) 1.01 0.45 2.27 0.984 
   Q4 19 (9.90) 173 (90.10) 1.50 0.68 3.31 0.310 
Male   Q1 45 (26.16) 127 (73.84) 1.54 0.90 2.65 0.116 
   Q2 30 (18.63) 131 (81.37) 1.00      
   Q3 40 (24.10) 126 (75.90) 1.39 0.80 2.42 0.242 
   Q4 40 (23.81) 128 (76.19) 1.40 0.79 2.49 0.245 
Joint effects of maternal TG and gender        
Female   Q2 13 (7.26) 166 (92.74) 1.00      
   Q1, Q3, Q4 46 (8.46) 498 (91.54) 1.17 0.61 2.24 0.631 
Male   Q2 30 (18.63) 131 (81.37) 2.87 1.43 5.76 0.003 
    Q1, Q3, Q4 125 (24.70) 381 (75.30) 4.04 2.20 7.41 <0.001 
NT was defined as free of any mental disorder diagnosis; ADHD was defined as any specialist ADHD diagnosis; 
covariates included maternal age at delivery, maternal race/ethnicity, maternal education, smoking during pregnancy, 





Table S6. The Joint association of child's gender and maternal HDL levels with the risk of any ADHD 
diagnosis (last diagnosis older than 6 years old). 
Gender Maternal HDL Level ADHD, No.(%) NT, No.(%) OR 95% CI P-value 
Female  51 (7.13) 664 (92.87) 1.00      
Male  132 (20.50) 512 (79.50) 3.22 2.27 4.57 <0.001 
Maternal HDL effects within gender        
Female   Q4 8 (4.10) 187 (95.90) 1.00      
   Q3 17 (8.99) 172 (91.01) 2.19 0.91 5.27 0.081 
   Q2 14 (9.09) 140 (90.91) 2.30 0.92 5.76 0.075 
   Q1 12 (6.78) 165 (93.22) 1.49 0.58 3.83 0.411 
Male   Q4 23 (16.43) 117 (83.57) 1.00      
   Q3 24 (15.38) 132 (84.62) 0.85 0.44 1.61 0.612 
   Q2 40 (21.05) 150 (78.95) 1.23 0.68 2.20 0.492 
   Q1 45 (28.48) 113 (71.52) 1.83 1.02 3.31 0.043 
Joint effects of maternal HDL and gender        
Female   > median 25 (6.51) 359 (93.49) 1.00      
   ≤ median 26 (7.85) 305 (92.15) 1.14 0.64 2.03 0.662 
Male   > median 47 (15.88) 249 (84.12) 2.63 1.57 4.41 <0.001 
    ≤ median 85 (24.43) 263 (75.57) 4.26 2.63 6.90 <0.001 
NT was defined as free of any mental disorder diagnosis; ADHD was defined as any ADHD diagnosis; covariates 
included maternal age at delivery, maternal race/ethnicity, maternal education, smoking during pregnancy, intrauterine 





Table S7. The Joint association of child's gender and maternal TG levels with the risk of any ADHD 
diagnosis (last diagnosis older than 6 years old). 
Gender Maternal TG Level ADHD, No.(%) NT, No.(%) OR 95% CI P-value 
Female  51 (7.13) 664 (92.87) 1.00      
Male  132 (20.50) 512 (79.50) 3.25 2.30 4.61 <0.001 
Maternal TG effects within gender        
Female   Q1 12 (6.98) 160 (93.02) 1.16 0.49 2.74 0.727 
   Q2 12 (6.74) 166 (93.26) 1.00      
   Q3 11 (6.25) 165 (93.75) 0.90 0.38 2.14 0.817 
   Q4 16 (8.47) 173 (91.53) 1.29 0.56 2.98 0.546 
Male   Q1 40 (23.95) 127 (76.05) 1.71 0.96 3.05 0.070 
   Q2 24 (15.48) 131 (84.52) 1.00      
   Q3 31 (19.75) 126 (80.25) 1.32 0.72 2.43 0.371 
   Q4 37 (22.42) 128 (77.58) 1.58 0.85 2.91 0.146 
Joint effects of maternal TG and gender        
Female   Q2 12 (6.74) 166 (93.26) 1.00      
   Q1, Q3, Q4 39 (7.26) 498 (92.74) 1.05 0.53 2.07 0.892 
Male   Q2 24 (15.48) 131 (84.52) 2.48 1.18 5.20 0.016 
    Q1, Q3, Q4 108 (22.09) 381 (77.91) 3.68 1.95 6.93 <0.001 
NT was defined as free of any mental disorder diagnosis; ADHD was defined as any ADHD diagnosis; covariates 
included maternal age at delivery, maternal race/ethnicity, maternal education, smoking during pregnancy, intrauterine 
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Objective: To investigate the prospective associations between early childhood lead exposure 
and subsequent risk of ADHD in childhood and its potential effect modifiers.  
Study design: We analyzed data from 1479 mother-infant pairs (299 ADHD, 1180 neurotypical) 
in the Boston Birth Cohort (BBC). The child’s first blood lead measurement and physician-
diagnosed ADHD was obtained from electronic medical records. Graphic plots and multiple 
logistic regression were employed to examine dose-response association between lead exposure 
and ADHD and potential effect modifiers, adjusting for pertinent covariables. 
Results: Our findings show that 8.9% of BBC children had elevated lead levels (5-10µg/dL) in 
early childhood, which was associated with a 66% increased risk of ADHD (OR=1.66, 
95%CI:1.08, 2.56). Among boys, the association was significantly stronger (OR: 2.49, 
95%CI:1.46, 4.26); in girls, the association was largely attenuated (p-value for sex-lead 
interaction: 0.017). The odds ratio of ADHD associated with elevated lead levels among boys 
was reduced by half if mothers had adequate high-density lipoprotein (HDL) levels compared to 
low HDL, or if mothers had low stress compared to high stress during pregnancy. 
Conclusions: Elevated early childhood blood lead levels increased the risk of ADHD. Boys were 
more vulnerable than girls at a given lead level. This risk of ADHD in boys was reduced by half 
if the mother had adequate HDL levels or low stress. These findings shed new light on the sex 
difference in ADHD and point to opportunities for early risk assessment and primary prevention 





Lead is a recognized environmental toxin.1-5 Since the removal of lead from paints and gasoline 
and the adoption of other environmental safety measures, environmental lead exposure has 
declined significantly over the past decades.6 However, exposure to low lead levels continues to 
be widespread in the general U.S. population, particularly in urban low-income populations.7  
To date, critical questions remain regarding the role of early life lead exposure in the 
development of ADHD.8-10 There are multiple drawbacks in the existing studies. First, they used 
cross-sectional designs.2,3,5 Lead measurement occurred either simultaneous to or after the 
ADHD diagnosis, thus the temporal relationship between lead exposure and ADHD could not be 
established. Second, despite the well-observed higher likelihood of ADHD in males compared to 
females, few studies have investigated if lead affects boys and girls differently.2 Additionally, 
most studies on ADHD only have examined lead exposure late in childhood (mean age of 
measurement ranging from 7 to 14 years).10 Lastly, prior studies did not consider potential 
modifiers of the lead-ADHD association, which is necessary both in terms of understanding the 
etiology of ADHD and informing intervention strategies. 11  
In this study, we sought to examine the association between early childhood lead exposure and 
development of ADHD using a prospective birth cohort design. We were particularly interested 
in identifying early life factors that could modify lead-ADHD associations in a predominantly 
urban low-income minority population in the U.S. We hypothesized that there is a significant 
association between early childhood blood lead levels and the risk of developing ADHD. 
Motivated by findings from our previous work, we further hypothesized that this association 
might be modified by prenatal factors, including child sex, maternal high-density lipoprotein 





This study used data from the Boston Birth Cohort (BBC), which recruited mother-infant pairs at 
birth from Boston Medical Center (BMC) since 1998, using a rolling enrollment. Details of the 
BBC recruitment have been published previously.13,14 Eligible mothers delivered a single live 
birth at Boston Medical Center (BMC). Pregnancies resulting from in vitro fertilization, 
multiple-gestation pregnancies, deliveries induced by maternal trauma, or newborns with 
substantial congenital disabilities were not eligible for enrollment. BBC mother-infant pairs who 
continued to receive pediatric primary care at BMC were enrolled in a postnatal follow-up 
study.13,15,16 The Institutional Review Board (IRB) of Boston University Medical Center and the 
IRB of Johns Hopkins Bloomberg School of Public Health approved the BBC study. Informed 
consent was obtained from each participant under the IRB approved protocol. 
There were 3098 mother-infant pairs enrolled in the postnatal follow-up study at BMC at the 
time of the study. Our study sample excluded participants who had missing data for lead 
measurements and key covariates. We further excluded those with lead measurement after 
ADHD diagnosis, incorrect lead measurement dates, lead measurement age older than 4 years, 
and a lead level higher than 10 µg/dL (to focus on the effects in the low lead exposure range). 
Since many neurodevelopmental disorders may have common risk factors, we excluded those 
with neurodevelopmental disorders diagnoses other than ADHD (Figure 5-1). Our final analyses 
consisted of 1479 mother-infant pairs, who were enrolled at birth from 1998 to 2013 and 
followed-up prospectively until the end of 2016 (Figure 5-1). Additionally, these mother-infant 
pairs consisted of 299 children with ADHD and 1176 neurotypical children (Figure 5-1).  
After recruiting mothers within 24 to 72 hours after delivery, a standard questionnaire interview 




during pregnancy. Stress during pregnancy was defined according to the response to the 
following question: “How would you characterize the amount of stress in your life during 
pregnancy?” The responses to the question included: “not stressful,” “average stressful,” and 
“very stressful.” A medical abstraction form was used to review participants’ medical records 
and collect clinical-related data including parity, pregnancy-related complications, intrauterine 
infection, and birth outcomes such as gestational age and birthweight. Since 2003, electronic 
medical records (EMRs) were implemented for routine clinical data collection at BMC, 
including both well-child and specialty medical visits. For each primary care visit, the EMRs 
contain the primary and secondary diagnoses from the International Classification of Diseases, 
Ninth Revision (ICD-9) (before October 1, 2015) and ICD-10 (after October 1, 2015). In this 
study, we extracted EMR data until the end of 2016. 
Maternal plasma HDL levels and lead levels in red blood cells were measured using non-fasting 
blood samples obtained between 24 to 72 hours after delivery. The child postnatal screening 
records of blood lead levels were obtained from the EMRs. The low detection limit of lead was 2 
µg/dL; 659 children had blood lead levels below this threshold. The below threshold lead level 
was coded as 1 µg/dL when lead was analyzed as a continuous variable. For each child with 
repeated measurements of lead levels, the level measured at the earliest age was selected for 
analysis in this study. 
In our study, the “ADHD” was defined as having any of the following ICD-9 codes: [314.0, 
314.00, 314.01, 314.1, 314.2, 314.8, and 314.9], or any of the following ICD-10 codes: [F90.0, 
F90.1, F90.2, F90.8, and F90.9] as documented in the child’s EMRs. The “neurotypical (NT)” 
was defined as not having any diagnosis of ASD, ADHD, conduct disorders, developmental 




ICD-10 codes for these neurodevelopmental disorders diagnosis are listed in 
 
Figure 5-6 online. Conceptual framework for the prospective association of early childhood lead 







The characteristics of the study sample for the ADHD and the NT groups were compared using t-
tests for continuous variables and χ2 tests for categorical variables. Variables with a p < 0.05 
were included in the subsequent multivariate logistic regression (MLR) analyses as covariates. 
The key predictor analyzed in this study was the child’s lead level, which was natural log-
transformed to approximate the normal distribution. Lead level was also analyzed as a binary (5 
µg/dL as the cutoff) and categorical variable (<2 µg/dL, 2-4 µg/dL, and 5-10 µg/dL) based on 
cut points used in previous studies and CDC guidelines.2,8 Maternal HDL levels were analyzed 
as a binary variable cut at the median (60.7 mg/dL).12 Maternal stress during pregnancy was 
converted from a three-category variable (not stressful, average, very stressful) into a binary 
variable (not stressful vs. stressful) for analysis.17 
We conducted multiple logistic regression (MLR) to examine the association between early 
childhood lead level and the risk of having ADHD, both categorically and continuously, 
adjusting for maternal age at delivery, maternal race/ethnicity, maternal education, smoking 
during pregnancy, intrauterine infection, parity, child's sex, mode of delivery, preterm birth, and 
birthweight. Gender-stratified analyses and the joint effect of the child's sex with lead levels on 
the risk of ADHD diagnosis were tested using MLR, and adjusted for the same covariates except 
for child’s sex. The interaction between child’s sex and lead level on the risk of ADHD was then 
tested using MLR and adding the interaction term into the model while adjusting for the same 
covariates. We further tested the joint associations among maternal HDL level, maternal stress 
during pregnancy, and early childhood lead level with the risk of ADHD diagnosis both across 
and within the child’s sex groups, adjusting for the same covariates except for child’s sex. For 




not exclude the samples with other neurodevelopmental disorders. One analysis included the 
samples with early childhood lead levels measured at age ≤ 2 years. The other analysis further 
adjusted for maternal lead levels (treated as a binary variable cut at 5 µg/dL) measured right after 
delivery, using the samples that had measurements for both maternal and early childhood lead 
levels. All analyses were performed using STATA® version 14.0 software (Stata Corporation, 
College Station, TX, USA).  
5.4 RESULTS 
Data from 1,479 mother-child pairs were analyzed in this study. The median age of the study 
children by our latest EMR extraction date (31 December 2016) was 9.6 years (inter-quartile 
range 7.4 to 12.5 years). Among them, 299 children (13.9% (before removing children with 
neurodevelopmental disorders diagnoses other than ADHD)) had a physician diagnosis of 
ADHD, and 131 children (8.9%) had lead levels of 5-10 µg/dL; 9.4% in boys and 8.3% in girls. 
The median age of the first diagnosis of ADHD was six years. The median age of the first lead 
measurement was 0.84 years (inter-quartile range 0.77 to 1.03 years). The comparison results of 
major characteristics between excluded and included samples indicate that the included sample 
had less exposure to multiple risk factors, such as less educational attainment, shorter gestational 
age, and lower birthweight (Table 5-2). Table 5-3 presents the bivariate comparisons of maternal 
and child characteristics between the “ADHD” and “NT” groups. Mothers of children with any 
ADHD diagnosis were more likely to have less than a college degree, ever smoked before or 
during pregnancy, delivered with a C-section, had high stress during pregnancy, and low HDL 
compared with the NT group. Children with an ADHD diagnosis were more likely to be male, 




Table 5-4 shows the results for both the crude and adjusted associations of early childhood lead 
levels with the risk of ADHD diagnosis. When lead levels were analyzed as three categories, 
compared to those with < 2 µg/dL lead levels, the adjusted OR for children with 2-4 µg/dL and 
5-10 µg/dL lead levels was 1.08, 95% CI (0.81, 1.44)) and 1.73, 95% CI (1.09, 2.73), 
respectively. The natural log-transformed linear trend of lead levels was significantly associated 
with an increased risk of ADHD diagnosis (adjusted OR=1.25, 95% CI (1.01, 1.56)). When lead 
was analyzed as a binary variable, children with 5-10 µg/dL lead levels had 66% increased odds 
of having any ADHD diagnosis as compared to children with < 5 µg/dL lead levels (adjusted 
OR=1.66, 95% CI (1.08, 2.56)). A test of interaction between sex and lead level (binary) was 
statistically significant (p-value for interaction was 0.017), which was further explored as 
described below. 
Figure 5-2 shows that the crude percentage of ADHD diagnosis was higher among boys 
compared to girls within each lead exposure level. Figure 5-3 (Lowess plot) shows a positive 
linear trend with the risk of ADHD diagnosis among boys, while the trend was flat among girls. 
Table 5-5 shows the adjusted associations between child’s lead levels and the risk of any ADHD 
diagnosis stratified by the child’s sex and the joint effect of child’s lead levels and the child’s sex 
on ADHD risk. When simultaneously considering child sex and lead levels, boys with 5-10 
µg/dL lead levels had 648% increased odds of having any ADHD diagnosis (adjusted OR=7.48, 
95% CI (4.29, 13.02)), compared to girls with < 5 µg/dL lead levels. Table 5-6 shows the results 
of the sensitivity analyses on the joint effects of early childhood lead exposure on ADHD 
diagnosis comparing to no ADHD group; and the findings were similar to those shown in Table 
5-5. Table 5-7 shows the results of the sensitivity analyses on the joint effects of early childhood 




the findings were similar. Table 5-8 shows the results of the sensitivity analyses on the joint 
effects of early childhood lead exposure by further adjusting for maternal lead measurements 
right after delivery; and the findings were also similar. Figure 5-4 displays the crude relationship 
between maternal lead and early childhood lead levels, which do not show correlation. 
Table 5-9 shows the joint association of child's sex, maternal HDL level, maternal stress during 
pregnancy, and early childhood lead measurement with the risk of ADHD diagnosis. Compared 
to girls with low lead levels (< 5 µg/dL) and adequate maternal HDL levels (> 60.7 mg/dL), boys 
with high lead levels and lower maternal HDL levels had 903% increased odds of having any 
ADHD diagnosis (OR=10.03, 95% CI (4.38, 22.97)). This increased risk was reduced by more 
than half if the mother had adequate maternal HDL levels (OR=4.77, 95% CI (1.76, 12.90)).  
Similarly, boys with high lead levels and high maternal stress during pregnancy had 1394% 
increased odds of having any ADHD diagnosis, compared to girls with low lead levels and low 
maternal stress (OR=14.94, 95% CI (6.88, 32.41)). This increased risk was reduced by more than 
half if the mother had low maternal stress during pregnancy (OR=6.10, 95% CI (2.18, 17.08)). 
Figure 5-5 shows the percentage of ADHD diagnosis by maternal HDL level, maternal stress 
during pregnancy, and early childhood lead measurement groups among boys. The within sex 
group comparison together with the findings shown in Figure 5-5 also indicate that the risk of 
ADHD diagnosis was lower for those born to mothers with adequate maternal HDL and low 
maternal stress during pregnancy given the same level of lead exposures for boys. 
Table 5-10 and Table 5-11 show the additional sensitivity analyses to examine the independent 
and joint effect of gestational age and birthweight with early childhood lead exposure on ADHD. 
There was no indication of interaction between early childhood lead exposures and gestational 





To our knowledge, this is the first large prospective birth cohort study to demonstrate a positive 
association between early childhood lead exposure and risk of developing ADHD in a U.S. 
predominantly urban, low-income minority cohort. Our findings are consistent with previous 
research regarding the effects of lead exposure on the risk of ADHD, although existing data were 
mostly cross-sectional in design.10 Our study has contributed the following new information to 
the field.  
We revealed a significant sex difference in the association between lead exposure and the risk of 
ADHD. When we stratified the MLR analysis by sex, we found no significant association 
between elevated lead levels (5-10 μg/dL) and ADHD among girls, but a strong association with 
ADHD among boys. This finding cannot be explained by a sex difference in lead exposure. In 
fact, the lead level distribution was similar between girls and boys: the percentages of elevated 
lead levels (5-10 μg/dL) were 8.3% and 9.4% for girls and boys, respectively, which is consistent 
with previous studies, indicating that there is no sex difference in blood lead levels among young 
children.18,19 Moreover, a small prospective study (n=195) also found similar boy-specific lead 
effects, which revealed that both prenatal and childhood average lead levels (<78 months) were 
associated with attention factor of neuropsychological measures only within boys.20 Taken 
together, the findings from previous studies and ours suggest that boys are more vulnerable than 
girls to the adverse effects of early life low level lead exposures. 
In the context of early childhood lead exposure and ADHD in boys, we identified several 
potential protective factors that may attenuate the lead-ADHD association. We found that high 
maternal HDL levels and low maternal stress during pregnancy could partially counteract the 




subgroups with sample sizes that were too small, our findings showed that high maternal HDL 
levels and low maternal stress during pregnancy could reduce the odds of ADHD by more than 
half compared to their counterparts. Conversely, boys born to mothers with low HDL and high 
stress during pregnancy were more vulnerable to the adverse effects of lead exposure on the risk 
of ADHD, given their level of lead exposure.  
Within a subset of samples with both early childhood and maternal blood lead levels measured at 
delivery, we further explored if the association we identified could be altered if we further 
adjusted for maternal lead levels. We found that the sex-specific relationship between the early 
childhood lead level and the risk of ADHD remained even after adjusting for maternal lead 
levels. Furthermore, we found no significant correlation between maternal lead levels and early 
childhood lead levels. This finding is consistent with the correlation results reported in a 
previous study, which measured the lead levels of nearly 100 mother-child pairs from 
Montevideo, Uruguay.21  
Although lead exposure in children has declined in the U.S. since the ban of leaded gasoline,9 
lead exposure has remained a significant risk factor for certain segments of children for two 
major reasons. First, accumulating evidence has revealed that even low-level lead exposures still 
have adverse effects on neurodevelopment. As a result, the identified blood lead level of concern 
for the fetus or young child has been revised many times from 40 µg/dL to the current CDC 
guidelines which specify that there is no safe level of exposure.6,9,22-24 Indeed, more recent  
research lends even further support for the CDC guidelines that there is no threshold for the 
adverse health effects of lead exposure.8,9  
Second, while any exposure is considered unsafe, there still are profound disparities in who is 




concentration was much higher in urban areas because of more potential lead sources based 
there, such as road networks and industries.25 Related to this, low-income and racial/ethnic 
minority individuals, including children aged younger than 6 years, have a much higher risk of 
lead exposure because they are the ones who tend to live in these urban areas and in 
neighborhoods that are closer to these lead sources.25 Additionally, children are more 
biologically susceptible to the toxic effects of lead compared to adults due to their much higher 
gastrointestinal bioaccessibility to lead.26 In the BBC, about 9% of children had blood lead levels 
above 5 µg/dL. Consistently, many other studies have also found that low-income minority 
populations are more likely to live in highly lead-contaminated areas and have higher median 
blood lead concentrations, particularly among children.25,27-29 Thirdly, our data suggest that 
urban low-income populations may be more vulnerable to lead toxicity due to other risk factors 
including maternal dyslipidemia and high stress, as we demonstrated in this study. As such, lead 
remains a significant public health concern, especially for poor pregnant mothers and their 
children living in lead-contaminated areas. 
The exact neurotoxicological pathways by which lead exposure affects ADHD risk remain 
unclear. Current biological studies suggest that lead disrupts the hippocampal region of the brain 
through interaction with the N-methyl-D-aspartate receptor both synaptically and extra-
synaptically.30 The lead-induced damage in the developing brain preferentially occurs in the 
prefrontal cortex (PFC), hippocampus, and cerebellum,31-33 and not surprisingly the brains of 
individuals with ADHD also show a reduction in the volume and activity of the PFC and 
cerebellum.34 The neurotoxicity induced by lead depends on both age35 and lead exposure 
level.36 Compared to adults, children not only absorb more lead, but they do so directly into the 




barrier.37,38 Moreover, the fetus is also at a high risk of lead exposure via transplacental transfer 
during pregnancy, which is a particularly sensitive period for fetal central nervous system 
development.39,40 
The striking sex difference in ADHD is well-observed but poorly understood. An animal study 
showed that lead toxicity behaves differently in males and females.41 After treating with lead 
acetate, female rabbits showed an earlier and higher increase in Zn protoporphyrin (a screening 
marker for lead poisoning42) than males.41 However, to date, no study has explained the 
biological mechanism behind male dominance in ADHD and sex differences in lead 
neurotoxicity in humans. Some have postulated that the sex difference in the lead-ADHD 
association might be explained by the sex difference in lead metabolism.43,44 Over 90% of lead is 
stored in bone with an average of a 10 year half-life.43 A study on occupational lead exposure 
showed that  the rate of bone lead release for women is slower than it is for men.44 Moreover, a 
study of Swedish twins showed that the genetic factors related to lead uptake and storage explain 
nearly 60% of the blood lead levels among nonsmoking women. In contrast, nonsmoking men’s 
blood lead levels mainly reflect environmental exposures. One study identified three 
polymorphic genes that influence lead accumulation and toxicokinetics.45 These genes are 
responsible for encoding enzyme delta-aminolevulinic acid dehydratase (ALAD), the vitamin D 
receptor (VDR), and the human hemochromatosis (HFE) protein.45 It is possible that the weak 
association between blood lead levels and risk of ADHD among girls might be due to a sex 
difference in the frequency and expression of these genes.46 
Our study had several limitations. First, the early childhood blood lead measurements obtained 
during routine pediatric screening could not precisely assess the very lowest lead exposures due 




between lead levels below 2 μg/dL and ADHD.2 Second, the EMR data used in our study (2003-
2016) spanned the transition of the diagnostic and statistical manual (DSM) from the DSM-IV-
TR to the DSM-V edition.47 However, this transition did not affect our ADHD determination48 in 
children, since the main changes from DSM-IV-TR to DSM-V were more relevant to the adult 
diagnostic criteria. Third, missing information on lead levels and major covariates can cause 
selection bias if the missing is not at random. However, we compared children with and without 
lead measurements and did not find a systematic difference among major covariates. Lastly, 
although we adjusted for multiple major risk factors identified in previous studies, data related to 
multiple family-related factors such as poor parenting,49,50 maltreatment,51 conflict/parent-child 
hostility,52 and severe early deprivation53,54 were not available in BBC. Thus, we could not 
wholly eliminate potential residual confounding in this study. However, those factors are less 
likely to share the same biological mechanism in their effect on neurodevelopment. Thus, would 
not anticipate any impact on the association between early childhood lead and risk of ADHD 
even if it was possible to adjust for those factors. 
5.6 CONCLUSIONS 
In this urban, low income, high-risk minority birth cohort, we found that about 9% of children 
had elevated early childhood blood lead levels (5-10 µg/dL), and that these moderately elevated 
levels were associated with an increased risk of ADHD in childhood, in particular, among boys. 
As illustrated in Figure 6, while early childhood lead levels are our primary exposure of interest, 
multiple pre-, peri- and post-natal risk factors of ADHD, such as child’s sex, maternal HDL, and 
maternal stress during pregnancy could also affect the risk of ADHD either in the context of risk 
factors, effect modifiers or confounders (Figure 6; online).  In our study population, boys were at 




analysis suggested that maternal factors could alter this risk. For example, the risk could be 
reduced by more than half if the mother had adequate HDL levels or had low stress during 
pregnancy. These findings shed new light on the sex difference seen in ADHD and its effect 
modifiers, and, if confirmed, may offer new opportunities for early risk assessment and primary 




5.7 TABLE AND FIGURES 
 






Figure 5-2 The percentage of ADHD diagnosis in the BBC children, stratified by child's sex and early childhood 



















Figure 5-5 online. The percentage of ADHD diagnosis within maternal HDL level (top), maternal stress during 





Figure 5-6 online. Conceptual framework for the prospective association of early childhood lead exposure and 






Table 5-1 online. List of ICD-9 and ICD-10 codes for the diagnosis of each neurodevelopmental disorder. 
Neurodevelopmental disorder ICD-9 codes ICD-10 codes 
ASD 299.0, 299.00, 299.01, 
299.8, 299.80, 299.81, 
299.9, 299.90, 299.91 
F84.0, F84.8, F84.9 
ADHD 314.0, 314.00, 314.01, 
314.1, 314.2, 314.8, 314.9 
F90, F90.0, F90.1, F90.2, 
F90.8, F90.9 
Disturbance of conduct 312.0-312.9 F91, F91.0, F91.2, F91.3, 
F91.8, F91.9 
Delays in development 315.0-315.9 F81.0, R48.0, F81.81, 
F81.2, F81.89, F80.1, 
F80.2, H93.25, F80.4, 
F80.81, F80.0, F80.82, 
F80.89, F82, F88, F81.9, 
F89 
Intellectual disabilities 317-317 F70, F71, F72, F73, F78, 
F79 
Failure to thrive 783.4, 783.40, 783.41, 
783.42, 783.43 
R62.50, R62.51, R62.0, 
R62.52 






Table 5-2 online. Maternal and child characteristics for participants excluded and included in the analysis. 
Variable Total Excluded Included P-valuea 
Total 3098 (100) 1619 (52.26) 1479 (47.74)  
Maternal Age (years, n (%))    0.106 
  <20 288 (9.30) 138 (8.52) 150 (10.14)  
  20-34 2246 (72.50) 1165 (71.96) 1081 (73.09)  
  >=35 556 (17.95) 308 (19.02) 248 (16.77)  
Education level, n (%)    <0.001 
  Below college degree 2642 (85.28) 1401 (86.53) 1241 (83.91)  
  College degree or above 420 (13.56) 182 (11.24) 238 (16.09)  
Maternal race, n (%)    <0.001 
  Black 1965 (63.43) 940 (58.06) 1025 (69.30)  
  White 227 (7.33) 115 (7.10) 112 (7.57)  
  Hispanic 682 (22.01) 448 (27.67) 234 (15.82)  
  Others 209 (6.75) 101 (6.24) 108 (7.30)  
Smoking during pregnancy, 
n (%) 
   0.412 
  Never 2496 (80.57) 1277 (78.88) 1219 (82.42)  
  Quitter 238 (7.68) 128 (7.91) 110 (7.44)  
  Continuous 330 (10.65) 180 (11.12) 150 (10.14)  
Child's sex, n (%)    0.008 
  Female 1529 (49.35) 762 (47.07) 767 (51.86)  
  Male 1567 (50.58) 855 (52.81) 712 (48.14)  
Delivery type, n (%)    0.057 
  C-section 1116 (36.02) 606 (37.43) 510 (34.48)  
  Vaginal 1967 (63.49) 998 (61.64) 969 (65.52)  
Gestational age, week    <0.001 
  Mean ± SD 37.6 ± 3.5 37.1 ± 3.9 38.2 ± 3.0  
Birthweight, g    <0.001 
  Mean ± SD 2898.3 ±819.7 2794.7 ±881.7 3011.6 ± 729.5  
Note: aThe p-values were obtained from chi-square test or t-test between children included and 






Table 5-3 Maternal and child characteristics for children with any ADHD diagnosis (ADHD) and neurotypical (NT) 
children. 
Variable Total NT ADHD 
P-
valuea 
Total 1,479 (100) 1,180 (79.78) 299 (20.22)  
Maternal Age (years, n (%))    0.094 
  <20 150 (10.14) 110 (9.32) 40 (13.38)  
  20-34 1,081 (73.09) 874 (74.07) 207 (69.23)  
  >=35 248 (16.77) 196 (16.61) 52 (17.39)  
Education level, n (%)    0.033 
  Below college degree 1,241 (83.91) 978 (82.88) 263 (87.96)  
  College degree or above 238 (16.09) 202 (17.12) 36 (12.04)  
Maternal race, n (%)    0.137 
  Black 1025 (69.30) 811 (68.73) 214 (71.57)  
  White 112 (7.57) 96 (8.14) 16 (5.35)  
  Hispanic 234 (15.82) 181 (15.34) 53 (17.73)  
  Others 108 (7.30) 92 (7.80) 16 (5.35)  
Parity, n (%)    0.715 
  Nulliparous 649 (43.88) 515 (43.64) 134 (44.82)  
  Multiparous 830 (56.12) 665 (56.36) 165 (55.18)  
Smoking during pregnancy, 
n (%) 
   <0.001 
  Never 1219 (82.42) 995 (84.32) 224 (74.92)  
  Quitter 110 (7.44) 71 (6.02) 39 (13.04)  
  Continuous 150 (10.14) 114 (9.66) 36 (12.04)  
Intrauterine infection, n (%)    0.073 
  No 1283 (86.75) 1033 (87.54) 250 (83.61)  
  Yes 196 (13.25) 147 (12.46) 49 (16.39)  
Child's sex, n (%)    <0.001 
  Female 767 (51.86) 681 (57.71) 86 (28.76)  
  Male 712 (48.14) 499 (42.29) 213 (71.24)  
Delivery type, n (%)    0.021 
  C-section 510 (34.48) 390 (33.05) 120 (40.13)  
  Vaginal 969 (65.52) 790 (66.95) 179 (59.87)  
Season of child's birth, n 
(%) 
   0.077 
  Jan to March 346 (23.39) 282 (23.90) 64 (21.40)  
  April to June 355 (24.00) 282 (23.90) 73 (24.41)  
  July to September 400 (27.05) 303 (25.68) 97 (32.44)  
  October to December 378 (25.56) 313 (26.53) 65 (21.74)  
Preterm birth (<37 weeks, n 
(%)) 
   <0.001 
  No 1,156 (78.16) 954 (80.85) 202 (67.56)  




Low birthweight (<2,500 g, 
n (%)) 
   <0.001 
  No 1,164 (78.70) 963 (81.61) 201 (67.22)  
  Yes 315 (21.30) 217 (18.39) 98 (32.78)  
Stress during pregnancy, n 
(%) 
   <0.001 
  Not stressful 562 (38.00) 475 (40.25) 87 (29.10)  
  Stressful 909 (61.46) 700 (59.32) 209 (69.90)  
Gestational age, week    <0.001 
  Mean ± SD 38.2 ± 3.0 38.5 ± 2.5 37.1 ± 4.2  
Birthweight, g    <0.001 
  Mean ± SD 3011.6 ±729.5 3069.9 ± 665.4 2781.6 ± 906.3  
Early Childhood lead, 
µg/dL 
   0.009 
  Mean ± SD 2.2 ± 1.6 2.1 ± 1.5 2.4 ± 1.9  
Maternal HDL, mg/dL    0.001 
  Median (25th-75th quantile) 60.7 (50.3-72.3) 61.5 (51.0-73.9) 57.4 (49.3-67.5)  
Note: NT was defined as without any neurodevelopmental disorder diagnosis; ADHD was 
defined as any ADHD diagnosis; aThe p-values were obtained from chi-square tests for 



























  <2 µg/dL  125 (18.97) 534 (81.03) 1.00   1.00   
  2-4 µg/dL  136 (19.74) 553 (80.26) 1.05 (0.80, 1.38) 0.720 1.08 (0.81, 1.44) 0.622 
  5-10 µg/dL  38 (29.01) 93 (70.99) 1.75 (1.14, 2.67) 0.010 1.73 (1.09, 2.73) 0.019 
Lead: 
binary 
  <5 µg/dL  261 (19.36) 1087 (80.64) 1.00   1.00   
  5-10 µg/dL  38 (29.01) 93 (70.99) 1.70 (1.14, 2.54) 0.009 1.66 (1.08, 2.56) 0.020 
Note: NT was defined as without any neurodevelopmental disorder diagnosis; ADHD was defined as any ADHD 
diagnosis; the multiple logistic regression model was adjusted for maternal age at delivery, maternal race/ethnicity, 






Table 5-5 The joint association of child's sex and early childhood lead levels with the risk of ADHD diagnosis. 
  
Sex Lead Level 
ADHD, n 
(%) 











Female  86 (11.21) 681 (88.79) 1.00   1.00   
Male  213 (29.92) 499 (70.08) 3.38 (2.57, 4.45) <0.001 3.42 (2.57, 4.55) <0.001 
Test for sex-based lead (binary) interaction    3.58 (1.25, 10.20) 0.017 
Lead effects within child’s sex        
Female   <5 µg/dL 80 (11.38) 623 (88.62) 1.00   1.00   
   5-10 µg/dL 6 (9.38) 58 (90.63) 0.81 (0.34, 1.93) 0.627 0.68 (0.27, 1.69) 0.401 
Male   <5 µg/dL 181 (28.06) 464 (71.94) 1.00   1.00   
   5-10 µg/dL 32 (47.76) 35 (52.24) 2.34 (1.41, 3.90) 0.001 2.49 (1.46, 4.26) 0.001 
Joint effects of child’s sex and lead        
Female   <5 µg/dL 80 (11.38) 623 (88.62) 1.00   1.00   
   5-10 µg/dL 6 (9.38) 58 (90.63) 0.81 (0.34, 1.93) 0.627 0.69 (0.28, 1.71) 0.426 
Male   <5 µg/dL 181 (28.06) 464 (71.94) 3.04 (2.27, 4.06) <0.001 3.02 (2.24, 4.06) <0.001 
   5-10 µg/dL 32 (47.76) 35 (52.24) 7.12 (4.18, 12.13) <0.001 7.48 (4.29, 13.02) <0.001 
Note: NT was defined as without any neurodevelopmental disorder diagnosis; ADHD was defined as any ADHD 
diagnosis; the multiple logistic regression model was adjusted for maternal age at delivery, maternal race/ethnicity, 






Table 5-6 online. The joint association of child's sex and early childhood lead levels with the risk of ADHD 
diagnosis comparing to no ADHD group. 
  















Female  86 (8.05) 982 (91.95) 1.00   1.00   
Male  213 (19.54) 877 (80.46) 2.77 (2.12, 3.62) <0.001 2.84 (2.16, 3.72) <0.001 
Test for sex-based lead (binary) interaction    3.13 (1.15, 8.48) 0.025 
Lead effects within child’s sex        
Female <5 µg/dL 80 (8.06) 912 (91.94) 1.00   1.00   
 5-10 µg/dL 6 (7.89) 70 (92.11) 0.98 (0.42, 2.32) 0.958 0.82 (0.34, 2.01) 0.668 
Male <5 µg/dL 181 (18.03) 823 (81.97) 1.00   1.00   
 5-10 µg/dL 32 (37.21) 54 (62.79) 2.69 (1.69, 4.29) <0.001 2.80 (1.74, 4.52) <0.001 
Joint effects of child’s sex and lead        
Female <5 µg/dL 80 (8.06) 912 (91.94) 1.00   1.00   
 5-10 µg/dL 6 (7.89) 70 (92.11) 0.98 (0.41, 2.32) 0.958 0.89 (0.37, 2.15) 0.802 
Male <5 µg/dL 181 (18.03) 823 (81.97) 2.51 (1.90, 3.32) <0.001 2.54 (1.91, 3.37) <0.001 
 5-10 µg/dL 32 (37.21) 54 (62.79) 6.76 (4.12, 11.06) <0.001 7.10 (4.29, 11.75) <0.001 
Note: No ADHD was defined as without any ADHD diagnosis; ADHD was defined as any ADHD diagnosis; the multiple 
logistic regression model was adjusted for maternal age at delivery, maternal race/ethnicity, maternal education, smoking 




Table 5-7 online. The joint association of child's sex and early childhood lead levels (age≤2 years) with the risk of 
ADHD diagnosis. 
  












Female  81 (11.11) 648 (88.89) 1.00   1.00   











Lead effects within child’s sex        
Female <5 µg/dL 78 (11.61) 594 (88.39) 1.00   1.00   







Male <5 µg/dL 173 (27.86) 448 (72.14) 1.00   1.00   







Joint effects of child’s sex and lead        
Female <5 µg/dL 78 (11.61) 594 (88.39) 1.00   1.00   





















Note: NT was defined as without any neurodevelopmental disorder diagnosis; ADHD was defined as any 
ADHD diagnosis; the multiple logistic regression model was adjusted for maternal age at delivery, maternal 
race/ethnicity, maternal education, smoking during pregnancy, intrauterine infection, parity, child's sex, mode 




Table 5-8 online. The joint association of child's sex and early childhood lead levels with the risk of ADHD 
diagnosis (further adjusted for maternal lead levels immediately after delivery). 
  
Sex Lead Level ADHD, n (%) NT, n (%) 
Crude 
OR 
95% CI P-Value 
Adjuste
d OR 
95% CI P-Value 
Female  22 (11.06) 177 (88.94) 1.00   1.00   











Lead effects within child’s sex       
Female   <5 µg/dL 21 (11.35) 164 (88.65) 1.00   1.00   







Male   <5 µg/dL 54 (31.40) 118 (68.60) 1.00   1.00   







Joint effects of child’s sex and lead       
Female   <5 µg/dL 21 (11.35) 164 (88.65) 1.00   1.00   





















Note: NT was defined as without any neurodevelopmental disorder diagnosis; ADHD was defined as any ADHD 
diagnosis; the multiple logistic regression model was adjusted for maternal lead levels right after delivery, maternal 
lead levels, maternal age at delivery, maternal race/ethnicity, maternal education, smoking during pregnancy, 





Table 5-9 online. The joint association among child's sex, maternal HDL level, maternal stress during pregnancy, 
and early childhood lead levels with the risk of ADHD diagnosis. 
  






NT, n (%) 
Across sex group Within sex group 
Adjusted 
OR 
95% CI P-Value 
Adjusted 
OR 
95% CI P-Value 
Joint effects of child’s sex, lead, and maternal HDL 
Female   <5 µg/dL ≤ median 30 (12.88) 203 (87.12) 1.06 (0.62, 1.82) 0.833 1.06 (0.61, 1.85) 0.827 
   <5 µg/dL > median 33 (11.46) 255 (88.54) 1.00   1.00   
   5-10 µg/dL ≤ median 2 (8.00) 23 (92.00) 0.62 (0.14, 2.84) 0.539 0.52 (0.11, 2.49) 0.414 
   5-10 µg/dL > median 3 (11.54) 23 (88.46) 0.80 (0.22, 2.97) 0.739 0.79 (0.20, 3.04) 0.730 
Male   <5 µg/dL ≤ median 91 (33.96) 177 (66.04) 3.55 (2.25, 5.59) <0.001 1.45 (0.96, 2.19) 0.075 
   <5 µg/dL > median 56 (25.00) 168 (75.00) 2.49 (1.53, 4.03) <0.001 1.00   
   5-10 µg/dL ≤ median 17 (56.67) 13 (43.33) 10.03 (4.38, 22.97) <0.001 4.02 (1.79, 8.99) 0.001 
   5-10 µg/dL > median 8 (40.00) 12 (60.00) 4.77 (1.76, 12.90) 0.002 1.94 (0.73, 5.18) 0.187 
Joint effects of child’s sex, lead, and maternal stress 
Female   <5 µg/dL 
Not 
stressful 
21 (7.50) 259 (92.50) 1.00   1.00   
   <5 µg/dL Stressful 59 (14.05) 361 (85.95) 2.00 (1.17, 3.41) 0.011 1.89 (1.09, 3.28) 0.023 
   5-10 µg/dL 
Not 
stressful 
0 (0.00) 19 (100.00) NA   NA   
   5-10 µg/dL Stressful 6 (13.33) 39 (86.67) 1.68 (0.62, 4.57) 0.310 1.59 (0.57, 4.42) 0.374 
Male   <5 µg/dL 
Not 
stressful 
59 (24.48) 182 (75.52) 4.18 (2.43, 7.20) <0.001 1.00   
   <5 µg/dL Stressful 121 (30.17) 280 (69.83) 5.10 (3.08, 8.44) <0.001 1.21 (0.83, 1.77) 0.312 
   5-10 µg/dL 
Not 
stressful 
7 (31.82) 15 (68.18) 6.10 (2.18, 17.08) 0.001 1.53 (0.58, 4.05) 0.389 
    5-10 µg/dL Stressful 23 (53.49) 20 (46.51) 14.94 (6.88, 32.41) <0.001 3.53 (1.75, 7.14) <0.001 
Note: NT was defined as without any neurodevelopmental disorder diagnosis; ADHD was defined as any ADHD 
diagnosis; the multiple logistic regression model was adjusted for maternal age at delivery, maternal race/ethnicity, 


























Term  202 (17.47) 954 (82.53) 1.00   1.00   
Preterm  97 (30.03) 226 (69.97) 2.03 (1.53, 2.69) <0.001 1.94 (1.43, 2.63) <0.001 
Test for gestational age lead (binary) interaction      0.715 
Lead’s effect within gestational age group        
Term <5 µg/dL 177 (16.73) 881 (83.27) 1.00   1.00   
 5-10 µg/dL 25 (25.51) 73 (74.49) 1.70 (1.05, 2.76) 0.030 1.75 (1.06, 2.89) 0.030 
Preterm <5 µg/dL 84 (28.97) 206 (71.03) 1.00   1.00   
 5-10 µg/dL 13 (39.39) 20 (60.61) 1.59 (0.76, 3.35) 0.219 1.63 (0.71, 3.71) 0.246 
Joint effect of gestational age and lead        
Term <5 µg/dL 177 (16.73) 881 (83.27) 1.00   1.00   
 5-10 µg/dL 25 (25.51) 73 (74.49) 1.70 (1.05, 2.76) 0.030 1.76 (1.06, 2.91) 0.028 
Preterm <5 µg/dL 84 (28.97) 206 (71.03) 2.03 (1.50, 2.74) <0.001 2.61 (1.80, 3.78) <0.001 
 5-10 µg/dL 13 (39.39) 20 (60.61) 3.24 (1.58, 6.62) 0.001 3.76 (1.69, 8.36) 0.001 
Note: NT is defined as without any mental disorder diagnosis; ADHD is defined as any ADHD diagnosis; the multiple 
logistic regression model was adjusted for maternal age at delivery, maternal race/ethnicity, maternal education, smoking 















95% CI P-Value 
Adjusted 
OR 




963 (82.73) 1.00   1.00   
Low  98 (31.11) 217 (68.89) 2.16 (1.63, 2.87) <0.001 2.10 (1.54, 2.85) <0.001 
Test for birthweight lead (binary) interaction      0.421 
Lead’s effect within birthweight group        
Normal <5 µg/dL 
174 
(16.38) 
888 (83.62) 1.00   1.00   
 5-10 µg/dL 27 (26.47) 75 (73.53) 1.84 (1.15, 2.94) 0.011 1.89 (1.16, 3.09) 0.011 
Low <5 µg/dL 87 (30.42) 199 (69.58) 1.00   1.00   
 5-10 µg/dL 11 (37.93) 18 (62.07) 1.40 (0.63, 3.08) 0.407 1.22 (0.51, 2.90) 0.658 
Joint effect of birthweight and lead        
Normal <5 µg/dL 
174 
(16.38) 
888 (83.62) 1.00   1.00   
 5-10 µg/dL 27 (26.47) 75 (73.53) 1.84 (1.15, 2.94) 0.011 1.88 (1.15, 3.07) 0.012 
Low <5 µg/dL 87 (30.42) 199 (69.58) 2.23 (1.65, 3.01) <0.001 2.69 (1.86, 3.90) <0.001 
 5-10 µg/dL 11 (37.93) 18 (62.07) 3.12 (1.45, 6.72) 0.004 3.16 (1.37, 7.26) 0.007 
Note: NT is defined as without any mental disorder diagnosis; ADHD is defined as any ADHD diagnosis; the multiple 
logistic regression model was adjusted for maternal age at delivery, maternal race/ethnicity, maternal education, smoking 










1. Eubig PA, Aguiar A, Schantz SL. Lead and PCBs as risk factors for attention 
deficit/hyperactivity disorder. Environ Health Perspect. 2010;118(12):1654-1667. 
2. Braun JM, Kahn RS, Froehlich T, Auinger P, Lanphear BP. Exposures to environmental toxicants 
and attention deficit hyperactivity disorder in U.S. children. Environ Health Perspect. 
2006;114(12):1904-1909. 
3. Froehlich TE, Lanphear BP, Auinger P, et al. Association of tobacco and lead exposures with 
attention-deficit/hyperactivity disorder. Pediatrics. 2009;124(6):e1054-1063. 
4. Nigg JT, Nikolas M, Mark Knottnerus G, Cavanagh K, Friderici K. Confirmation and extension 
of association of blood lead with attention-deficit/hyperactivity disorder (ADHD) and ADHD 
symptom domains at population-typical exposure levels. Journal of child psychology and 
psychiatry, and allied disciplines. 2010;51(1):58-65. 
5. Wang HL, Chen XT, Yang B, et al. Case-control study of blood lead levels and attention deficit 
hyperactivity disorder in Chinese children. Environ Health Perspect. 2008;116(10):1401-1406. 
6. Bernard SM. Should the Centers for Disease Control and Prevention's childhood lead poisoning 
intervention level be lowered? Am J Public Health. 2003;93(8):1253-1260. 
7. Ahrens KA, Haley BA, Rossen LM, Lloyd PC, Aoki Y. Housing Assistance and Blood Lead 
Levels: Children in the United States, 2005-2012. Am J Public Health. 2016;106(11):2049-2056. 
8. Centers for Disease Control and Prevention. CDC Response to Advisory Committee on 
Childhood Lead Poisoning Prevention Recommendations in “Low Level Lead Exposure Harms 
Children: A Renewed Call of Primary Prevention”. 2012. Retrieved August. 2012;25. 
9. Gilbert SG, Weiss B. A rationale for lowering the blood lead action level from 10 to 2 microg/dL. 
Neurotoxicology. 2006;27(5):693-701. 
10. Goodlad JK, Marcus DK, Fulton JJ. Lead and Attention-Deficit/Hyperactivity Disorder (ADHD) 
symptoms: a meta-analysis. Clin Psychol Rev. 2013;33(3):417-425. 
11. Rodriguez A, Bohlin G. Are maternal smoking and stress during pregnancy related to ADHD 
symptoms in children? Journal of child psychology and psychiatry, and allied disciplines. 
2005;46(3):246-254. 
12. Ji Y, Riley AW, Lee LC, et al. A Prospective Birth Cohort Study on Maternal Cholesterol Levels 
and Offspring Attention Deficit Hyperactivity Disorder: New Insight on Sex Differences. Brain 
Sci. 2017;8(1). 
13. Wang G, Divall S, Radovick S, et al. Preterm birth and random plasma insulin levels at birth and 
in early childhood. JAMA. 2014;311(6):587-596. 
14. Wang X, Zuckerman B, Pearson C, et al. Maternal cigarette smoking, metabolic gene 
polymorphism, and infant birth weight. JAMA. 2002;287(2):195-202. 
15. Li M, Fallin MD, Riley A, et al. The Association of Maternal Obesity and Diabetes With Autism 
and Other Developmental Disabilities. Pediatrics. 2016;137(2):e20152206. 
16. Kumar R, Tsai HJ, Hong X, et al. Race, ancestry, and development of food-allergen sensitization 
in early childhood. Pediatrics. 2011;128(4):e821-829. 
17. Yu Y, Zhang S, Wang G, et al. The combined association of psychosocial stress and chronic 
hypertension with preeclampsia. American journal of obstetrics and gynecology. 2013;209(5):438 
e431-438 e412. 
18. Baghurst PA, Tong SL, McMichael AJ, Robertson EF, Wigg NR, Vimpani GV. Determinants of 
blood lead concentrations to age 5 years in a birth cohort study of children living in the lead 
smelting city of Port Pirie and surrounding areas. Arch Environ Health. 1992;47(3):203-210. 
19. Stromberg U, Lundh T, Schutz A, Skerfving S. Yearly measurements of blood lead in Swedish 





20. Ris MD, Dietrich KN, Succop PA, Berger OG, Bornschein RL. Early exposure to lead and 
neuropsychological outcome in adolescence. J Int Neuropsychol Soc. 2004;10(2):261-270. 
21. Kordas K, Ardoino G, Ciccariello D, et al. Association of maternal and child blood lead and 
hemoglobin levels with maternal perceptions of parenting their young children. Neurotoxicology. 
2011;32(6):693-701. 
22. Centers for Disease Control and Prevention. Low level lead exposure harms children: a renewed 
call for primary prevention. Report of Advisory Committee on Childhood Lead Poisoning 
Prevention Atlanta, GA: CDC. 2012. 
23. Hubbs-Tait L, Nation JR, Krebs NF, Bellinger DC. Neurotoxicants, Micronutrients, and Social 
Environments: Individual and Combined Effects on Children's Development. Psychol Sci Public 
Interest. 2005;6(3):57-121. 
24. Bellinger DC, Chen A, Lanphear BP. Establishing and Achieving National Goals for Preventing 
Lead Toxicity and Exposure in Children. JAMA Pediatr. 2017;171(7):616-618. 
25. Aelion CM, Davis HT, Lawson AB, Cai B, McDermott S. Associations between soil lead 
concentrations and populations by race/ethnicity and income-to-poverty ratio in urban and rural 
areas. Environ Geochem Health. 2013;35(1):1-12. 
26. Bearer CF. Environmental health hazards: how children are different from adults. Future Child. 
1995;5(2):11-26. 
27. Diawara MM, Litt JS, Unis D, et al. Arsenic, cadmium, lead, and mercury in surface soils, 
Pueblo, Colorado: implications for population health risk. Environ Geochem Health. 
2006;28(4):297-315. 
28. Campanella R, Mielke HW. Human geography of New Orleans' high-lead geochemical setting. 
Environ Geochem Health. 2008;30(6):531-540. 
29. Zahran S, Mielke HW, Weiler S, Berry KJ, Gonzales C. Children's blood lead and standardized 
test performance response as indicators of neurotoxicity in metropolitan New Orleans elementary 
schools. Neurotoxicology. 2009;30(6):888-897. 
30. Karri V, Schuhmacher M, Kumar V. Heavy metals (Pb, Cd, As and MeHg) as risk factors for 
cognitive dysfunction: A general review of metal mixture mechanism in brain. Environ Toxicol 
Pharmacol. 2016;48:203-213. 
31. Costa LG, Aschner M, Vitalone A, Syversen T, Soldin OP. Developmental neuropathology of 
environmental agents. Annu Rev Pharmacol Toxicol. 2004;44:87-110. 
32. Finkelstein Y, Markowitz ME, Rosen JF. Low-level lead-induced neurotoxicity in children: an 
update on central nervous system effects. Brain Res Brain Res Rev. 1998;27(2):168-176. 
33. Nigg JT, Knottnerus GM, Martel MM, et al. Low blood lead levels associated with clinically 
diagnosed attention-deficit/hyperactivity disorder and mediated by weak cognitive control. Biol 
Psychiatry. 2008;63(3):325-331. 
34. Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-
deficit hyperactivity disorder (ADHD). Ann Pharmacother. 2014;48(2):209-225. 
35. Landrigan PJ. Pediatric lead poisoning: is there a threshold? Public health reports. 
2000;115(6):530-531. 
36. Bradbury MW, Deane R. Permeability of the blood-brain barrier to lead. Neurotoxicology. 
1993;14(2-3):131-136. 
37. Goyer RA. Results of lead research: prenatal exposure and neurological consequences. Environ 
Health Perspect. 1996;104(10):1050-1054. 
38. Ruff HA, Markowitz ME, Bijur PE, Rosen JF. Relationships among blood lead levels, iron 
deficiency, and cognitive development in two-year-old children. Environ Health Perspect. 
1996;104(2):180-185. 
39. Chen Z, Myers R, Wei T, et al. Placental transfer and concentrations of cadmium, mercury, lead, 
and selenium in mothers, newborns, and young children. Journal of exposure science & 




40. Lidsky TI, Schneider JS. Lead neurotoxicity in children: basic mechanisms and clinical 
correlates. Brain. 2003;126(Pt 1):5-19. 
41. Wibowo AA, Zielhuis RL. Different effects on hemesynthesis in male and female rabbits treated 
with lead acetate. Arch Toxicol. 1980;45(1):67-73. 
42. Martin CJ, Werntz CL, 3rd, Ducatman AM. The interpretation of zinc protoporphyrin changes in 
lead intoxication: a case report and review of the literature. Occup Med (Lond). 2004;54(8):587-
591. 
43. WHO. Environmental Health Criteria 165. International Programme on Chemical Safety Geneva: 
World Health Organization. 1995. 
44. Popovic M, McNeill FE, Chettle DR, Webber CE, Lee CV, Kaye WE. Impact of occupational 
exposure on lead levels in women. Environ Health Perspect. 2005;113(4):478-484. 
45. Onalaja AO, Claudio L. Genetic susceptibility to lead poisoning. Environ Health Perspect. 
2000;108 Suppl 1:23-28. 
46. Vahter M, Akesson A, Liden C, Ceccatelli S, Berglund M. Gender differences in the disposition 
and toxicity of metals. Environ Res. 2007;104(1):85-95. 
47. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-
5®). American Psychiatric Pub; 2013. 
48. Fuse T, Forsyth JP, Marx B, Gallup GG, Weaver S. Factor structure of the Tonic Immobility 
Scale in female sexual assault survivors: an exploratory and Confirmatory Factor Analysis. 
Journal of anxiety disorders. 2007;21(3):265-283. 
49. Patterson GR, DeGarmo D, Forgatch MS. Systematic changes in families following prevention 
trials. J Abnorm Child Psychol. 2004;32(6):621-633. 
50. Scott S, O'Connor TG, Futh A, Matias C, Price J, Doolan M. Impact of a parenting program in a 
high-risk, multi-ethnic community: the PALS trial. Journal of child psychology and psychiatry, 
and allied disciplines. 2010;51(12):1331-1341. 
51. Jaffee SR, Caspi A, Moffitt TE, Polo-Tomas M, Price TS, Taylor A. The limits of child effects: 
evidence for genetically mediated child effects on corporal punishment but not on physical 
maltreatment. Dev Psychol. 2004;40(6):1047-1058. 
52. Lifford KJ, Harold GT, Thapar A. Parent-child relationships and ADHD symptoms: a 
longitudinal analysis. J Abnorm Child Psychol. 2008;36(2):285-296. 
53. O'Connor TG, Rutter M. Attachment disorder behavior following early severe deprivation: 
extension and longitudinal follow-up. English and Romanian Adoptees Study Team. J Am Acad 
Child Adolesc Psychiatry. 2000;39(6):703-712. 
54. Rutter M, Beckett C, Castle J, et al. Effects of profound early institutional deprivation: An 
overview of findings from a UK longitudinal study of Romanian adoptees. European Journal of 





Chapter 6 AIM 3: MATERNAL BIOMARKERS OF 
ACETAMINOPHEN USE AND OFFSPRING ATTENTION DEFICIT 
HYPERACTIVITY DISORDER  
This work is under review by Pediatrics 
Yuelong Ji, MSPH1; Anne W. Riley, PhD1; Li-Ching Lee, PhD2,3; Xiumei Hong, MD1; 
Guoying Wang, MD1; Hui-Ju Tsai, PhD4; Noel T. Mueller, PhD2; Colleen Pearson, BA5; 
Anita Panjwani, MPH6; Hongkai Ji, PhD7; Tami R. Bartell, MPH8; Irina Burd, MD9; M. 
Daniele Fallin, PhD2,3; Xiaobin Wang, ScD1,10* 
 
Affiliations: 
1 Center on the Early Life Origins of Disease, Department of Population, Family and 
Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, 615 N 
Wolfe St, Baltimore, MD 21205, USA;  
2 Department of Epidemiology, Johns Hopkins University Bloomberg School of Public 
Health, 615 N Wolfe St, Baltimore, MD 21205, USA; 
3 Wendy Klag Center for Autism and Developmental Disabilities & Department of Mental 
Health, 615 N Wolfe St, Baltimore, MD 21205, USA; 
4 Division of Biostatistics and Bioinformatics, Institute of Population Health Sciences, 
National Health Research Institutes, Zhunan 35053, Taiwan; 
5 Department of Pediatrics, Boston University School of Medicine and Boston Medical 
Center, 1 Boston Medical Center Pl, Boston, MA 02118, USA; 
6 Department of International Health, Johns Hopkins University Bloomberg School of 
Public Health, 615 N Wolfe St, Baltimore, MD 21205, USA; 
7 Department of Biostatistics, Johns Hopkins University Bloomberg School of Public 
Health, 615 N Wolfe St, Baltimore, MD 21205, USA; 
8 Stanley Manne Children’s Research Institute, Mary Ann & J. Milburn Smith Child 
Health Research, Outreach and Advocacy Center, Ann & Robert H. Lurie Children’s Hospital of 
Chicago, 2430 N Halsted St, Chicago, IL 60614, USA; 
9 Integrated Research Center for Fetal Medicine, Department of Gynecology and 
Obstetrics, Johns Hopkins University School of Medicine, 1800 Orleans St, Baltimore, MD 
21287, USA; 
10 Division of General Pediatrics & Adolescent Medicine, Department of Pediatrics, Johns 
Hopkins University School of Medicine, 1800 Orleans St, Baltimore, MD 21287, USA. 
*Correspondence and reprint requests should be addressed to: 
Xiaobin Wang, MD, MPH, ScD 
Center on the Early Life Origins of Disease 
Department of Population, Family and Reproductive Health 




615 N. Wolfe Street, Baltimore, MD 21205-2179 
Phone 410-955-5824 
Fax 410-502-5831 




6.1 TABLE OF CONTENTS SUMMARY 
This birth cohort study investigated the prospective association between maternal plasma 
acetaminophen metabolites and attention deficit hyperactivity disorder (ADHD) diagnosis in the 
offspring. 
 
6.2 WHAT’S KNOWN ON THIS SUBJECT 
Multiple large prospective studies have suggested a positive association between self-reported 
maternal acetaminophen use during pregnancy and ADHD diagnosis in offspring. The major 
limitations of these studies were self-reported use, lack of dose quantification, and unmeasured 
confounders. 
 
6.3 WHAT THIS STUDY ADDS 
This study provides the first evidence of the association between maternal biomarkers of 
acetaminophen use (an objective measurement within 1-3 days postpartum) and offspring ADHD 






Background and Objective: Previous studies have suggested a positive association between self-
reported maternal acetaminophen use during pregnancy and risk of attention deficit hyperactivity 
disorder (ADHD) in offspring. We sought to examine the prospective association between 
maternal plasma biomarkers of acetaminophen intake and ADHD diagnosis in the offspring.  
Method: This report analyzed 1180 children enrolled at birth and followed prospectively as part 
of the Boston Birth Cohort, including 188 with ADHD diagnosis based on electronic medical 
record review of all the study children at Boston Medical Center. Maternal biomarkers of 
acetaminophen intake were measured in plasma samples obtained within 1-3 days postpartum. 
Odds ratios (ORs) for having ADHD diagnosis or other developmental disorders were estimated 
using multinomial logistic regression models, adjusting for pertinent covariables.   
Results: Compared to neurotypical children, we observed significant positive associations with 
ADHD diagnosis for each maternal acetaminophen biomarker: unchanged acetaminophen (Third 
tertile vs. First tertile): OR=2.05, 95% confidence interval [CI] 1.27-3.32; 3-(N-Acetyl-L-
cystein-S-yl) acetaminophen (Above median vs. No detection): OR=2.03, 95% CI 1.26-3.27; and 
acetaminophen glucuronide (Above median vs. No detection): OR=2.00, 95% CI 1.26-3.18. The 
dose-response associations persisted after adjusting for pertinent covariables; and were specific 
to ADHD, rather than other neurodevelopmental disorders. In the stratified analyses, differential 
point estimates of the associations were observed across some strata of covariates. However, 




Conclusions: Maternal acetaminophen biomarkers were explicitly associated with increased risk 






Attention deficit hyperactivity disorder (ADHD) is one of the most common lifelong 
neurodevelopmental disorders in the world. Its prevalence among children ages 4-17 years in the 
U.S. increased significantly from 7.0% to 10.2% during the past two decades.1 The rapid rise of 
ADHD cannot be attributed to genetic mutations. Indeed, multiple social and environmental risk 
factors have been associated with the development of ADHD, including family-related factors,2-
14 maternal obesity,15 maternal smoking,7,16,17, maternal drinking,7 low birthweight and preterm 
birth,18 exposure to organophosphates,19 polychlorinated biphenyls,20,21 and lead exposure.20,22-24  
These findings underscore the role of environmental factors in the etiology of ADHD, and the 
need to explore other important yet unknown risk factors for ADHD.25 Acetaminophen is widely 
used and recommended over-the-counter medication for fever and pain relief during pregnancy. 
The extent of acetaminophen use during pregnancy is over 65% in the U.S. and over 50% in 
Europe.26,27 The inhibition of prostaglandin synthesis is part of the therapeutic effect of 
acetaminophen.28 Prostaglandins not only act as fever determinants but also play essential roles 
in brain function, including long-term potentiation,29 learning,30 and cerebellar development.28 
Because of its widespread use and role in brain function, the potential unknown adverse effects 
of acetaminophen use on developing fetal brain need to be clarified.31  
Since 2013, research studies analyzing five prospective cohorts from Europe and New Zealand 
have consistently shown a positive association between maternal intake of acetaminophen during 
pregnancy and increased risk of ADHD and its related symptoms in offspring.32-36 The Society 
for Maternal-Fetal Medicine and the Food and Drug Administration expressed concern that the 
data from these recent studies are still too inconclusive to draw any causal inference between 




included the use of self-reported exposure, lack of dose quantification, and unmeasured 
confounders.37 To address the concerns and criticisms related to previous studies and improve 
our understanding of acetaminophen’s effect during pregnancy, there is need for a well-designed 
prospective birth cohort study with blood samples available to measure maternal acetaminophen 
levels. Currently, no such study exists. In this study, using the data from the Boston Birth 
Cohort, we sought to examine the prospective association between maternal plasma 
acetaminophen metabolites levels measured within a few days after delivery and ADHD 
diagnosis in the offspring. We hypothesized that maternal levels of acetaminophen biomarkers 
are positively associated with risk of offspring ADHD diagnosis.  
6.6 METHODS 
6.6.1 Sample 
Since 1998, mother/infant pairs were recruited at birth from the Boston Medical Center (BMC) 
for participation in the Boston Birth Cohort (BBC).39,40 The BMC serves a predominately low 
income, urban, minority population and is also the largest safety net hospital in New England. 
Eligible mothers were those who delivered a singleton live birth at BMC. They were approached 
for consent and enrollment within 24 to 72 hours after delivery. Infants who continued to receive 
primary or specialty care at BMC were invited (beginning at age 6 months) to participate in the 
follow-up study in which they are prospectively followed from birth onwards.39,41,42 After 
obtaining informed consent, a standardized questionnaire was administered by trained research 
staff and a maternal venous blood sample was obtained. Mothers who conceived via in vitro 
fertilization, multiple-gestation pregnancies, deliveries induced by maternal trauma, and/or 




baseline and the follow-up study have been approved by the Institutional Review Boards (IRB) 
of Boston University Medical Center and Johns Hopkins Bloomberg School of Public Health. 
As illustrated in the study flowchart, of the 3098 children followed in the BBC, we excluded 
1686 participants who had missing data for maternal acetaminophen metabolites measurements 
and 232 participants who had missing data for key covariates. Our final sample comprised 1180 
mother-infant pairs with pertinent data (Supplemental Figure 1). This sample was similar to the 
excluded sample in terms of baseline maternal and newborn characteristics (Supplemental Table 
2), except for having a slightly higher percentage of black children, longer gestation and higher 
birthweight.    
6.6.2 Definitions for ADHD, ASD, other DD, and Neurotypical Children 
We extracted information regarding each child’s neuro-developmental diagnoses as documented 
in their EMRs. Beginning in 2003, BMC implemented EMR as part of routine data collection for 
both well-child and specialty clinical visits. The primary and secondary diagnoses for each 
clinical visit were coded in the EMR using the International Classification of Diseases, Ninth 
Revision (ICD-9) (before October 1, 2015) and ICD-10 (after October 1, 2015). Thus, all 
children in the BBC postnatal follow-up study with a related ICD-9 (314.0, 314.00, 314.01, 
314.1, 314.2, 314.8, or 314.9) or ICD-10 (F90.0, F90.1, F90.2, F90.8, or F90.9) code included in 
their EMR between 2003 and 2016 were classified as having ADHD. Similarly, children with an 
ICD-9 (299.0, 299.00, 299.01, 299.8, 299.80, 299.81, 299.9, 299.90, or 299.91) or ICD-10 
(F84.0, F84.8, or F84.9) code were classified as having an autism spectrum disorder (ASD). 
Furthermore, children with any of following developmental disorder diagnoses noted in their 
EMR were classified as having other developmental disorders (other DD): conduct disorders, 




without any diagnosis of ASD, ADHD, conduct disorders, developmental delays, intellectual 
disabilities, failure to thrive, or congenital anomalies were classified as neurotypical (NT). 
Supplemental Table 1 lists the ICD-9 and ICD-10 codes for each developmental disorder 
diagnosis. 
6.6.3 Maternal biomarkers of acetaminophen use 
Maternal plasma biomarkers of acetaminophen use were measured using nonfasting blood 
samples obtained within 1-3 days postpartum. As illustrated in Figure 6-1, the main metabolites 
(and proportion) of acetaminophen include unchanged acetaminophen (~5%), acetaminophen 
glucuronide (52-57%), acetaminophen sulfate (30-44%), and hepatotoxic N-acetyl-p-
benzoquinone imine (NAPQI) (5-10%). NAPQI can be further detoxified as 3-(N-Acetyl-L-
cystein-S-yl) acetaminophen.43 The peak intensity of unchanged acetaminophen, acetaminophen 
glucuronide, and 3-(N-Acetyl-L-cystein-S-yl) acetaminophen in maternal blood was measured 
using liquid chromatography tandem-mass spectrometry (LC-MS) techniques at the MIT Broad 
Institute Metabolite Profiling Laboratory. All the intensity levels were inverse normal 
transformed for the subsequent statistical analyses. 
6.6.4 Covariates 
Based on previous literature,32-36 the following covariates were included as potential 
confounders: maternal age at delivery, maternal race/ethnicity, maternal education, smoking 
from 6 months before pregnancy to birth (never smoked, quit during this period, continued to 
smoke during this period), ever drank alcohol from 6 months before pregnancy to birth, maternal 
pre-pregnancy BMI, parity, maternal fever during pregnancy, intrauterine 
infection/inflammation, baby's sex, delivery type, gestational age, birthweight, breastfeeding, and  




questionnaire interview. Maternal and child clinically-related covariates were abstracted from 
their medical records, respectively. The lead levels of the children were collected as part of the 
pediatric routine lead screening and extracted from their EMRs. The first lead levels measured 
were chosen for the analysis. 
6.6.5 Statistical analyses 
The characteristics of the study sample for the ADHD, ASD (excluding participants with ADHD 
diagnosis), other DD, and NT groups were compared using one-way ANOVA for continuous 
variables and χ2 tests for categorical variables. The main exposures analyzed in this study were 
maternal acetaminophen metabolite levels, which were inverse normal transformed to 
approximate the normal distribution. The inverse normal transformed unchanged acetaminophen 
levels were also categorized into tertiles. Due to the high rate of non-detection, the inverse 
normal transformed acetaminophen glucuronide and 3-(N-Acetyl-L-cystein-S-yl) acetaminophen 
levels were categorized into three groups: no detection, below the median, and above the median 
of detected values. Based on previous findings regarding the proportions of acetaminophen 
metabolites typically found in blood samples,43 we further calculated a variable to reflect overall 
“acetaminophen burden” by combining all of the acetaminophen metabolites  levels with a 
weighting of their proportions in the acetaminophen metabolic pathway [acetaminophen 
burden=(unchanged acetaminophen/5%+ acetaminophen glucuronide/50%+ 3-(N-Acetyl-L-
cystein-S-yl) acetaminophen/5%)/60%].43 The acetaminophen burden levels were then also 
categorized into three groups: no detection, below median, above median. Each child’s early life 





We conducted sequential multinomial logistic regression models to examine the association 
between maternal acetaminophen metabolite levels and the risk of having ADHD diagnosis, 
ASD diagnosis (excluding ADHD diagnosis), or other DD diagnosis in offspring. Models 
included a crude model (Model 1); a model adjusted for maternal age at delivery, maternal 
race/ethnicity, maternal education, smoking during pregnancy, drinking during pregnancy, 
parity, maternal pre-pregnancy BMI, baby's sex, delivery type, gestational age, and birthweight 
(Model 2); and models further adjusted for maternal fever during pregnancy (Model 3), 
intrauterine infection/inflammation (Model 4), and breastfeeding (Model 5), respectively and 
combined (Model 6). We also performed stratified analyses by each stratum of covariates for 
binary acetaminophen burden (detected vs. no detection) using simple logistic regression 
comparing those with an ADHD diagnosis to the NT group. For the sensitivity analyses, we 
repeated the sequential models for each of the following outcomes: “ADHD only” (excluding 
ASD diagnosis), “ASD only” (excluding ADHD diagnosis), and “ADHD and ASD” (having 
both diagnoses), all compared to the NT group. STATA® version 14.0 software was used to 
perform all analyses (Stata Corporation, College Station, TX, USA). 
6.7 RESULTS 
In the final sample there were 188 children with a diagnosis of ADHD, 44 children with a 
diagnosis of ASD (without ADHD diagnosis), 344 children with a diagnosis of other DD, and 
604 NT children (without any diagnoses of developmental disorders). The median age at first 
ADHD diagnosis was 7 years. Figure 6-2 shows the distribution of each acetaminophen 
metabolite and acetaminophen burden across diagnosis groups. Both the ADHD diagnosis and 
ASD diagnosis (without ADHD diagnosis) groups had more mothers with higher levels of 




presents the crude comparisons of maternal and child characteristics among the ADHD 
diagnosis, ASD diagnosis (without ADHD diagnosis), other DD diagnosis, and NT groups. The 
ADHD and ASD groups had the highest percentage of detectable unchanged acetaminophen and 
its metabolites.  Mothers of children with any ADHD diagnosis were also more likely to have 
below college degree education, ever smoked before or during pregnancy, and C-section 
delivery, compared with the NT group. Children with any ADHD, ASD, or any other DD 
diagnosis were more likely to be male, born prematurely and have had low birthweight, 
compared with the NT group.  
Table 6-2 shows the sequential multinomial logistic regression model results for the relationship 
between acetaminophen metabolites and the risk of ADHD diagnosis, ASD diagnosis (excluding 
ADHD), or other DD diagnosis, before and after adjusting for pertinent covariates. The group 
with the highest plasma level of each acetaminophen metabolite was significantly associated 
with the risk of ADHD diagnosis, and the effect size was similar across all models. Moreover, 
we identified dose-responsive patterns across all acetaminophen metabolites and burden. 
Compared to levels in the non- detection category, below median and above median levels of 
maternal acetaminophen burden were associated with a 58% and 88% increase in the odds of 
ADHD diagnosis respectively (Model 6: OR for below median =1.58, 95% CI (1.02, 2.46); OR 
for above median =1.88, 95% CI (1.18, 3.00)). In contrast, the risks of ASD diagnosis and other 
DD diagnoses were not significantly associated with maternal plasma levels of acetaminophen 
metabolites across all models. Supplemental Table 3 further confirms that in our sensitivity 
analyses the acetaminophen metabolite levels were explicitly associated with the risk of having 




We also explored if the associations between acetaminophen metabolites and ADHD varied by 
strata of covariables. Figure 6-3 presents the forest plot of the stratified analyses for binary 
acetaminophen burden (detected vs. non-detection) by each stratum of covariates using simple 
logistic regression comparing ADHD diagnosis to NT. The point estimates of the acetaminophen 
burden-ADHD associations were similar among strata of maternal age, smoking before or during 
pregnancy, and maternal obesity. On the other hand, larger difference in the point estimate of the 
odds ratios was observed across strata of child’s sex, alcohol drinking before or during 
pregnancy, intrauterine infection/inflammation, delivery type, birthweight, gestational age, and 
breastfeeding. However, tests of interaction between each covariate and binary acetaminophen 
burden (detected vs. non-detection) were not significant. 
I further did stratified analysis and interaction test to investigate the potential protective effects 
of optimal maternal cholesterol levels in reducing the risk of ADHD caused by maternal 
acetaminophen exposure. Supplemental Table 4 presents the association between maternal 
acetaminophen burden and the risk of ADHD diagnosis in offspring by maternal HDL levels 
groups. The maternal acetaminophen levels only significantly associate with the risk of ADHD 
diagnosis when maternal HDL ≥60 mg/dL (OR=1.57, 95% CI (1.12, 2.22)). There is no 
indication of interaction between maternal HDL levels and maternal acetaminophen levels on the 
risk of ADHD diagnosis. This result is not presented in the manuscript for Pediatric.   
6.8 DISCUSSION 
In this prospective birth cohort study, we found a significant positive association between 
maternal blood acetaminophen metabolite levels measured within 1-3 days postpartum and 




disorders. This association remained even after adjusting for potential confounders including 
indications of acetaminophen use such as maternal fever and intrauterine infection/inflammation 
during pregnancy. This study has contributed the following new information to the field. 
Even though positive associations between maternal reported intake of acetaminophen during 
pregnancy and risk of ADHD diagnosis in their offspring have been reported by multiple 
independent large cohort studies, 32-36 there has been a dearth of prospective birth cohort studies 
to examine the biomarkers of acetaminophen use to address specific concerns about self-reported 
exposure and lack of dose quantification in those studies.  
To our knowledge, this is the first prospective birth cohort study to examine the association 
between maternal plasma biomarkers of acetaminophen and offspring ADHD diagnosis, and to 
take into account a large number of potential covariables. Our study was further strengthened by 
the diagnosis of ADHD by both general pediatricians and developmental specialists. By 
demonstrating a prospective and dose-response relationship using biomarkers specific to 
acetaminophen intake, our study findings lend further support to the previous studies that found a 
positive association between self-report of acetaminophen and ADHD. 
Although the causality and biological mechanisms underlying the maternal acetaminophen and 
child ADHD association remain to be determined, the potential for neurotoxicity is plausible 
according to previous findings. First, acetaminophen can be transferred through the placenta and 
remains in fetal/infant circulation much longer than it does in adults.45 The prolonged detection 
of acetaminophen among children is due to their undeveloped liver, which slowly metabolizes 
the acetaminophen.46 On the one hand, the low metabolic capacity in early life makes it safer for 
children to use acetaminophen because of slower production of toxic NAPQI, but on the other 




pregnancy. Second, the therapeutic effect of acetaminophen inhibits prostaglandin production.28 
Prostaglandin synthesis involves multiple essential biological processes underlying the function 
and development of the brain, such as long-term potentiation,29 learning,30 and cerebellar 
development.28 Third, accumulating studies have shown that acetaminophen not only rapidly 
enters the cerebrospinal fluid but also shows a profound influence on adult brain function. 47-50 
Thus, the long-term exposure of the fetus to maternal acetaminophen metabolites during 
pregnancy in addition to limited metabolic capacity might lead to both direct toxic damage from 
maternal NAPQI and potential disruption in neurodevelopment function due to prostaglandin 
inhibition. 
While tests of interaction were not significant (likely due to lack of power), our stratified 
analyses identified multiple maternal and fetal factors that may enhance the association between 
maternal acetaminophen metabolites and ADHD diagnosis in offspring. There is biological 
plausibility for their influence on the association, which is worthwhile for future studies to 
investigate. For instance, we found that the effect size of acetaminophen use on the risk of 
ADHD diagnosis is more pronounced among women who drank alcohol 6 months before or 
during pregnancy. Effect modification by alcohol is supported by biological studies.51,52 A 
mechanistic study showed that ethanol could cause induction of cytochrome P450 2E1 and 
selective depletion of mitochondrial glutathione, which could lead to limited clearance capacity 
of the toxic NAPQI.52 Additionally, the stronger and more significant acetaminophen-ADHD 
association among male children indicates the need to investigate further the potential sex-
specific biological mechanism underlying the acetaminophen exposure.  
Our study also had some limitations. First, this study only included a one-time measurement of 




strengthened if we could have included maternal acetaminophen metabolite measures taken at 
least once for each trimester. Given the fact that the rate of prenatal acetaminophen use during 
pregnancy is over 65% in the U.S.,27 the one-time measurement in our study at best reflects 
maternal acetaminophen use around the time of delivery. Second, although we adjusted for major 
known risk factors of ADHD, we could not adjust for multiple familial factors identified in 
previous studies such as maternal personality,53 poor parenting,2,3 maltreatment,4 conflict/parent-
child hostility,12 and severe early deprivation.13,14 We also cannot rule out the possibility of 
unmeasured or unknown residual confounding. Lastly, our study sample consists of the 
predominantly urban low-income minority population. This characteristic may limit the 
generalization of our results to all pregnant women living in the U.S. However, longitudinal 
research on this topic using biomarker data did not exist in the past. Our study findings help to 
fill in this critical data gap, with particular relevance to an urban low-income minority 
population, a population known at high risk of ADHD. 
6.9 CONCLUSION 
Maternal plasma biomarkers of acetaminophen use measured within a few days of delivery were 
associated with higher risk of ADHD diagnosis in offspring, but they were not associated with 
other developmental disorders. This association remained after adjusting for multiple previously 
identified potential confounders. While our study provides the first biomarker evidence of the 
relationship between prenatal acetaminophen use and ADHD diagnosis in offspring, we could 
not provide definitive support for a causal inference of this relationship, given the observational 
nature of this study and the limitations outlined above. However, by specifically addressing 
concerns raised by the Society for Maternal-Fetal Medicine and the Food and Drug 




and ADHD. Taking past findings together with the novel findings from this study, the potential 
adverse effect of maternal acetaminophen use on ADHD risk in offspring warrants additional 




6.10 TABLES AND FIGURES 
Table 6-1 Maternal and child characteristics for children with ADHD diagnosis, ASD diagnosis (excluding ADHD), 
other developmental disorder diagnosis (other DD), and neurotypical children (NT). 
Variable Total, N (%) NT, N (%) ADHD, N (%) ASD, N (%) Other DD, N (%) P-valueǂ 
Total 1180(100) 604(51.19) 188(15.93) 44(3.73) 344(29.15)  
Maternal Age      0.101 
  <35 965 (81.78) 510(84.44) 151 (80.32) 34 (77.27) 270 (78.49)  
  ≥35 215 (18.22) 94(15.56) 37 (19.68) 10 (22.73) 74 (21.51)  
Maternal 
race/ethnicity 
     0.073 
  Black 809 (68.56) 425(70.36) 126 (67.02) 26 (59.09) 232 (67.44)  
  White 48 (4.07) 24(3.97) 11 (5.85) 2 (4.55) 11 (3.20)  
  Hispanic 256 (21.69) 112(18.54) 44 (23.40) 15 (34.09) 85 (24.71)  
  Others 67 (5.68) 43(7.12) 7 (3.72) 1 (2.27) 16 (4.65)  
Education level      0.208 
  Below college 
degree 
1033 (87.54) 520(86.09) 172 (91.49) 37 (84.09) 304 (88.37)  
  College degree 
or above 
147 (12.46) 84(13.91) 16 (8.51) 7 (15.91) 40 (11.63)  
Smoking before or during pregnancy    0.018 
  Never 977 (82.80) 520(86.09) 141 (75.00) 38 (86.36) 278 (80.81)  
  Quitter 90 (7.63) 38(6.29) 18 (9.57) 3 (6.82) 31 (9.01)  
  Continuous 113 (9.58) 46(7.62) 29 (15.43) 3 (6.82) 35 (10.17)  
Drinking before or during pregnancy    0.491 
  No 1086 (92.03) 560(92.72) 173 (92.02) 38 (86.36) 315 (91.57)  
  Yes 94 (7.97) 44(7.28) 15 (7.98) 6 (13.64) 29 (8.43)  
Parity      0.484 
  Nulliparous 527 (44.66) 281(46.52) 85 (45.21) 18 (40.91) 143 (41.57)  
  Multiparous 653 (55.34) 323(53.48) 103 (54.79) 26 (59.09) 201 (58.43)  
Child's sex      <0.001 
  Female 576 (48.81) 351(58.11) 49 (26.06) 14 (31.82) 162 (47.09)  
  Male 604 (51.19) 253(41.89) 139 (73.94) 30 (68.18) 182 (52.91)  
Delivery type      0.008 
  C-section 426 (36.10) 192(31.79) 75 (39.89) 22 (50.00) 137 (39.83)  
  Vaginal 754 (63.90) 412(68.21) 113 (60.11) 22 (50.00) 207 (60.17)  
Maternal fever      0.594 
  No 1108 (93.90) 570(94.37) 178 (94.68) 42 (95.45) 318 (92.44)  
  Yes 72 (6.10) 34(5.63) 10 (5.32) 2 (4.55) 26 (7.56)  
Intrauterine infection/inflammation    0.136 
  No 1023 (86.69) 537(88.91) 157 (83.51) 38 (86.36) 291 (84.59)  
  Yes 157 (13.31) 67(11.09) 31 (16.49) 6 (13.64) 53 (15.41)  
Maternal BMI      0.304 
  <18.50 41 (3.47) 20(3.31) 9 (4.79) 2 (4.55) 10 (2.91)  




  25-29.99 337 (28.56) 164(27.15) 58 (30.85) 11 (25.00) 104 (30.23)  
  >30 288 (24.41) 136(22.52) 49 (26.06) 16 (36.36) 87 (25.29)  
Breastfeeding      0.351 
  Bottle only 286 (24.24) 142(23.51) 55 (29.26) 9 (20.45) 80 (23.26)  
  Both or 
breastfed only 
894 (75.76) 462(76.49) 133 (70.74) 35 (79.55) 264 (76.74)  
Unchanged acetaminophen*     0.027 
  First tertile 411 (34.83) 227(37.58) 46 (24.47) 13 (29.55) 125 (36.34)  
  Second tertile 375 (31.78) 192(31.79) 66 (35.11) 12 (27.27) 105 (30.52)  
  Third tertile 394 (33.39) 185(30.63) 76 (40.43) 19 (43.18) 114 (33.14)  
3-(N-Acetyl-L-cystein-S-yl) acetaminophen*    0.013 
  No detection 441 (37.37) 248(41.06) 51 (27.13) 15 (34.09) 127 (36.92)  
  Below median 361 (30.59) 182(30.13) 62 (32.98) 10 (22.73) 107 (31.10)  
  Above median 378 (32.03) 174(28.81) 75 (39.89) 19 (43.18) 110 (31.98)  
Acetaminophen glucuronide*     0.018 
  No detection 531 (45.00) 299(49.50) 68 (36.17) 15 (34.09) 149 (43.31)  
  Below median 315 (26.69) 152(25.17) 52 (27.66) 15 (34.09) 96 (27.91)  
  Above median 334 (28.31) 153(25.33) 68 (36.17) 14 (31.82) 99 (28.78)  
Acetaminophen burden**     0.027 
  No detection 531 (45.00) 299(49.50) 68 (36.17) 15 (34.09) 149 (43.31)  
  Below median 315 (26.69) 151(25.00) 54 (28.72) 14 (31.82) 96 (27.91)  
  Above median 334 (28.31) 154(25.50) 66 (35.11) 15 (34.09) 99 (28.78)  
Gestational age, week     <0.001 
  Mean (SD) 37.9(3.3) 38.5(2.5) 37.3(3.6) 37.0(4.6) 37.2(4.0)  
Birthweight, g      <0.001 




Note: NT was defined as free of any developmental disorder diagnosis; ADHD was defined as any ADHD 
diagnosis; ASD was defined as any ASD diagnosis without having an ADHD diagnosis; other DD was defined as 
any developmental disorder diagnosis other than ASD and ADHD; ǂThe p-values were obtained from χ2 tests or one-
way ANOVA among the four diagnosis groups. 
* Inverse normal transformed intensity 




Table 6-2 The association between maternal acetaminophen metabolites and the risk of ADHD diagnosis, ASD 
diagnosis (excluding ADHD), and other DD diagnosis in offspring. 
Model 
ADHD, 188(15.9%) ASD, 44(3.7%) Other DD, 344(29.2%) 
Odds 
Ratio 
95% CI P-value 
Odds 
Ratio 
95% CI P-value 
Odds 
Ratio 
95% CI P-value 
Unchanged acetaminophen* 
Model 1   Second tertile 1.70 (1.11,2.59) 0.014 1.09 (0.49,2.45) 0.832 0.99 (0.72,1.37) 0.967 
   Third tertile 2.03 (1.34,3.07) 0.001 1.79 (0.86,3.73) 0.118 1.12 (0.81,1.54) 0.490 
Model 2   Second tertile 1.72 (1.10,2.70) 0.018 0.98 (0.43,2.27) 0.970 0.99 (0.71,1.40) 0.977 
   Third tertile 2.08 (1.29,3.35) 0.003 1.38 (0.60,3.18) 0.451 0.94 (0.65,1.35) 0.732 
Model 3   Second tertile 1.73 (1.10,2.72) 0.017 0.99 (0.43,2.30) 0.989 0.97 (0.69,1.37) 0.883 
   Third tertile 2.08 (1.29,3.35) 0.003 1.39 (0.60,3.20) 0.443 0.93 (0.65,1.35) 0.706 
Model 4   Second tertile 1.71 (1.09,2.68) 0.020 0.98 (0.42,2.27) 0.968 0.98 (0.70,1.39) 0.931 
   Third tertile 2.06 (1.28,3.33) 0.003 1.38 (0.60,3.18) 0.453 0.93 (0.65,1.35) 0.705 
Model 5   Second tertile 1.72 (1.10,2.70) 0.018 0.98 (0.42,2.26) 0.961 0.99 (0.70,1.39) 0.958 
   Third tertile 2.06 (1.28,3.32) 0.003 1.40 (0.61,3.23) 0.432 0.94 (0.65,1.36) 0.749 
Model 6   Second tertile 1.74 (1.10,2.73) 0.017 0.99 (0.43,2.29) 0.979 0.97 (0.69,1.37) 0.869 
   Third tertile 2.05 (1.27,3.32) 0.003 1.40 (0.60,3.24) 0.433 0.93 (0.65,1.35) 0.718 
3-(N-Acetyl-L-cystein-S-yl) acetaminophen* 
Model 1   Below median 1.66 (1.09,2.51) 0.018 0.91 (0.40,2.07) 0.819 1.15 (0.83,1.58) 0.399 
   Above median 2.10 (1.40,3.14) <0.001 1.81 (0.89,3.65) 0.100 1.23 (0.90,1.70) 0.198 
Model 2   Below median 1.68 (1.08,2.61) 0.021 0.73 (0.31,1.72) 0.474 1.08 (0.77,1.52) 0.644 
   Above median 2.06 (1.28,3.31) 0.003 1.21 (0.53,2.75) 0.653 0.96 (0.66,1.40) 0.835 
Model 3   Below median 1.70 (1.09,2.65) 0.020 0.74 (0.31,1.75) 0.494 1.05 (0.75,1.48) 0.763 
   Above median 2.06 (1.28,3.31) 0.003 1.22 (0.53,2.78) 0.640 0.95 (0.65,1.38) 0.789 
Model 4   Below median 1.66 (1.06,2.58) 0.025 0.73 (0.31,1.72) 0.468 1.06 (0.76,1.49) 0.716 
   Above median 2.04 (1.27,3.28) 0.003 1.20 (0.53,2.75) 0.661 0.95 (0.65,1.38) 0.785 
Model 5   Below median 1.67 (1.07,2.60) 0.024 0.74 (0.31,1.75) 0.497 1.09 (0.78,1.53) 0.619 
   Above median 2.04 (1.27,3.28) 0.003 1.23 (0.54,2.82) 0.621 0.97 (0.67,1.41) 0.868 
Model 6   Below median 1.68 (1.08,2.63) 0.022 0.75 (0.32,1.78) 0.513 1.06 (0.75,1.49) 0.734 
   Above median 2.03 (1.26,3.27) 0.004 1.23 (0.54,2.82) 0.626 0.96 (0.66,1.39) 0.811 
Acetaminophen glucuronide* 
Model 1   Below median 1.50 (1.00,2.27) 0.051 1.97 (0.94,4.13) 0.074 1.27 (0.92,1.75) 0.150 
   Above median 1.95 (1.33,2.88) 0.001 1.82 (0.86,3.88) 0.118 1.30 (0.94,1.79) 0.110 
Model 2   Below median 1.49 (0.96,2.31) 0.074 1.47 (0.68,3.19) 0.332 1.14 (0.81,1.60) 0.465 
   Above median 2.03 (1.28,3.22) 0.003 1.26 (0.53,2.99) 0.602 1.07 (0.73,1.55) 0.738 
Model 3   Below median 1.51 (0.97,2.34) 0.068 1.50 (0.69,3.29) 0.306 1.11 (0.78,1.56) 0.569 
   Above median 2.03 (1.28,3.23) 0.003 1.28 (0.54,3.04) 0.579 1.05 (0.72,1.53) 0.787 
Model 4   Below median 1.47 (0.95,2.29) 0.085 1.47 (0.67,3.21) 0.333 1.12 (0.80,1.58) 0.516 
   Above median 2.01 (1.26,3.18) 0.003 1.26 (0.53,3.00) 0.599 1.05 (0.73,1.53) 0.784 
Model 5   Below median 1.49 (0.96,2.31) 0.075 1.47 (0.68,3.20) 0.330 1.13 (0.81,1.59) 0.466 
   Above median 2.01 (1.27,3.19) 0.003 1.27 (0.54,3.02) 0.584 1.07 (0.74,1.55) 0.726 
Model 6   Below median 1.51 (0.97,2.35) 0.068 1.50 (0.69,3.28) 0.308 1.11 (0.78,1.56) 0.564 





Model 1   Below median 1.57 (1.05,2.36) 0.029 1.85 (0.87,3.93) 0.110 1.28 (0.92,1.76) 0.139 
   Above median 1.88 (1.28,2.78) 0.001 1.94 (0.92,4.08) 0.080 1.29 (0.94,1.78) 0.119 
Model 2   Below median 1.56 (1.01,2.42) 0.045 1.39 (0.63,3.06) 0.410 1.14 (0.81,1.61) 0.439 
   Above median 1.91 (1.21,3.04) 0.006 1.36 (0.58,3.20) 0.477 1.05 (0.73,1.53) 0.779 
Model 3   Below median 1.58 (1.02,2.45) 0.041 1.43 (0.64,3.15) 0.381 1.11 (0.79,1.57) 0.543 
   Above median 1.92 (1.21,3.05) 0.006 1.38 (0.59,3.25) 0.457 1.04 (0.72,1.52) 0.824 
Model 4   Below median 1.54 (1.00,2.39) 0.052 1.39 (0.63,3.08) 0.411 1.13 (0.80,1.59) 0.488 
   Above median 1.89 (1.19,3.01) 0.007 1.37 (0.58,3.22) 0.475 1.04 (0.72,1.51) 0.826 
Model 5   Below median 1.56 (1.01,2.41) 0.045 1.39 (0.63,3.07) 0.409 1.14 (0.81,1.61) 0.442 
   Above median 1.90 (1.20,3.02) 0.007 1.38 (0.59,3.25) 0.459 1.06 (0.73,1.54) 0.763 
Model 6   Below median 1.58 (1.02,2.46) 0.040 1.43 (0.64,3.15) 0.382 1.11 (0.79,1.57) 0.539 
    Above median 1.88 (1.18,3.00) 0.008 1.39 (0.59,3.27) 0.456 1.05 (0.72,1.52) 0.815 
Note: NT was defined as free of any developmental disorder diagnosis; ADHD was defined as any ADHD 
diagnosis; ASD was defined as any ASD diagnosis without having an ADHD diagnosis; other DD was defined as 
any developmental disorder diagnosis other than ASD and ADHD;  
Model 1: Multinomial logistic regression without adjustment;  
Model 2: Model 1 further adjusted for maternal age at delivery, maternal race/ethnicity, maternal education, 
smoking before or during pregnancy, drinking before or during pregnancy, maternal BMI, parity, child's sex, 
delivery type, preterm birth, and birthweight;  
Model 3: Model 2 further adjusted for maternal fever during pregnancy;  
Model 4: Model 2 further adjusted for maternal intrauterine infection/inflammation during pregnancy;  
Model 5: Model 2 further adjusted for breastfeeding;  
Model 6: Model 2 further adjusted for maternal fever, maternal intrauterine infection/inflammation during 
pregnancy, and breastfeeding.  
* Inverse normal transformed intensity ** Sum of all the acetaminophen metabolites. 





Figure 6-1 Pathways of acetaminophen metabolism. 
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Figure 6-3 The forest plot for the crude association between maternal binary acetaminophen burden (detected vs. no 





6.11 SUPPLEMENTARY MATERIALS 
Supplemental Table 1. List of ICD-9 and ICD-10 codes for the diagnosis of each developmental disorder. 
Developmental disorder ICD-9 codes ICD-10 codes 
ASD 299.0, 299.00, 299.01, 299.8, 
299.80, 299.81, 299.9, 299.90, 
299.91 
F84.0, F84.8, F84.9 
ADHD 314.0, 314.00, 314.01, 314.1, 
314.2, 314.8, 314.9 
F90, F90.0, F90.1, F90.2, 
F90.8, F90.9 
Disturbance of conduct 312.0-312.9 F91, F91.0, F91.2, F91.3, 
F91.8, F91.9 
Delays in development 315.0-315.9 F81.0, R48.0, F81.81, F81.2, 
F81.89, F80.1, F80.2, H93.25, 
F80.4, F80.81, F80.0, F80.82, 
F80.89, F82, F88, F81.9, F89 
Intellectual disabilities 317-317 F70, F71, F72, F73, F78, F79 
Failure to thrive 783.4, 783.40, 783.41, 783.42, 
783.43 
R62.50, R62.51, R62.0, 
R62.52 




Supplemental Table 2. Maternal and child characteristics for participants excluded and included in the 
analysis.  
Variable Total, N (%) Excluded, N (%) Included, N (%) P-valueǂ 
Total 3098 (100) 1918 (61.91) 1180 (38.09)  
Maternal Age    0.796 
  <35 2534 (81.79) 1569 (81.80) 965 (81.78)  
  ≥35 556 (17.95) 341 (17.78) 215 (18.22)  
Education level    0.109 
  Below college degree 2642 (85.28) 1609 (83.89) 1033 (87.54)  
  College degree or above 420 (13.56) 273 (14.23) 147 (12.46)  
Maternal race/ethnicity    <0.001 
  Black 1965 (63.43) 1156 (60.27) 809 (68.56)  
  White 227 (7.33) 179 (9.33) 48 (4.07)  
  Hispanic 682 (22.01) 426 (22.21) 256 (21.69)  
  Other 209 (6.75) 142 (7.40) 67 (5.68)  
Smoking before or during pregnancy   0.222 
  Never 2496 (80.57) 1519 (79.20) 977 (82.80)  
  Quitter 238 (7.68) 148 (7.72) 90 (7.63)  
  Continuous 330 (10.65) 217 (11.31) 113 (9.58)  
Drinking before or during pregnancy    0.627 
  No 2740 (88.44) 1654 (86.24) 1086 (92.03)  
  Yes 247 (7.97) 153 (7.98) 94 (7.97)  
Child's sex    0.617 
  Female 1529 (49.35) 953 (49.69) 576 (48.81)  
  Male 1567 (50.58) 963 (50.21) 604 (51.19)  
Delivery type    0.930 
  C-section 1116 (36.02) 690 (35.97) 426 (36.10)  
  Vaginal 1967 (63.49) 1213 (63.24) 754 (63.90)  
Gestational age, week    0.003 
  Mean (SD) 37.6(3.5) 37.5(3.6) 37.9(3.3)  
Birthweight, g    <0.001 
  Mean (SD) 2898.3(819.7) 2856.5(834.9) 2966.2(789.9)  






Supplemental Table 3. The association between maternal acetaminophen metabolites and the risk of 
ADHD diagnosis only, ASD diagnosis only, and diagnoses of both ADHD and ASD in offspring. 
Model 
ADHD only, N=166 ASD only, N=44 ADHD and ASD, N=22 
Odds 
Ratio 
95% CI P-value 
Odds 
Ratio 
95% CI P-value 
Odds 
Ratio 
95% CI P-value 
Unchanged acetaminophen* 
Model 1 Second tertile 1.92 (1.22,3.01) 0.005 1.09 (0.49,2.45) 0.832 0.79 (0.28,2.25) 0.657 
 Third tertile 2.29 (1.47,3.57) <0.001 1.79 (0.86,3.73) 0.118 0.95 (0.35,2.61) 0.928 
Model 2 Second tertile 1.96 (1.20,3.20) 0.007 0.96 (0.41,2.25) 0.932 0.85 (0.28,2.64) 0.785 
 Third tertile 2.32 (1.38,3.89) 0.001 1.32 (0.57,3.07) 0.523 0.92 (0.27,3.20) 0.901 
Model 3 Second tertile 1.96 (1.20,3.20) 0.007 0.97 (0.41,2.28) 0.947 0.91 (0.29,2.83) 0.868 
 Third tertile 2.32 (1.38,3.89) 0.001 1.32 (0.57,3.08) 0.516 0.92 (0.26,3.21) 0.891 
Model 4 Second tertile 1.95 (1.19,3.18) 0.008 0.96 (0.41,2.25) 0.926 0.85 (0.27,2.63) 0.778 
 Third tertile 2.30 (1.37,3.86) 0.002 1.31 (0.56,3.05) 0.534 0.91 (0.26,3.14) 0.884 
Model 5 Second tertile 1.97 (1.21,3.22) 0.007 0.96 (0.41,2.24) 0.920 0.85 (0.28,2.64) 0.783 
 Third tertile 2.29 (1.37,3.85) 0.002 1.33 (0.57,3.10) 0.509 0.93 (0.27,3.24) 0.912 
Model 6 Second tertile 2.01 (1.22,3.29) 0.006 0.98 (0.42,2.29) 0.958 0.91 (0.29,2.85) 0.872 
 Third tertile 2.28 (1.36,3.84) 0.002 1.33 (0.57,3.10) 0.516 0.92 (0.26,3.22) 0.892 
3-(N-Acetyl-L-cystein-S-yl) acetaminophen* 
Model 1 Below median 1.82 (1.17,2.83) 0.008 0.91 (0.40,2.07) 0.819 0.91 (0.32,2.60) 0.858 
 Above median 2.31 (1.50,3.55) <0.001 1.81 (0.89,3.65) 0.100 1.11 (0.41,3.03) 0.841 
Model 2 Below median 1.90 (1.18,3.05) 0.008 0.77 (0.33,1.82) 0.557 0.98 (0.32,2.99) 0.974 
 Above median 2.28 (1.37,3.80) 0.002 1.19 (0.52,2.73) 0.688 0.90 (0.26,3.13) 0.868 
Model 3 Below median 1.91 (1.18,3.08) 0.008 0.78 (0.33,1.86) 0.576 1.12 (0.37,3.43) 0.843 
 Above median 2.28 (1.37,3.81) 0.002 1.19 (0.52,2.75) 0.680 0.91 (0.26,3.18) 0.888 
Model 4 Below median 1.87 (1.16,3.01) 0.010 0.76 (0.32,1.80) 0.537 1.00 (0.33,3.07) 0.996 
 Above median 2.25 (1.34,3.76) 0.002 1.17 (0.51,2.70) 0.717 0.89 (0.26,3.08) 0.860 
Model 5 Below median 1.88 (1.17,3.03) 0.009 0.78 (0.33,1.85) 0.576 1.00 (0.33,3.05) 0.994 
 Above median 2.25 (1.35,3.75) 0.002 1.21 (0.52,2.78) 0.660 0.91 (0.26,3.18) 0.882 
Model 6 Below median 1.93 (1.19,3.11) 0.008 0.80 (0.33,1.89) 0.604 1.15 (0.37,3.53) 0.812 
 Above median 2.24 (1.34,3.76) 0.002 1.20 (0.52,2.78) 0.676 0.91 (0.26,3.20) 0.889 
Acetaminophen glucuronide* 
Model 1 Below median 1.69 (1.09,2.60) 0.018 1.97 (0.94,4.13) 0.074 0.66 (0.21,2.07) 0.471 
 Above median 2.16 (1.44,3.26) <0.001 1.82 (0.86,3.88) 0.118 0.98 (0.36,2.65) 0.964 
Model 2 Below median 1.67 (1.04,2.68) 0.033 1.39 (0.63,3.07) 0.411 0.51 (0.15,1.79) 0.293 
 Above median 2.30 (1.40,3.78) 0.001 1.20 (0.50,2.88) 0.680 0.88 (0.24,3.20) 0.845 
Model 3 Below median 1.67 (1.04,2.69) 0.034 1.42 (0.64,3.15) 0.390 0.56 (0.16,2.00) 0.373 
 Above median 2.30 (1.40,3.78) 0.001 1.22 (0.51,2.92) 0.663 0.88 (0.24,3.22) 0.851 
Model 4 Below median 1.66 (1.04,2.66) 0.035 1.38 (0.63,3.05) 0.422 0.51 (0.14,1.79) 0.293 
 Above median 2.26 (1.37,3.72) 0.001 1.19 (0.49,2.86) 0.702 0.88 (0.24,3.17) 0.845 
Model 5 Below median 1.68 (1.05,2.69) 0.032 1.39 (0.63,3.06) 0.418 0.51 (0.15,1.78) 0.290 
 Above median 2.28 (1.38,3.75) 0.001 1.21 (0.50,2.91) 0.668 0.89 (0.24,3.25) 0.858 
Model 6 Below median 1.74 (1.08,2.81) 0.023 1.44 (0.65,3.20) 0.373 0.56 (0.16,2.02) 0.378 





Model 1 Below median 1.77 (1.15,2.71) 0.009 1.85 (0.87,3.93) 0.110 0.66 (0.21,2.08) 0.478 
 Above median 2.08 (1.38,3.14) 0.001 1.94 (0.92,4.08) 0.080 0.97 (0.36,2.64) 0.954 
Model 2 Below median 1.76 (1.10,2.80) 0.018 1.32 (0.59,2.95) 0.495 0.52 (0.15,1.81) 0.303 
 Above median 2.16 (1.31,3.55) 0.003 1.30 (0.55,3.08) 0.553 0.86 (0.24,3.12) 0.819 
Model 3 Below median 1.76 (1.10,2.82) 0.019 1.35 (0.60,3.02) 0.471 0.57 (0.16,2.03) 0.387 
 Above median 2.16 (1.31,3.55) 0.003 1.31 (0.55,3.12) 0.539 0.86 (0.24,3.14) 0.822 
Model 4 Below median 1.74 (1.09,2.79) 0.020 1.31 (0.59,2.93) 0.506 0.52 (0.15,1.82) 0.303 
 Above median 2.12 (1.28,3.50) 0.003 1.28 (0.54,3.06) 0.572 0.86 (0.24,3.09) 0.819 
Model 5 Below median 1.77 (1.11,2.82) 0.017 1.31 (0.59,2.93) 0.505 0.52 (0.15,1.80) 0.299 
 Above median 2.13 (1.29,3.52) 0.003 1.31 (0.55,3.12) 0.539 0.87 (0.24,3.17) 0.832 
Model 6 Below median 1.84 (1.14,2.96) 0.012 1.37 (0.61,3.07) 0.452 0.57 (0.16,2.05) 0.392 
 Above median 2.11 (1.27,3.49) 0.004 1.30 (0.55,3.12) 0.550 0.86 (0.24,3.15) 0.823 
Note: NT was defined as free of any developmental disorder diagnosis; ADHD only was defined as any ADHD 
diagnosis without having an ASD diagnosis; ASD only was defined as any ASD diagnosis without having an 
ADHD diagnosis; ADHD and ASD was defined as having both ADHD and ASD diagnosis;  
Model 1: Multinomial logistic regression without adjustment;  
Model 2: Model 1 further adjusted for maternal age at delivery, maternal race/ethnicity, maternal education, 
smoking before or during pregnancy, drinking before or during pregnancy, maternal BMI, parity, child's sex, 
delivery type, preterm birth, and birthweight;  
Model 3: Model 2 further adjusted for maternal fever during pregnancy;  
Model 4: Model 2 further adjusted for maternal intrauterine infection/inflammation during pregnancy;  
Model 5: Model 2 further adjusted for breastfeeding;  
Model 6: Model 2 further adjusted for maternal fever, maternal intrauterine infection/inflammation during 
pregnancy, and breastfeeding.  
* Inverse normal transformed intensity ** Sum of all the acetaminophen metabolites. 




Supplemental Table 4. The stratified analysis results on the association between maternal 
acetaminophen burden and the risk of ADHD in offspring by maternal HDL groups 
  ADHD otherDD 
Variable  OR 95% CI P-value OR 95% CI P-value 
Maternal HDL ≥60 mg/dL 1.57 (1.12,2.22) 0.010 1.17 (0.90,1.52) 0.231 
 <60 mg/dL 1.10 (0.82,1.48) 0.532 0.85 (-0.67,1.07) 0.170 
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This chapter begins with a summary of my key findings, followed by a discussion of the 
strengths and limitations of the research approach, then a summary of the research, policy, and , 
clinical and public health implications of this work, and ends with the conclusions reached based 
on the research findings.  
7.2 KEY FINDINGS 
7.2.1 Aim 1: Prospective association between maternal cholesterol levels and ADHD in 
the offspring 
The multiple logistic regression results showed that a low maternal high-density lipoprotein level 
(HDL) (≤60 mg/dL) was associated with an increased risk of ADHD, compared to a higher 
maternal HDL level, after adjusting for pertinent covariables. A “J” shaped relationship was 
observed between triglycerides (TG) and ADHD risk. The associations with ADHD for maternal 
HDL and TG were more pronounced among boys. 
7.2.2 Aim 2: Prospective association between early childhood lead levels and ADHD in the 
offspring 
Nearly one-tenth of BBC children had elevated lead levels (5-10µg/dL) in early childhood, 
which was associated with a 66% increased risk of ADHD. Among boys, the association was 
significantly stronger (p-value for sex-lead interaction: 0.017). The odds ratio of ADHD 
associated with elevated lead levels among boys was reduced by about half if mothers had 
adequate HDL levels compared to low HDL, or if mothers had low stress compared to high 




7.2.3 Aim 3: Prospective association between maternal blood acetaminophen metabolites 
levels and ADHD in the offspring 
Compared to neurotypical children, significant positive associations with ADHD diagnosis were 
identified for each maternal acetaminophen biomarker: unchanged acetaminophen (Third tertile 
vs. First tertile): OR=2.05, 95% CI: 1.27-3.32; 3-(N-Acetyl-L-cystein-S-yl) acetaminophen 
(Above median vs. No detection): OR=2.03, 95% CI: 1.26-3.27; and acetaminophen glucuronide 
(Above median vs. No detection): OR=2.00, 95% CI: 1.26-3.18. The dose-response associations 
persisted after adjusting for pertinent covariables; these associations were specific to ADHD 
rather than other neurodevelopmental disorders.  
7.3 STRENGTHS AND LIMITATIONS 
7.3.1 Strengths 
Study design: This study used a prospective longitudinal birth cohort established in the U.S. to 
investigate the development of ADHD. The birth cohort design makes it feasible to investigate 
early life factors on ADHD during the critical neurodevelopmental window. Moreover, the 
temporal nature between the exposure and outcome measurements help us to understand better 
the temporal and causal pathways underlying the development of ADHD. Additionally, the large 
sample size of male and female ADHD cases in this study made it possible to investigate sex 
interactions with the risk factors of interest. 
ADHD diagnosis: This study used physician diagnosis extracted from the EMR to define 
ADHD cases. More than half of the children with ADHD had over three ADHD diagnoses in 




neurobehavioral specialist, thus, with much higher specificity and lesser probability of case 
misclassification.  
High-risk population: The BBC’s study population is mainly comprised of a low-income, 
urban, minority population from the Boson area. The mothers from this population have much 
higher rates of obesity1 and lead exposure2 than the national average. As such, higher rates for 
these adverse conditions provided greater power to investigate their potential effects on ADHD 
in offspring. 
Cholesterol biomarkers: This is the first study to investigate the inter-generational effect of 
maternal lipid profiles on the risk of ADHD in offspring. Moreover, this is the first study to 
illustrate the potential protective effects of maternal cholesterols against lead toxicity. 
Early lead measurement: Most previous studies examined the consequences of postnatal lead 
exposure either at the time of ADHD diagnosis (cross-sectional) or after the diagnosis 
(retrospective), with a mean age of measurement ranged from age 7-14 years.3 This is the first 
large longitudinal study to investigate ADHD with lead levels measured before the age of 2 
years. 
Sex-specific effects: This is the first study to show that boys are more vulnerable than girls to 
suboptimal maternal cholesterol levels and early childhood lead exposure in terms of ADHD 
development. 
Acetaminophen metabolites: This is the first prospective birth cohort study to examine the 
association between maternal plasma biomarkers of acetaminophen and offspring ADHD 




of acetaminophen use such as maternal fever and intrauterine infection/inflammation during 
pregnancy. 
7.3.2 Limitations 
Transition from DSM-IV to DSM-V and from ICD-9 to ICD-10: this study occurred during 
the transition of the American Psychiatric Association’s Diagnostic and Statistical Manual 
(DSM) from the 4th to the 5th edition. The transition to DSM-5 and ICD-10 raises concerns 
about the consistency of the diagnoses over time.  Fortunately, this transition did not affect the 
ADHD determination in children, since the main changes from DSM-IV-TR to DSM-5 were 
more relevant to the adult diagnostic criteria. 4 
Generalizability of the study findings: The study population mainly consisted of urban, low-
income, minority women who live in the Boston area. This population has been shown to have 
much higher levels of exposure to common ADHD risk factors and other risk factors of interest 
compared to the general U.S. population. Since this sample is not representative of the US 
general population, caution is needed to generalize the findings beyond US urban low-income 
setting. 
Unmeasured confounders: Although adjustments for major known risk factors were made 
during the analyses, there may still have been unmeasured or unknown factors that may have 
influenced levels of exposure and/or outcomes. My analyses adjusted for known risk factors of 
ADHD, but could not adjust for multiple familial factors identified in previous studies such as 
maternal personality,5 poor parenting,6,7 maltreatment,8 conflict/parent-child hostility,9 and 
severe early deprivation.10,11  Moreover, the adjustment for known risk factors did not include 
some post-natal factors that could be related to both maternal cholesterol levels and ADHD risk, 




One-time measurement of biomarkers of interest: This study only had a one-time 
measurement of maternal cholesterol and acetaminophen metabolite levels within 1-3 days 
postpartum. In the ideal situation, maternal cholesterol and acetaminophen metabolites would be 
collected at least once for each trimester. However, this was not feasible for my study sample. 
The one-time measurement for these exposures can at best reflect these two exposures around the 
time of delivery. 
Non-fasting blood samples: This study used non-fasting blood samples. The values for total 
cholesterol and TG levels may have been inflated in non-fasting blood samples and thus may 
have biased my study results towards the null. Further studies using fasting blood samples should 
be conducted to provide a more precise assessment of optimal TG levels during pregnancy. 
7.4 STUDY IMPLICATIONS 
This research provides new insights into the effects of maternal cholesterol levels, early 
childhood lead and maternal acetaminophen use on the risk of ADHD diagnosis in the offspring. 
Additionally, these investigations have for the first time identified sex-specific effects of 
maternal cholesterol and early childhood lead exposure on ADHD. As detailed below, these 
findings, if further confirmed, would have tremendous implications for research, policy, and 
clinical intervention. 
7.4.1 Research implications 
7.4.1.1 Understanding of ADHD etiology 
This dissertation research has provided multiple new insights into the role of early life factors in 




Aim 1 was the first study designed to explore the prospective relationship between 
maternal cholesterols and childhood ADHD. The findings provided several lines of support for 
casual evidence, such as a strong dose-responsive HDL-ADHD association, temporal 
relationship between maternal HDL and offspring ADHD, and sex-specific responses to maternal 
HDL levels.  
Aim 2 was the first birth cohort study in a US urban low-income minority population to 
examine the lead-ADHD relationship. The findings provided several supports for casual 
evidence, including a temporal relationship, sex difference, and biological plausibility.  
Aim 3 was the first study to investigate prospective relationship between maternal 
acetaminophen biomarkers and offspring ADHD risk.  The findings provided several supports 
for casual evidence, including temporal and dose-response associations. Moreover, these 
associations are ADHD-specific.  
However, given that this is an observational study, the findings be regarded as hypothesis 
generating, rather than conclusive. To establish a causal relationship between risk factors and 
ADHD, it requires multiple levels of evidence, including a strong association, consistency across 
different situations, specificity between exposure and outcome, as well as a temporal 
relationship, a dose-responsive relationship, biological plausibility and coherence, outcome 
changes after exposure manipulation, and analogy to other comparable situation with better 
understanding of risk factors. 12  As such, the study findings warrant additional investigation.   
7.4.1.2 Need of Repeated Cholesterol and Acetaminophen measurements 
The study findings suggest that maternal HDL and acetaminophen levels may influence ADHD 




within 1-3 days postpartum, these biomarkers at best reflect the exposure during the perinatal 
period. Under ideal conditions, maternal blood samples be collected at least once for each 
trimester, and this should be considered in future studies. Using such detailed data on lipid 
profiles and medication use specific to each trimester, future studies could identify critical period 
when fetal development is most vulnerable to suboptimal HDL and acetaminophen exposure. 
Moreover, with the help of OMICs technology, the multipoint measurements across pregnancy 
might ultimately help to unravel the biological pathways of ADHD development.   
7.4.1.3 Study population 
As mentioned above, the study population had much higher levels of exposure to common 
ADHD risk factors and other risk factors of interest compared to the general U.S. population. 
Future research could attain more generalizable findings by studying a nationally representative 
population. 
7.4.1.4 New insights in sex difference in ADHD risk 
The long-observed and striking sex difference in ADHD risk remains poorly understood. The 
study findings included here reveal that boys and girls respond differently to prenatal and 
postnatal factors. In Aim 1 and Aim 2, I found that the effects of maternal HDL, maternal TG, 
and early childhood lead levels on ADHD were most pronounced among boys. Sex differences 
in response to prenatal suboptimal nutritional status are also found in other chronic diseases such 
as hypertension. Both human and animal studies have shown that the male fetus is more likely to 
develop hypertension in response to the mother’s unfavorable nutrition and metabolic status 
during pregnancy.13-17 These sex differences have been explained by hypotheses that male 
fetuses are more vulnerable to suboptimal maternal nutrition due to their more rapid in-utero 




sex differences, studies on postnatal sex-specific responses are extremely rare. In the future, new 
studies on early life risk factors should focus more on the sex-risk interactions, by including 
enough female ADHD cases to make those analyses feasible.   
In summary, based on the collective findings generated from this dissertation, I have the 
following research recommendations: 
• Additional studies should be pursued to provide evidence of consistency across different 
populations with different socio-demographic characteristics. 
• Additional studies should be conducted among a nationally representative population. 
• Maternal plasma should be collected at least once for each trimester. 
• Future studies should also consider potential interaction between sex and early life risk 
factors. 
7.4.2 Policy implications 
7.4.2.1 labeling change for acetaminophen and searching for alternatives 
Although multiple previous large cohort studies have provided consistent self-reported evidence 
for potential acetaminophen neurotoxicity during pregnancy,18-22 the Society for Maternal-Fetal 
Medicine (SMFM) and the Food and Drug Administration (FDA) have issued statements 
regarding their belief that current studies are still too inconclusive to draw any causal inference 
between prenatal acetaminophen use and ADHD in offspring. 23,24 Their primary criticism 
included self-reported exposure, lack of dose quantification, unmeasured confounders, and lack 
of adjustment for multiple testing. 23 In fact, the findings detailed in this dissertation provide 
dose-responsive evidence in support of acetaminophen’s neurotoxicity, even after adjusting for 
several previously identified potential confounders. My research findings lent further support to 
the concern that prenatal acetaminophen use may increase the risk of ADHD in offspring. The 
impulse to reject the possible causality must be supported by stronger evidence than opinion.25 




labels for acetaminophen state that they are “safe, gentle, and effective”. 26 Given the fact that no 
other ‘safer’ medications are available for use during pregnancy, two steps are needed for 
government to minimize the impact of the potential neurotoxicity of acetaminophen. First, the 
FDA should request that pharmaceutical manufacturers add information to the labels of 
acetaminophen-containing medications, which should state that acetaminophen is not 
recommended for the pregnant women if their symptom or discomfort has no strong indication or 
presents little risk. 25 Taking it under unnecessary condition could harm the neurodevelopment of 
the fetus. 25 Second, the FDA should create fast approval incentives to inspire the search for safer 
alternative treatments. 
7.4.2.2 Correcting dyslipidemia as a potential intervention target  
ADHD is one of the most common and costly neurodevelopmental disorders in the U.S. Nearly 
one-tenth of children ages 4-17 are diagnosed with ADHD in the U.S, and most of their 
symptoms will be carried into adolescence and adulthood. This high prevalence and these 
persistent symptoms across the lifespan can have a severe impact on both the individuals 
themselves and on society. The most recent estimation of the annual cost of ADHD to society, 
including costs related to health care utilization, medication utilization, education, crime, and 
unemployment, is $14,500 per individual ($42.5 billion in total). 27 Currently, the most common 
clinical practice is still symptom control using behavioral or pharmaceutical interventions. At 
such a high prevalence, clearly this type of symptom control practice has and will likely continue 
to lead to a huge financial burden to society. To reverse the rising trend of ADHD and associted 
rising costs to manage ADHD, the government should allocate more resources to the primary 
prevention of ADHD. For instance, the study findings included herein show that maternal 




and diabetes epidemics are growing, the percentage of pregnant women with dyslipidemia during 
pregnancy is also likely to increase. If the government invests more resources in pre- and 
perinatal dyslipidemia control programs, the incidence of ADHD and related financial burden are 
likely to decrease. For instance, the government can optimize the Women, Infants, and Children 
(WIC) program’s food voucher selections to make it more beneficial for maintaining healthy 
cholesterol levels. Moreover, given the essential role of cholesterol in brain development, this 
change might also reduce other neurodevelopment risks.  
In summary, based on the collective findings generated from the studies presented in this 
dissertation, I have the following policy recommendations: 
• The FDA should discourage the use of acetaminophen for minor symptoms and 
discomforts during pregnancy and peripartum, by requesting additional warning to be 
added to the labels of acetaminophen-containing medications. 
• The FDA should create fast approval incentives to accelerate the search for safer 
alternative treatments. 
• If further confirmed by future studies, the government should invest more resources in 
pre- and perinatal dyslipidemia control programs as a primary prevention strategy to 
reduce the incidence of ADHD. 
7.4.3 Clinical and Public Health Implications 
7.4.3.1 Limiting acetaminophen use in obstetrics and gynecology practice 
Acetaminophen is a widely used and recommended over-the-counter medication for fever and 
pain relief during pregnancy. The percentage of pregnant women who use acetaminophen during 
pregnancy is over 65% in the U.S. and over 50% in Europe.28,29 The primary concern is related to 
the fact that the inhibition of prostaglandin synthesis is part of the therapeutic effect of 
acetaminophen. 30 Biological evidence suggests that prostaglandins not only act as a fever 
determinant but also play essential roles in brain function, including long-term potentiation,31 




neuronal function, it is too risky to ignore any potential unknown side effects.25 As a result, 
based on the findings presented here I strongly urge clinicians to provide advice to pregnant 
women about using this drug carefully, avoiding overdose and high-frequency use as well as 
unnecessary use for minor conditions. 
7.4.3.2 An emphasis of primary prevention of ADHD 
The hope is that the findings presented here may help to transform clinical practice from 
secondary- and tertiary-prevention into primary prevention of ADHD. Currently, major clinical 
practice is still focused on symptom control using behavioral or pharmaceutical interventions. 
Clearly, as ADHD prevalence continues to increase, this practice will not be sustainable due to a 
growing financial burden on individuals, families and society. Moreover, the ADHD medications 
in use today not only cannot cure the disease but also have multiple side effects. Shifting to 
primary prevention of ADHD by reducing the major modifiable risk factors and optimizing 
maternal nutritional profiles as early as the prenatal period would largely reduce the onset of 
ADHD in the future. For instance, the findings for Aim 1 of the research strategy indicate that 
maternal dyslipidemia is an important risk factor for ADHD diagnosis in offspring. Dyslipidemia 
is modifiable by dietary and lifestyle changes and is treatable with pharmaceuticals. Thus, adding 
lipid screening to the prenatal care guidelines would offer a relatively inexpensive way to move 
toward the primary prevention of ADHD.   
7.4.3.3 Guideline changes for cholesterol levels during pregnancy 
The findings for Aim 1 underscore the need to refine the cholesterol level cut-off points for 
pregnant women in consideration of the potential adverse impact on fetal and child 
neurodevelopment. For instance, my data suggest that pregnant women should maintain a 




pregnancy and to reduce ADHD risk; this is particularly important for the male fetus. My data 
indicate that the current clinical cut point for HDL (>50 mg/dL) for nonpregnant women, as 
recommended by the American Heart Association for reducing the risk of heart disease 33,34 may 
not be adequate for pregnant women for protecting against ADHD in offspring; thus, a higher 
cut-off point (>60 mg/dL) may be needed for identifying the fetus at risk for future ADHD. 
In summary, based on the collective findings generated from the studies presented in this 
dissertation, I have the following clinical recommendations: 
• Clinicians should provide advice to pregnant women about how to use drugs containing 
acetaminophen carefully. 
• Clinical practice should shift from secondary- and tertiary-prevention to the primary 
prevention of ADHD by controlling major modifiable risk factors. 
• Pregnancy-specific guidelines for optimal cholesterol levels should be developed. 
7.5 CONCLUSIONS 
ADHD is one of the most common neurodevelopmental disorders that imposes an enormous cost 
on individual, family, and society in the U.S. Unfortunately, the current understanding of this 
highly prevalent and costly disorder is insufficient. The exact cause of ADHD is still unknown, 
not to mention the biological mechanisms behind the sex difference in ADHD risk. My thesis 
research revealed that maternal cholesterol levels,35 early childhood lead exposure,36-38 and 
maternal plasma acetaminophen metabolite levels18-22,39 are each highly possible to influence the 
risk of ADHD in offspring, using the data of mother-infant pairs already enrolled and followed in 
the Boston Birth Cohort (BBC). 
First, I evaluated the prospective association of maternal cholesterol levels measured within a 




BBC. I  showed that suboptimal maternal cholesterol levels might increase the risk of ADHD in 
offspring and that the male fetus appeared to be particularly vulnerable to suboptimal levels. 
Second, I investigated the prospective associations between early childhood lead exposure and 
ADHD diagnosis and its potential effect modifiers among 1479 BBC mother-infant pairs. 
Elevated early childhood blood lead levels increased the risk of ADHD, and boys were more 
vulnerable than girls at a given lead level. This risk of ADHD was reduced by half if the mother 
had adequate high-density lipoprotein (HDL) levels or low stress during pregnancy. 
Third, I examined the prospective association between maternal plasma biomarkers of 
acetaminophen intake measured within a few days of delivery and ADHD diagnosis in the 
offspring among 1180 BBC mother-infant pairs. Maternal acetaminophen use was specifically 
associated with a higher risk of ADHD diagnosis in offspring, not with other developmental 
disorders.  
In conclusion, maternal low HDL levels, early childhood lead exposure, and perinatal 
acetaminophen use were associated with a higher risk of ADHD. The male fetus was more 
sensitive to both low levels of HDL and lead exposure. Maternal adequate HDL levels and low-
stress levels could reduce the adverse effect of lead on the risk of ADHD. Given the 
observational nature of these studies, the findings are regarded as hypothesis generating rather 
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